Archive for October, 2012

Eastern Virginia Bankshares (EVBS) Announces Third Quarter 2012 Results

TAPPAHANNOCK, Va., Oct. 19, 2012 /PRNewswire/ — Eastern Virginia Bankshares (NASDAQ: EVBS) today reported its results of operations for the three and nine months ended September 30, 2012.

For the three months ended September 30, 2012, EVBS reported net income of $861 thousand, an increase of $372 thousand over the net income of $489 thousand reported for the same period of 2011.  Net income to common shareholders was $486 thousand, or $0.08 per common share assuming dilution, compared to net income of $115 thousand or $0.02 per common share assuming dilution for the same period in 2011.  For the nine months ended September 30, 2012, EVBS reported net income of $2.5 million, an increase of $1.3 million over the net income of $1.2 million reported for the same period of 2011.  Net income to common shareholders was $1.4 million, or $0.23 per common share assuming dilution, compared to net income of $64 thousand or $0.01 per common share assuming dilution for the same period in 2011.  The difference between net income and net income to common shareholders is the deduction for the effective dividend to the U.S. Treasury on preferred stock.

For the three months ended September 30, 2012, the following key points were significant factors in our reported results:

  • Provision expense for the allowance for loan losses of $625 thousand compared to $1.7 million for the same period in 2011;
  • Net charge-offs of $1.4 million to write off uncollectible balances on nonperforming assets;
  • Decrease in nonperforming assets by $2.8 million during the third quarter of 2012;
  • Gain on the sale of available for sale securities of $135 thousand resulting from adjustments in the composition of the investment portfolio as part of our overall asset/liability management strategy;
  • Gain of $197 thousand on the sale of the credit card loan portfolio;
  • Decrease in net interest income by $194 thousand from the same period in 2011;
  • Impairment losses of $769 thousand related to valuation adjustments on other real estate owned;
  • Gain of $12 thousand on the sale of other real estate owned;
  • Expenses related to FDIC insurance premiums of $586 thousand, compared to $790 thousand for the same period in 2011; and
  • Expenses related to collection, repossession and other real estate owned of $190 thousand, compared to $354 thousand for the same period in 2011.

For the nine months ended September 30, 2012, the following key points were significant factors in our reported results:

  • Provision expense for the allowance for loan losses of $4.8 million compared to $5.2 million for the same period in 2011;
  • Net charge-offs of $6.8 million to write off uncollectible balances on nonperforming assets;
  • Decrease in nonperforming assets by $18.4 million during the first nine months of 2012;
  • Gain on the sale of available for sale securities of $3.5 million resulting from adjustments in the composition of the investment portfolio as part of our overall asset/liability management strategy;
  • Gain of $197 thousand on the sale of the credit card loan portfolio;
  • Decrease in net interest income by $1.3 million from the same period in 2011;
  • Impairment losses of $1.7 million related to valuation adjustments on other real estate owned;
  • Losses of $105 thousand on the sale of other real estate owned;
  • Expenses related to FDIC insurance premiums of $1.8 million, compared to $2.2 million for the same period in 2011; and
  • Expenses related to collection, repossession and other real estate owned of $845 thousand, compared to $1.4 million for the same period in 2011.

The return on average assets (ROA) and return on average equity (ROE), on an annualized basis, for the three months ended September 30, 2012 were 0.18% and 2.62%, respectively compared to 0.04% and 0.63%, respectively for the three months ended September 30, 2011.  For the nine months ended September 30, 2012, on an annualized basis, ROA and ROE were 0.18% and 2.56%, respectively compared to 0.01% and 0.12%, respectively for the same period of 2011.

In announcing these results, Joe A. Shearin, President and Chief Executive Officer commented “As a Company we laid out a plan to improve our operating performance and strengthen our balance sheet by focusing on asset quality issues, containing our noninterest expenses and lowering our cost of funding.  To date, we have been successful in the execution of this plan.  With the close of the third quarter of 2012, we are not only reporting our seventh straight quarter of net income, but our fifth straight quarter of improved net income.”  Shearin further commented, “We had another strong quarter liquidating our troubled assets, reducing our classified assets and improving our overall asset quality.  During the third quarter of 2012 we were able to reduce our nonperforming assets by another 12.5%, bringing our year to date reduction to 48.7%.  Our loan and asset quality metrics continue to improve as evidenced by end of quarter nonperforming loans to total loans of 1.82% and nonperforming assets to total assets of 1.83%.  Despite our aggressive approach in liquidating troubled assets, our allowance for loan losses remains quite healthy at quarter end producing a ratio of allowance for loan losses to nonperforming loans of 172.37% and a ratio of allowance for loan losses to total loans of 3.14%.”  Shearin concluded, “Although macro-economic and political issues continue to temper the global economic outlook, we remain cautiously optimistic regarding the signs of improvement seen in our local markets and believe that our local markets are poised for stronger growth in the coming months and years.”

Operations Analysis

Net interest income for the three months ended September 30, 2012 was $8.4 million, a decrease of $194 thousand or 2.3% from the $8.6 million for the same period of 2011.  This decrease was due to a 9 basis point decrease in the net interest margin (tax equivalent basis) from 3.45% (includes a tax equivalent adjustment of $92 thousand) in the third quarter of 2011, to 3.36% (includes a tax equivalent adjustment of $11 thousand) in the third quarter of 2012.  The year over year decline in interest income was primarily driven by the impact of declining loan balances due to weak loan demand, charge-offs, and the natural amortization of the portfolio.  While the average investment securities balance increased $46.3 million to $266.2 million during the three months ended September 30, 2012, the yield on investment securities declined 98 basis points from 2.84% to 1.86% for the third quarter of 2012.  The lower yield resulted from portfolio restructurings, accelerated prepayments on our Agency mortgage-backed and Agency CMO securities, and investing in lower risk, shorter duration investments.  As a result, the yield on our average interest-earning assets declined 39 basis points to 4.49% for the three months ended September 30, 2012 as compared to the same period in 2011.  The decline in interest income was somewhat offset by a lower cost of funding.  Our lower cost of funding was driven by the continuation of our deposit re-pricing strategy, reductions in the level of time deposits, and increased levels of interest-bearing checking and savings accounts with lower rates.  As a result, the average cost of interest-bearing deposits decreased 40 basis points to 0.85% for the three months ended September 30, 2012 as compared to the same period in 2011.

Net interest income for the nine months ended September 30, 2012 was $25.1 million, a decrease of $1.3 million or 5.0% from the $26.5 million for the same period of 2011.  The net interest margin (tax equivalent basis) decreased 17 basis points from 3.56% (includes a tax equivalent adjustment of $344 thousand) for the nine months ended September 30, 2011 to 3.39% (includes a tax equivalent adjustment of $191 thousand) in the same period of 2012.  The tax equivalent yield on average interest-earning assets declined 48 basis points in the nine months ended September 30, 2012 compared with the same period of 2011, but was partially offset by a 32 basis point decrease in the cost of interest-bearing liabilities over the same period.  Average interest-earning assets were $998.1 million in the nine months ended September 30, 2012, which was a decrease of $8.0 million or 0.8% from the same period of 2011.  Total average loans were 72.2% of total interest-earning assets in the nine months ended September 30, 2012, compared to 75.7% in the nine months ended September 30, 2011.  This decline was driven by the impact of declining loan balances due to the items discussed in the quarterly analysis above and our desire to increase liquidity through the expansion of the investment portfolio.

Noninterest income for the three months ended September 30, 2012 was $1.9 million, a decrease of $1.1 million or 35.9% over the same period of 2011.  Debit/credit card fees increased $93 thousand, or 25.1% in the third quarter of 2012, which was primarily attributable to an increase in debit card income.  Net gains on the sale of available for sale securities decreased $1.3 million to $135 thousand for the three months ended September 30, 2012, down from $1.4 million for the same period in 2011.  In addition to the aforementioned items, the three months ended September 30, 2012 includes a $197 thousand gain on the sale of our credit card loan portfolio, which was not present during the same period of 2011.  The sale of our credit card loan portfolio to TCM Bank was completed to not only decrease risk exposure and compliance burdens, but also to continue offering our customers a valuable service with many additional features and benefits in an evolving competitive marketplace.

Noninterest income for the nine months ended September 30, 2012 was $8.0 million, an increase of $1.3 million or 19.2% over the same period of 2011.  Service charges and fees on deposit accounts decreased $251 thousand, or 9.6% in the first nine months of 2012, which was primarily attributable to a decrease in non-sufficient funds (“NSF”) fees.  Other operating income decreased $191 thousand, or 20.0% in the first nine months of 2012, which was driven by lower rental income on OREO properties, lower earnings from our subsidiary EVB Financial Services, Inc. (Investment, Mortgage) and increased write downs of our investments in community and housing development funds.  Net gains on the sale of available for sale securities increased $1.7 million to $3.5 million for the nine months ended September 30, 2012, up from $1.8 million for the same period of 2011.  As mentioned in the quarterly analysis above, the first nine months of 2012 include a $197 thousand gain on the sale of our credit card loan portfolio.  In addition to the aforementioned items, the nine months ended September 30, 2011 included a $256 thousand gain on the sale of our former Aylett branch office, which was not present during the same period of 2012.

Noninterest expense for the three months ended September 30, 2012 was $8.5 million, a decrease of $849 thousand or 9.0% over noninterest expense of $9.4 million for the three months ended September 30, 2011.  FDIC insurance expense decreased $204 thousand, or 25.8% in the third quarter of 2012, due to modifications of the risk-based assessment system and the base assessment rates beginning in the second quarter of 2011.  Expenses related to collection, repossession and OREO decreased $164 thousand, or 46.3% in the third quarter of 2012 primarily due to the overall decrease in the carrying balance of OREO and the Company’s efforts to focus resources internally to more efficiently manage collection and repossession activities.  Other operating expenses increased $220 thousand, or 13.8% in the third quarter of 2012, primarily due to an increase of $190 thousand or 487.2% in consultant fees.  For the third quarter of 2012, noninterest expense includes $769 thousand in impairment losses related to valuation adjustments on OREO compared to $974 thousand for the same period in 2011.  In addition, noninterest expense for the three months ended September 30, 2012 includes gains on the sale of OREO of $12 thousand compared to losses of $362 thousand for the same period of 2011.

Noninterest expense for the nine months ended September 30, 2012 was $25.2 million, a decrease of $1.8 million or 6.6% over noninterest expense of $27.0 million for the nine months ended September 30, 2011.  FDIC insurance expense decreased $457 thousand, or 20.6% in the nine months ended September 30, 2012 due to the items described in the quarterly analysis above.  Expenses related to collection, repossession and OREO decreased $529 thousand, or 38.5% in the nine months ended September 30, 2012 due to the items described in the quarterly analysis above.  For the nine months ended September 30, 2012, noninterest expense includes $1.7 million in impairment losses related to valuation adjustments on OREO compared to $1.2 million for the same period in 2011.  In addition, noninterest expense for the nine months ended September 30, 2012 includes losses on the sale of OREO of $105 thousand compared to $657 thousand for the same period of 2011.

Balance Sheet and Asset Quality

Total assets decreased $14.7 million or 1.4% between September 30, 2011 and September 30, 2012, and are down $8.7 million from June 30, 2012.  Between September 30, 2011 and September 30, 2012, investment securities increased $30.4 million or 14.1% to $246.1 million, and are down $8.6 million from June 30, 2012.  Loans, net of unearned income decreased $40.9 million or 5.5% from September 30, 2011 to $703.2 million at September 30, 2012, and are down $11.7 million from $714.8 million as of June 30, 2012.  Total deposits decreased $22.3 million or 2.7% from September 30, 2011 to $819.3 million at September 30, 2012, and are down $12.8 million from $832.1 million as of June 30, 2012.  Year to date average investment securities were $249.5 million as of September 30, 2012, an increase of $33.8 million or 15.7% compared to the same period in 2011.  Year to date average loans were $720.4 million as of September 30, 2012, a decrease of $41.2 million or 5.4% compared to the same period in 2011.  Year to date average total deposits were $831.0 million as of September 30, 2012, a decrease of $17.1 million or 2.0% compared to the same period in 2011.

The asset quality measures depicted below continue to reflect the Company’s efforts to prudently charge-off loans and maintain an appropriate allowance for potential future loan losses.

The following table depicts the net charge-off activity for the three and nine months ended September 30, 2012 and 2011.

Three months ended

Nine months ended

(dollars in thousands)

September 30,

September 30,

2012

2011

2012

2011

Net charge-offs

$ 1,387

$ 2,729

$ 6,782

$ 4,764

Net charge-offs to average loans

0.77%

1.44%

1.26%

0.84%

The following table depicts the level of the allowance for loan losses for the periods presented.

(dollars in thousands)

September 30,

December 31,

September 30,

2012

2011

2011

Allowance for loan losses

$        22,103

$       24,102

$        25,674

Allowance for loan losses to period end loans

3.14%

3.28%

3.45%

Allowance for loan losses to nonaccrual loans

205.15%

79.56%

98.14%

Allowance for loan losses to nonperforming loans

172.37%

79.12%

96.53%

The following table depicts the level of nonperforming assets for the periods presented.

(dollars in thousands)

September 30,

December 31,

September 30,

2012

2011

2011

Nonaccrual loans

$        10,774

$       30,293

$        26,162

Loans past due 90 days and accruing interest

2,049

168

435

Total nonperforming loans

$        12,823

$       30,461

$        26,597

Other real estate owned (“OREO”)

6,577

7,326

7,768

Total nonperforming assets

$        19,400

$       37,787

$        34,365

Nonperforming assets to total loans and OREO

2.73%

5.09%

4.57%

The following tables present the change in the balances of OREO and nonaccrual loans for the nine months ended September 30, 2012.

OREO:

Nonaccrual Loans:

(dollars in thousands)

(dollars in thousands)

Balance at December 31, 2011

$ 7,326

Balance at December 31, 2011

$ 30,293

Transfers from loans

4,708

Loans returned to accrual status

(7,951)

Capitalized costs

Net principal curtailments

(8,689)

Sales proceeds

(3,676)

Charge-offs

(6,692)

Impairment losses on valuation adjustments

(1,676)

Loan collateral moved to OREO

(4,708)

Loss on disposition

(105)

Loans placed on nonaccrual during period

8,521

Balance at September 30, 2012

$ 6,577

Balance at September 30, 2012

$ 10,774

In general, the modification or restructuring of a loan constitutes a troubled debt restructuring (“TDR”) when we grant a concession to a borrower experiencing financial difficulty.  The following table depicts the balances of TDRs for the periods presented.

September 30,

December 31,

September 30,

(dollars in thousands)

2012

2011

2011

Performing TDRs

$          4,483

$         5,517

$          4,917

Nonperforming TDRs*

7,301

13,378

12,417

Total TDRs

$        11,784

$       18,895

$        17,334

*

Included in nonaccrual loans.  At September 30, 2012, $693 thousand is included in past due 90 days and accruing interest.

Forward-Looking Statements

Certain statements contained in this release that are not historical facts may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  In addition, certain statements may be contained in the Company’s future filings with the SEC, in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements within the meaning of the Act.  Examples of forward-looking statements include, but are not limited to: (i) projections of revenues, expenses, income or loss, earnings or loss per share, the payment or nonpayment of dividends, capital structure and other financial items; (ii) statements of plans, objectives and expectations of the Company or its management or Board of Directors, including those relating to products or services, the performance or disposition of portions of the Company’s asset portfolio, the payment of dividends or the ability to realize deferred tax assets; (iii) statements of future economic performance; (iv) statements regarding the impact of the Written Agreement on our financial condition, operations and capital strategies, including strategies related to payment of dividends on the Company’s outstanding common and preferred stock and to payment of interest on the Company’s outstanding Junior Subordinated Debentures related to the Company’s trust preferred debt; (v) statements regarding the adequacy of the allowance for loan losses; (vi) statements regarding the effect of future sales of investment securities or foreclosed properties; (vii) statements regarding the Company’s liquidity; (viii) statements of management’s expectations regarding future trends in interest rates, real estate values, and economic conditions generally and in the Company’s markets; (ix) statements regarding future asset quality, including expected levels of charge-offs; (x) statements regarding potential changes to laws, regulations or administrative guidance; and (xi) statements of assumptions underlying such statements.  Words such as “believes,” “anticipates,” “expects,” “intends,” “targeted,” “continue,” “remain,” “will,” “should,” “may” and other similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those in such statements.  Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

  • our ability and efforts to assess, manage and improve our asset quality;
  • the strength of the economy in our target market area, as well as general economic, market, political or business factors;
  • changes in the quality or composition of our loan or investment portfolios, including adverse developments in borrower industries, decline in real estate values in our markets, or in the repayment ability of individual borrowers or issuers;
  • the effects of our adjustments to the composition of our investment portfolio;
  • the impact of government intervention in the banking business;
  • an insufficient allowance for loan losses;
  • our ability to meet the capital expectations of our regulatory agencies;
  • changes in laws, regulations and the policies of federal or state regulators and agencies;
  • adverse reactions in financial markets related to the budget deficit of the United States government;
  • changes in the interest rates affecting our deposits and our loans;
  • the loss of any of our key employees;
  • changes in our competitive position, competitive actions by other financial institutions and the competitive nature of the financial services industry and our ability to compete effectively against other financial institutions in our banking markets;
  • our potential growth, including our entrance or expansion into new markets, the opportunities that may be presented to and pursued by us and the need for sufficient capital to support that growth;
  • changes in government monetary policy, interest rates, deposit flow, the cost of funds, and demand for loan products and financial services;
  • our ability to maintain internal control over financial reporting;
  • our ability to raise capital as needed by our business;
  • our reliance on secondary sources, such as Federal Home Loan Bank advances, sales of securities and loans, federal funds lines of credit from correspondent banks and out-of-market time deposits, to meet our liquidity needs;
  • our ability to comply with the Written Agreement, which requires us to designate a significant amount of resources to complying with the agreement and may have a material adverse effect on our operations and the value of our securities;
  • possible changes to our Board of Directors, including in connection with deferred dividends on our Capital Purchase Program preferred stock; and
  • other circumstances, many of which are beyond our control.

Although the Company believes that its expectations with respect to the forward-looking statements are based upon reliable assumptions and projections within the bounds of its knowledge of its business and operations, there can be no assurance that actual results, performance, actions or achievements of the Company will not differ materially from any future results, performance, actions or achievements expressed or implied by such forward-looking statements.  Readers should not place undue reliance on such statements, which speak only as of the date of this report.  The Company does not undertake any steps to update any forward-looking statement that may be made from time to time by it or on its behalf.

Contact: Adam Sothen
Chief Financial Officer
Voice: (804) 443-8404
Fax: (804) 445-1047

Selected Financial Information

Three months ended

Nine months ended

(dollars in thousands, except per share data)

September 30,

September 30,

Statement of Operations

2012

2011

2012

2011

Interest and dividend income

$    11,229

$    12,197

$    34,059

$    37,755

Interest expense

2,822

3,596

8,911

11,289

Net interest income

8,407

8,601

25,148

26,466

Provision for loan losses

625

1,650

4,783

5,150

Net interest income after provision for loan losses

7,782

6,951

20,365

21,316

Service charges and fees on deposit accounts

815

845

2,374

2,625

Other operating income

275

292

762

953

Debit/credit card fees

463

370

1,143

1,103

Gain on sale of available for sale securities, net

135

1,429

3,498

1,751

(Loss) gain on sale of bank premises and equipment

(1)

2

(1)

258

Gain on sale of loans

197

197

Noninterest income

1,884

2,938

7,973

6,690

Salaries and employee benefits

3,910

4,020

11,624

12,132

Occupancy and equipment

1,273

1,285

3,784

3,917

FDIC expense

586

790

1,761

2,218

Collection, repossession and other real estate owned

190

354

845

1,374

(Gain) loss on sale of other real estate owned

(12)

362

105

657

Impairment losses on other real estate owned

769

974

1,676

1,203

Other operating expenses

1,820

1,600

5,416

5,493

Noninterest expenses

8,536

9,385

25,211

26,994

Income before income taxes

1,130

504

3,127

1,012

Income tax expense (benefit)

269

15

604

(174)

Net income

$         861

$         489

$      2,523

$      1,186

Less: Effective dividend on preferred stock

375

374

1,125

1,122

Net income available to common shareholders

$         486

$         115

$      1,398

$           64

Income per common share: basic and diluted

$        0.08

$        0.02

$        0.23

$        0.01

Selected Ratios

Return on average assets

0.18%

0.04%

0.18%

0.01%

Return on average common equity

2.62%

0.63%

2.56%

0.12%

Net interest margin (tax equivalent basis)

3.36%

3.45%

3.39%

3.56%

Period End Balances

Loans, net of unearned income

$  703,156

$  744,104

$  703,156

$  744,104

Total assets

1,057,770

1,072,501

1,057,770

1,072,501

Total deposits

819,289

841,629

819,289

841,629

Total borrowings

133,332

129,972

133,332

129,972

Total capital

97,817

96,708

97,817

96,708

Shareholders’ equity

73,817

72,708

73,817

72,708

Book value per common share

12.24

12.12

12.24

12.12

Average Balances

Loans, net of unearned income

$  713,125

$  749,869

$  720,362

$  761,525

Total earning assets

995,291

998,822

998,104

1,006,070

Total assets

1,063,135

1,068,892

1,066,258

1,079,416

Total deposits

825,216

838,096

831,007

848,095

Total borrowings

133,030

130,225

131,560

133,052

Total capital

97,956

96,392

97,007

94,040

Shareholders’ equity

73,956

72,392

73,007

70,040

Asset Quality at Period End

Allowance for loan losses

$    22,103

$    25,674

$    22,103

$    25,674

Nonperforming assets

19,400

34,365

19,400

34,365

Net charge-offs

1,387

2,729

6,782

4,764

Net charge-offs to average loans

0.77%

1.44%

1.26%

0.84%

Allowance for loan losses to period end loans

3.14%

3.45%

3.14%

3.45%

Allowance for loan losses to nonaccrual loans

205.15%

98.14%

205.15%

98.14%

Nonperforming assets to total assets

1.83%

3.20%

1.83%

3.20%

Nonperforming assets to total loans and other real estate owned

2.73%

4.57%

2.73%

4.57%

Other Information

Number of shares outstanding – period end

6,069,551

6,016,292

6,069,551

6,016,292

Average shares outstanding – basic

6,069,483

6,012,926

6,044,730

6,003,280

Average shares outstanding – diluted

6,069,483

6,012,926

6,044,730

6,003,280

Friday, October 19th, 2012 Uncategorized Comments Off on Eastern Virginia Bankshares (EVBS) Announces Third Quarter 2012 Results

RADCOM (RDCM) Receives Credit Facility

TEL AVIV, Israel, October 19, 2012 /PRNewswire/ —

RADCOM Ltd. (NASDAQ: RDCM), a leading service assurance provider, today announced that it has received a credit facility from the First International Bank of Israel in an amount of US$ 1.5 million. The facility has an initial 6 month term, and may be renewed for additional periods based on compliance with certain covenants. The facility carries interest rates varying between Libor + 3.25%-4% for USD denominated advances and Prime + 1-2% for NIS denominated advances, and is secured by a floating charge on all of Radcom’s assets.

The company will use the proceeds of the facility mainly in order to finance its ongoing operations and working capital needs.

“Due to the current high working capital needs of our business associated with our sales mix shift to multi-million dollar Tier-1 deals, this credit facility is an efficient way for RADCOM to access cash, from time to time, as we work through our strong backlog,” said Gilad Yehudai, CFO of RADCOM. “We look forward to a fruitful long-term partnership with the First International Bank of Israel.”

About RADCOM

RADCOM develops, manufactures, markets and supports innovative network test and service monitoring solutions for communications service providers and equipment vendors. The Company specializes in next-generation Cellular as well as IMS, Voice, Data and VoIP networks. Its solutions are used in the development and installation of network equipment and in the maintenance of operational networks. The Company’s products facilitate fault management, network service performance monitoring and analysis, troubleshooting and pre-mediation. RADCOM’s shares are listed on the NASDAQ Capital Market under the symbol RDCM. For more information, please visit http://www.RADCOM.com.

Risks Regarding Forward-Looking Statements

Certain statements made herein that use the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results, performance or achievements of RADCOM to be materially different from those that may be expressed or implied by such statements, including, among others, changes in general economic and business conditions and specifically, decline in the demand for RADCOM’s products, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on prices resulting from competition. For additional information regarding these and other risks and uncertainties associated with RADCOM’s business, reference is made to RADCOM’s reports filed from time to time with the United States Securities and Exchange Commission. RADCOM does not undertake to revise or update any forward-looking statements for any reason.

Contact:
Gilad Yehudai
CFO
+972-77-774-5060
gilady@radcom.com

Friday, October 19th, 2012 Uncategorized Comments Off on RADCOM (RDCM) Receives Credit Facility

A123 (AONE) Receives Court Approval of “First Day” Motions to Support Business

Obtains Interim Approval to Access $15.5 Million of DIP Financing from Johnson Controls Company Authorized to Continue Payment of Employee Wages, Salaries and Benefits

WALTHAM, Mass., Oct. 19, 2012 /PRNewswire/ — A123 Systems, Inc. (Nasdaq: AONE) (“A123” or “the Company”), a developer and manufacturer of advanced Nanophosphate® lithium iron phosphate batteries and systems, today announced that yesterday the United States Bankruptcy Court for the District of Delaware (the “Court”) granted the Company’s request for certain “first day” orders that help support its business.

The Court granted A123 interim approval to use $15.5 million of its $72.5 million Debtor-in Possession (“DIP”) financing from Johnson Controls, Inc. (NYSE: JCI) (“Johnson Controls”) to support the Company’s operations throughout the transaction process. A court hearing for final approval of the DIP has been scheduled for October 30, 2012. The Company also received approval to, among other things, continue paying employee wages, salaries, benefits and other employee obligations.

As previously announced, A123 entered an asset purchase agreement with Johnson Controls, in which Johnson Controls expects to acquire A123’s automotive business assets.  A123 also continues to engage in active discussions regarding strategic alternatives for its grid, commercial, government and other operations, and has received several indications of interest for these businesses. To facilitate the transaction process, A123 and all of its U.S. subsidiaries filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The Company’s subsidiaries located outside the U.S. were not included in the filings.

Additional information, including the terms of the Company’s updated DIP agreement with Johnson Controls, which is expected to be filed shortly, is available on A123’s website at www.a123systems.com or by calling A123’s Restructuring Hotline, toll-free in the U.S., at 1-800-224-7654. For calls originating outside the U.S., please dial +1 973-509-3190. Court documents and additional information can be found at a dedicated website administrated by the Company’s Claims Agent, Logan & Company: www.loganandco.com.

Latham & Watkins LLP and Richards, Layton & Finger are serving as legal advisors, Lazard is serving as financial advisor, and Alvarez & Marsal is serving as restructuring advisor to A123.

About A123 Systems

A123 Systems, Inc. (Nasdaq: AONE) is a leading developer and manufacturer of advanced lithium-ion batteries and energy storage systems for transportation, electric grid and commercial applications. The company’s proprietary Nanophosphate® lithium iron phosphate technology is built on novel nanoscale materials initially developed at the Massachusetts Institute of Technology and is designed to deliver high power and energy density, increased safety and extended life. A123 leverages breakthrough technology, high-quality manufacturing and expert systems integration capabilities to deliver innovative solutions that enable customers to bring next-generation products to market. For additional information please visit www.a123systems.com.

Safe Harbor Disclosure

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are subject to risks, uncertainties and other important factors, including statements with respect to the expected benefits of A123’s proposed asset sale and financing transactions with Johnson Controls, the potential of the transactions and Chapter 11 filing to create value for A123 and its stakeholders, the satisfaction of conditions to closing of the transactions, the anticipated growth of the market for energy efficient vehicles, the expectation that a Chapter 11 filing will enable A123 to sell its automotive and other assets in an orderly manner and maximize value to its stakeholders, and the necessity of bankruptcy court and other approvals, including antitrust and other regulatory approvals, to conduct and complete the transactions and other potential asset sales. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: failure to obtain required bankruptcy court and other approvals, failure to satisfy the conditions to closing of the transactions, delays in the development of A123’s products, adverse economic conditions in general and adverse economic conditions specifically affecting the markets in which A123 and Johnson Controls operate, and other risks detailed in A123 Systems’ quarterly report on Form 10-Q for the quarter ended June 30, 2012 and other publicly available filings with the Securities and Exchange Commission. All forward-looking statements reflect A123’s expectations only as of the date of this release and should not be relied upon as reflecting A123’s views, expectations or beliefs at any date subsequent to the date of this release.

Friday, October 19th, 2012 Uncategorized Comments Off on A123 (AONE) Receives Court Approval of “First Day” Motions to Support Business

Rambus (RMBS) Reports Third Quarter Financial Results

Revenue of $57.5 million; GAAP net loss of $0.52 a share; Non-GAAP net income of $0.08 per share

Rambus Inc. (NASDAQ:RMBS), one of the world’s premier technology licensing companies, today reported financial results for the third quarter ended September 30, 2012.

GAAP Financial Results:

Revenue for the third quarter of 2012 was $57.5 million, up 2% sequentially from the second quarter of 2012. This quarter-over-quarter increase was primarily due to recognition of one-time royalty revenue during the third quarter of 2012 from patent license agreement with Fujitsu. As compared to the third quarter of 2011, revenue was down 43% primarily due to recognition of one-time royalty revenue during the third quarter of 2011 from patent license agreements signed in the second and third quarter of 2011, lower royalties reported by certain licensees and a decrease in contract revenue. The decreased revenue for the third quarter of 2012 as compared to the prior year period was partially offset by revenue recognized from various new patent license agreements signed in 2012.

Revenue for the nine months ended September 30, 2012 was $176.6 million, down 23% from the same period last year, for the same reasons as discussed above.

Total operating costs and expenses for the third quarter of 2012 were $104.6 million, which included $2.6 million of general litigation expenses, $5.1 million of stock-based compensation expenses, $6.6 million of restructuring charges, $35.5 million of impairment of goodwill and long-lived assets, $8.0 million of amortization expenses and $4.4 million of retention bonuses from past business acquisitions. This is compared to total operating costs and expenses for the second quarter of 2012 of $78.0 million, which included general litigation expenses of $4.5 million, $6.2 million of stock-based compensation expenses, $7.9 million of amortization expenses and $7.7 million of acquisition-related deal costs and retention bonuses from past business acquisitions. Total operating costs and expenses for the third quarter of 2011 were $89.5 million, which included general litigation expenses of $23.5 million, $7.2 million of stock-based compensation expenses, $6.9 million of amortization expenses and $7.7 million of acquisition-related deal costs and retention bonuses from past business acquisitions.

Total operating costs and expenses for the nine months ended September 30, 2012 were $263.0 million, which included $11.2 million of general litigation expenses, $18.0 million of stock-based compensation expenses, $6.6 million of restructuring charges, $35.5 million of impairment of goodwill and long-lived assets, $23.5 million of amortization expenses and $21.5 million of acquisition-related deal costs and retention bonuses from past business acquisitions. This is compared to total operating costs and expenses for the nine months ended September 30, 2011 of $212.4 million, which included a $6.2 million gain related to the Samsung settlement, $44.2 million of general litigation expenses, $21.5 million of stock-based compensation expenses, $12.9 million of amortization expenses and $14.0 million of acquisition-related deal costs and retention bonuses from past business acquisitions. The change in total operating costs and expenses was primarily attributable to the impairment of goodwill and long-lived assets and restructuring charge taken during the third quarter of 2012, higher acquisition-related deal costs, retention bonuses and amortization expenses for business acquisitions, a lack of any gain from settlement, partially offset by lower general litigation expenses.

Net loss for the third quarter of 2012 was $58.1 million as compared to net loss of $32.2 million in the second quarter of 2012 and net income of $0.5 million in the third quarter of 2011. Diluted net loss per share for the third quarter of 2012 was $0.52 as compared to diluted net loss per share of $0.29 in the second quarter of 2012 and diluted net income per share of $0.00 in the third quarter of 2011.

Net loss for the nine months ended September 30, 2012 was $118.2 million as compared to a net loss of $14.3 million for the same period of 2011. Diluted net loss per share for the nine months ended September 30, 2012 was $1.07 as compared to a diluted net loss per share of $0.13 for the same period of 2011.

The Company updated the amount of the pre-tax charge it expects to record in the third quarter of 2012 in relation to its restructuring program announced on August 22, 2012. The charge is primarily driven by the reduction of overall corporate expenses which is expected to improve future profitability while refining some of the Company’s research and development efforts. The Company recorded a pre-tax charge of approximately $6.6 million during the third quarter of 2012 related primarily to the reduction in workforce, which included approximately $1.8 million in early termination payments to certain employees related to their previous retention bonus arrangements.

Additionally, the Company recorded a non-cash charge for the impairment of goodwill and long-lived assets within its Lighting and Display Technology division of approximately $35.5 million in the third quarter of 2012. The Company conducted this impairment review under the accounting rules as a result of the change in business strategy with less focus on display technology licensing and an increased focus on its general lighting technologies. Under generally accepted accounting principles, when indicators of potential impairment are identified, companies are required to conduct a review of the carrying amounts of goodwill and other long-lived assets to determine if impairment exists.

Non-GAAP Financial Results (1):

Customer licensing income in the third quarter of 2012 was $62.4 million, up 9% sequentially from the second quarter of 2012 for the reasons set out in the Company’s discussion of GAAP financial results above. As compared to the third quarter of 2011, customer licensing income was down 32% due to several factors, including recognition of one-time royalty revenue during the third quarter of 2011 from patent license agreements signed in the second and third quarter of 2011, lower royalties reported by certain licensees and the absence of new development contracts. This decline was partially offset by revenue recognized from various new patent license agreements signed in 2012. Customer licensing income for the nine months ended September 30, 2012 was $185.1 million as compared to $233.3 million in the same period of 2011 for the same reasons.

Total non-GAAP operating costs and expenses in the third quarter of 2012 were $45.0 million, which included general litigation expenses of $2.6 million. This is compared to total non-GAAP operating costs and expenses for the second quarter of 2012 of $56.0 million, which included general litigation expenses of $4.5 million. Total non-GAAP operating costs and expenses in the third quarter of 2011 were $66.8 million, which included general litigation expenses of $23.5 million. Non-GAAP operating costs and expenses for the nine months ended September 30, 2012 were $157.7 million as compared to $167.4 million in the same period of 2011 due primarily to lower litigation expenses, partially offset by higher headcount related costs from the increase in employee headcount attributable to business acquisitions and higher consulting costs.

Non-GAAP net income in the third quarter of 2012 was $9.0 million as compared to non-GAAP net loss of $1.1 million in the second quarter of 2012 and non-GAAP net income of $14.0 million in the third quarter of 2011. Non-GAAP diluted net income per share was $0.08 in the third quarter of 2012 as compared to non-GAAP diluted net loss per share of $0.01 in the second quarter of 2012 and non-GAAP net income of $0.12 in the third quarter of 2011. Non-GAAP net income for the nine months ended September 30, 2012 was $11.5 million as compared to $36.6 million in the same period of 2011. Non-GAAP diluted net income per share was $0.10 for the nine months ended September 30, 2012 as compared to non-GAAP diluted net income per share of $0.33 for the nine months ended September 30, 2011.

Other Financial Highlights:

Cash, cash equivalents, and marketable securities as of September 30, 2012 were $207.1 million, an increase of approximately $3.9 million from June 30, 2012 as a result of positive cash flows provided from operating activities.

During the third quarter of 2012, the Company recorded an income tax provision of approximately $3.9 million. As the Company continues to maintain a full valuation allowance against its U.S. deferred tax assets, the Company’s tax provision consists of primarily foreign withholding taxes, current state taxes and foreign taxes.

The Company will host a conference call at 2:00 p.m. PT today to discuss its financial results. The call, audio and slides will be available online at http://investor.rambus.com/events.cfm. A replay will be available following the call on Rambus’ Investor Relations website for one week at the following numbers: (855) 859-2056 (domestic) or (404) 537-3406 (international) with ID# 38404730.

(1) Non-GAAP Financial Information:

In the commentary set forth above and in the financial statements included in this earnings release, the Company presents the following non-GAAP financial measures: customer licensing income, operating costs and expenses, operating income (loss) and net income (loss). In computing each of these non-GAAP financial measures, the Company combined revenue, other patent royalties received but not recognized as revenue and gain from settlement, and excluded charges or gains relating to: stock-based compensation expenses, acquisition-related deal costs and retention bonus expense, amortization expenses, costs of restatement and related legal activities, restructuring charges, impairment charges and non-cash interest expense. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Management believes the non-GAAP financial measures are appropriate for both its own assessment of, and to show investors, how the Company’s performance compares to other periods. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Reconciliation from GAAP to non-GAAP results is included in the financial statements contained in this release.

The Company’s non-GAAP financial measures reflect adjustments based on the following items:

Customer licensing income. Customer licensing income includes the Company’s measure of the total cash royalties received from its customers under its licensing agreements with them. Prior to the second quarter of 2011, the Company bifurcated royalty payments that it received from Samsung between revenue and gain from settlement, which was reflected as reducing operating expenses. The Company has combined revenue from its customers, including Samsung, and the gain from the Samsung settlement as customer licensing income to reflect the total amounts received from all of its customers for the periods presented. In addition, customer licensing income includes other patent royalties received but not recognized as revenue. In the second quarter of 2011, a one-time receipt of a patent royalty payment from a customer was not recognized as revenue as not all revenue recognition criteria were met during the period. Upon meeting all of the revenue recognition criteria, the Company recognized this cash payment as revenue in the third quarter of 2011. In the third quarter of 2012, a receipt of a patent royalty payment from a customer was not recognized as revenue as not all revenue recognition criteria were met during the period. Additionally, since the third quarter of 2011, the Company received patent royalty payments from certain patent license agreements assumed in the acquisition of CRI which were treated as favorable contracts. Cash received from these acquired favorable contracts reduced the favorable contract intangible asset on the Company’s balance sheet. The Company has combined these cash royalty payments as customer licensing income to reflect the total amounts received from its customers.

Stock-based compensation expense. These expenses consist primarily of expenses related to employee stock options, employee stock purchase plans, and employee non-vested equity stock and non-vested stock units. The Company excludes stock-based compensation expense from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results. Additionally, given the fact that other companies may grant different amounts and types of equity awards and may use different option valuation assumptions, excluding stock-based compensation expense permits more accurate comparisons of the Company’s results with other peer companies.

Acquisition-related deal costs and retention bonus expense. These expenses include all direct costs of certain acquisitions and the current periods’ portion of any retention bonus expense associated with the acquisitions. The Company excludes these expenses in order to provide better comparability between periods.

Restructuring charges. These charges may consist of severance, contractual retention payments, exit costs and other charges and are excluded because such charges are not directly related to ongoing business results and do not reflect expected future operating expenses.

Impairment of goodwill and long-lived assets. These charges consist of non-cash charges to goodwill and long-lived assets and are excluded because such charges are non-recurring and do not reduce the Company’s liquidity.

Amortization expense. The Company incurs expenses for the amortization of intangible assets in connection with acquisitions. The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred. These amounts arise from the Company’s prior acquisitions and have no direct correlation to the core operation of the Company’s business.

Costs of restatement and related legal activities. These expenses consist primarily of investigation, audit, legal and other professional fees related to the 2006-2007 stock option investigation and related litigation, as well as recoveries received from third parties. The Company excludes these costs and recoveries from its non-GAAP measures primarily because the Company believes that these non-recurring costs and recoveries have no direct correlation to the core operation of the Company’s business.

Non-cash interest expense. The Company incurs non-cash interest expense related to its convertible notes. The Company excludes non-cash interest expense related to its convertible notes to provide more accurate comparisons of the Company’s results with other peer companies and to more accurately reflect the Company’s ongoing operations.

Income tax adjustments. For purposes of internal forecasting, planning and analyzing future periods that assumes net income from operations, the Company estimates a fixed, long-term projected tax rate of approximately 36 percent. Accordingly, the Company has applied the 36 percent tax rate to its non-GAAP financial results to assist the Company’s planning for future periods.

On occasion in the future, there may be other items, such as significant gains or losses from contingencies that the Company may exclude in deriving its non-GAAP financial measures if it believes that doing so is consistent with the goal of providing useful information to investors and management.

About Rambus Inc.:

Rambus is one of the world’s premier technology licensing companies. As a company of inventors, Rambus focuses on the development of technologies that enrich the end-user experience of electronic systems. Additional information is available at www.rambus.com.

RMBSFN

Rambus Inc.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

September 30,2012 December 31,2011
ASSETS
Current assets:
Cash and cash equivalents $ 152,206 $ 162,244
Marketable securities 54,880 127,212
Accounts receivable 452 1,026
Prepaids and other current assets 9,759 8,096
Deferred taxes 1,807 2,798
Total current assets 219,104 301,376
Intangible assets, net 160,408 181,955
Goodwill 124,969 115,148
Property, plant and equipment, net 84,255 81,105
Deferred taxes, long-term 7,575 7,531
Other assets 5,514 6,539
Total assets $ 601,825 $ 693,654
LIABILITIES & STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 7,841 $ 16,567
Accrued salaries and benefits 29,785 31,763
Accrued litigation expenses 10,035 10,502
Other accrued liabilities 13,448 6,479
Total current liabilities 61,109 65,311
Long-term liabilities:
Convertible notes, long-term 143,875 133,493
Long-term imputed financing obligation 45,878 43,793
Other long-term liabilities 20,137 21,263
Total long-term liabilities 209,890 198,549
Total stockholders’ equity 330,826 429,794
Total liabilities and stockholders’ equity $ 601,825 $ 693,654
Rambus Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2012 2011 2012 2011
Revenue:
Royalties $ 57,361 $ 96,216 $ 175,127 $ 216,421
Contract revenue 169 4,047 1,481 12,583
Total revenue 57,530 100,263 176,608 229,004
Operating costs and expenses:
Cost of revenue (1) 7,529 7,425 22,032 16,632
Research and development (1) 30,674 32,318 107,415 79,855
Marketing, general and administrative (1) 24,255 48,952 91,283 119,416
Restructuring charges 6,622 6,622
Impairment of goodwill and long-lived assets 35,471 35,471
Costs of restatement and related legal activities 79 832 192 2,703
Gain from settlement (6,200 )
Total operating costs and expenses 104,630 89,527 263,015 212,406
Operating income (loss) (47,100 ) 10,736 (86,407 ) 16,598
Interest and other income (expense), net (12 ) 172 175 471
Interest expense (7,121 ) (6,350 ) (20,420 ) (18,462 )
Interest and other expense, net (7,133 ) (6,178 ) (20,245 ) (17,991 )
Income (loss) before income taxes (54,233 ) 4,558 (106,652 ) (1,393 )
Provision for income taxes 3,865 4,080 11,552 12,944
Net income (loss) $ (58,098 ) $ 478 $ (118,204 ) $ (14,337 )
Net income (loss) per share:
Basic $ (0.52 ) $ 0.00 $ (1.07 ) $ (0.13 )
Diluted $ (0.52 ) $ 0.00 $ (1.07 ) $ (0.13 )
Weighted average shares used in per share calculation
Basic 110,826 112,334 110,580 109,997
Diluted 110,826 115,552 110,580 109,997
_________

(1) Total stock-based compensation expense for the three and nine month periods ended September 30, 2012 and September 30, 2011 are presented as follows:

Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2012 2011 2012 2011
Cost of revenue $ 5 $ 90 $ 20 $ 499
Research and development $ 2,221 $ 2,775 $ 7,572 $ 7,777
Marketing, general and administrative $ 2,863 $ 4,354 $ 10,438 $ 13,262
Rambus Inc.

Supplemental Reconciliation of GAAP to Non-GAAP Results

(In thousands)

(Unaudited)

Three Months Ended Nine Months Ended
September 30,
2012
June 30,
2012
September 30,
2011
September 30,
2012
September 30,
2011
Revenue $ 57,530 $ 56,215 $ 100,263 $ 176,608 $ 229,004
Adjustments:
Gain from settlement 6,200
Other patent royalties received 4,875 1,201 (8,625 ) 8,490 (1,875 )
Total customer licensing income $ 62,405 $ 57,416 $ 91,638 $ 185,098 $ 233,329
Operating costs and expenses $ 104,630 $ 77,964 $ 89,527 $ 263,015 $ 212,406
Adjustments:
Stock-based compensation (5,089 ) (6,215 ) (7,219 ) (18,030 ) (21,538 )
Acquisition-related deal costs and retention bonuses (4,437 ) (7,699 ) (7,702 ) (21,487 ) (14,037 )
Amortization (7,977 ) (7,943 ) (6,927 ) (23,536 ) (12,909 )
Restructuring charges (6,622 ) (6,622 )
Impairment of goodwill and long-lived assets (35,471 ) (35,471 )
Costs of restatement and related legal activities (79 ) (83 ) (832 ) (192 ) (2,703 )
Gain from settlement 6,200
Non-GAAP operating costs and expenses $ 44,955 $ 56,024 $ 66,847 $ 157,677 $ 167,419
Operating income (loss) $ (47,100 ) $ (21,749 ) $ 10,736 $ (86,407 ) $ 16,598
Adjustments:
Other patent royalties received 4,875 1,201 (8,625 ) 8,490 (1,875 )
Stock-based compensation 5,089 6,215 7,219 18,030 21,538
Acquisition-related deal costs and retention bonuses 4,437 7,699 7,702 21,487 14,037
Amortization 7,977 7,943 6,927 23,536 12,909
Restructuring charges 6,622 6,622
Impairment of goodwill and long-lived assets 35,471 35,471
Costs of restatement and related legal activities 79 83 832 192 2,703
Non-GAAP operating income $ 17,450 $ 1,392 $ 24,791 $ 27,421 $ 65,910
Income (loss) before income taxes $ (54,233 ) $ (28,379 ) $ 4,558 $ (106,652 ) $ (1,393 )
Adjustments:
Other patent royalties received 4,875 1,201 (8,625 ) 8,490 (1,875 )
Stock-based compensation 5,089 6,215 7,219 18,030 21,538
Acquisition-related deal costs and retention bonuses 4,437 7,699 7,702 21,487 14,037
Amortization 7,977 7,943 6,927 23,536 12,909
Restructuring charges 6,622 6,622
Impairment of goodwill and long-lived assets 35,471 35,471
Costs of restatement and related legal activities 79 83 832 192 2,703
Non-cash interest expense on convertible notes 3,789 3,557 3,254 10,856 9,326
Non-GAAP income (loss) before income taxes $ 14,106 $ (1,681 ) $ 21,867 $ 18,032 $ 57,245
Non-GAAP provision for (benefit from) income taxes 5,078 (606 ) 7,872 6,491 20,618
Non-GAAP net income (loss) $ 9,028 $ (1,075 ) $ 13,995 $ 11,541 $ 36,627
Non-GAAP basic net income (loss) per share $ 0.08 $ (0.01 ) $ 0.12 $ 0.10 $ 0.33
Non-GAAP diluted net income (loss) per share $ 0.08 $ (0.01 ) $ 0.12 $ 0.10 $ 0.33
Weighted average shares used in non-GAAP per share calculation:
Basic 110,826 110,553 112,334 110,580 109,997
Diluted 117,738 110,553 115,552 117,569 112,525

Thursday, October 18th, 2012 Uncategorized Comments Off on Rambus (RMBS) Reports Third Quarter Financial Results

National Graphite (NGRC) Secures $2,500,000 Financing Commitment

LAS VEGAS, Oct. 18, 2012 /PRNewswire/ — National Graphite Corp. (OTCBB: NGRC) is pleased to announce that it has entered into an equity financing agreement for up to $2,500,000 with a private investment group.

The Company will receive up to $2,500,000 by issuing restricted common shares. The Company can draw down the financing in tranches of $250,000 each. The price of the shares being issued will be determined by a 10% discount to the average daily trading price of the company’s shares over the previous five day period.

“The Company is pleased with the financing agreement as these funds will allow us to accelerate the advancement of the Chedic Graphite Mine back into production,” stated the President of the Company.

As part of the terms of the financing, management have agreed to cancel 8,000,000 of their common shares in order to minimize dilution as a result of this transaction.

To date, National Graphite Corp. has received an aggregate amount of over $1,000,000 from the issuance of common stock to investors who are “accredited investors,” as defined under the Securities Act.

About National Graphite Corp.

National Graphite Corp. is an American based graphite development company focused on bringing the Chedic Graphite Mine back into commercial production to supply the fast growing graphite mineral market. The mineral is used in the manufacture of Lithium-ion batteries and is considered critical to U.S. industry sectors like Consumer Electronics, Green Technology and Alternative Energy. National Graphite is committed to long-term sustainable graphite production within North American.

For more information, visit our website at: nationalgraphitecorp.com. or Contact the Company at 1-702-839-4029

This information is not an offer to purchase, a solicitation of an offer to purchase or a solicitation of consent with respect to any securities. Additional details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

“Safe Harbor” Statement:

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.  Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the programs it is commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products.  Investors are encouraged to review the risk factors listed or described from time to time in the Company’s filings (10K, 10Q’s, S-1 and others) with the Securities and Exchange Commission.

Thursday, October 18th, 2012 Uncategorized Comments Off on National Graphite (NGRC) Secures $2,500,000 Financing Commitment

Prospect Global (PGRX) Cost Feasibility Study Confirms Potash Project’s Strong Economics

On track to meet 2012 goals; timing in line for bankable feasibility study in 2013

DENVER, Oct. 18, 2012 /PRNewswire/ — Prospect Global Resources Inc. (NASDAQ: PGRX) announced that a new interim engineering report shows the Company to be on track to meet key targets within previous expectations as to capital and operating expenses, infrastructure, permitting, and site plan for its American West Potash project in Holbrook, AZ.

According to the report, a cost feasibility study by the international engineering firm of Tetra Tech Inc., key capital expense elements are in line with 2012 expectations, and operating expenses are comfortably within confidence levels set by the December 2011 preliminary economic assessment.  The changes to capital expense and operating expense include more focus on potash recovery, reliability and optimization. Prospect Global believes that the bankable feasibility study in 2013 will increase resources and optimize the mine plan.

The interim report is another milestone on Prospect Global’s path to demonstrate that the Holbrook Basin project, a promising potash field in the Holbrook Basin of eastern Arizona, will be globally competitive. Another important step, the bankable feasibility study, is scheduled for the first half of 2013, in line with Company expectations.

Patrick Avery, CEO of Prospect Global, commented: “This full interim report, focusing on capital and operating expenses, is a welcome confirmation of our progress. We are meeting key technical and operational milestones to build a world class project. We also have made great advances in our site plan, permitting, and infrastructure.”

So far, the Company has hit the following operational targets:

  • Process design parameters and process flow diagrams have been set.
  • Equipment lists have been prepared and are in final vendor selection.
  • Detailed engineering has begun and drawings prepared.
  • Conducted detailed mine planning with Vulcan software on the KR-2 bed.
  • Completed 2012 drilling program on time and on budget.

This Press Release may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from projections or estimates contained herein. Factors that could cause actual results to differ materially from projections or estimates include, among others, potash prices, economic and market conditions, as well as the additional risks described in our filings with the SEC, including our Annual Report on Form 10-K for the year ended March 31, 2012 and our Prospectus dated June 29, 2012. Most of these factors are beyond our ability to predict or control. The forward looking statements are made as of today’s date and, except as required under applicable securities legislation, we do not assume any obligation to update any forward-looking statements. You are cautioned not to put undue reliance on forward-looking statements.

About Prospect Global Resources Inc.:
Prospect Global Resources Inc. is a Denver based company engaged in the exploration and development of a large, high-quality potash deposit located in the Holbrook Basin of eastern Arizona.

Thursday, October 18th, 2012 Uncategorized Comments Off on Prospect Global (PGRX) Cost Feasibility Study Confirms Potash Project’s Strong Economics

Deyu Agriculture (DEYU) Expands Board of Directors, Appoints New President

BEIJING, Oct.18, 2012 /PRNewswire-FirstCall/ — Deyu Agriculture Corp. (OTCBB: DEYU) (the “Company“), a Beijing, China based vertically integrated producer, processor, marketer and distributor of organic and other agricultural products made from corn and grains, today announced that effective October 11, 2012, the Board expanded the number of members serving on the Company’s Board from five to seven in accordance with the Company’s Bylaws, and subsequently filled the vacancies created by the expansion by appointing Mr. Greg Chen and Mr. Jan Poulsen to serve on the Board until the next following annual meeting of the stockholders of the Company, at which such directors shall be eligible for election by the stockholders.

Additionally, Mr. Chen was appointed the President of Deyu, where his responsibilities shall include assisting the Company with its international and domestic market development, enhancing the Company’s investor relations programs and the execution of those programs and assisting the Company with its corporate and operational strategies and business planning.

Also effective October 11, 2012, Mr. Longjiang Yuan resigned as a member of Deyu’s Audit Committee, and Mr. Poulsen was appointed to serve on the Audit Committee. Mr. Yuan will still serve as a Board member of the Company.

“We are excited to have Greg and Jan join our Board, and to appoint Greg as President,” said Jianming Hao, Chief Executive Officer and Chairman of Deyu. “Greg’s proven record of growing brands and companies, plus Jan’s deep experience in asset management and business development, will be instrumental to our future growth. In particular, we are looking forward to Greg and Jan assisting us with the launch of a series of investor relations programs in the near future that we are confident will help us garner more attention from the investment community and maximize shareholder value.

“We truly appreciate the support of our shareholders, and we are determined to better reward those of whom stay the course with their investments in Deyu,” continued Mr. Hao. “All of us at Deyu are optimistic about our future and our team is prepared to capitalize on the many opportunities that we see on the horizon, and with the added support of Greg and Jan, we believe now is an ideal time to increase awareness in the investment community of our growing business through extensive investor relation programs geared towards further strengthening and rewarding our shareholder base.”

Mr. Chen has over fifteen (15) years of international business strategy, development and management experience in the investment, fine arts, media, technology and manufacturing sectors. Prior to joining the Company, Mr. Chen has served as Chief Executive Officer of the P-Media Group, a company providing commercial promotion and marketing strategies and related services in China, since August 2009. From May 2007 to July 2009, Mr. Chen served as Director of China Operations for Capital Market Services Inc, a New York based financial firm, to oversee its China strategy development and operations. Prior to May 2007, Mr. Chen served as Managing Director of Titian International Inc, an international business development services firm. Mr. Chen was instrumental in the first major global Chinese contemporary art exhibition by Sotheby’s in 2006, a ground-breaking event in the international contemporary art landscape. Educated in US and China, Mr. Chen is fluent in Mandarin, has a Masters of Science degree in EE/Control-Theory.

Mr. Poulsen has over twenty (20) years of management experience working for international organizations within the food & beverage industry and from the auditing firm PricewaterhouseCoopers. Mr. Poulsen has extensive experience in a wide variety of areas including financial management, strategy and business development, M&A activities, turnaround expertise as well as technology implementations. Since August 2011, Mr. Poulsen has served as an M&A advisor for H.T. Capital, an investment bank in New York. From 2001 to August 2011, Mr. Poulsen had various management positions at Arla Foods, a global company within the dairy industry. Mr. Poulsen served as the Chief Financial Officer for Arla Foods Inc. in the USA from September 2009 to August 2011, as the Finance Manager and Business Development Manager from 2006 until August 2009, and as Project Manager for Group Finance from 2001 to 2006. Mr. Poulsen has a Masters of Science in Business Administration and an Auditing degree from Aarhus School of Business in Aarhus, Denmark, extensive leadership education from Columbia University and IMD in Switzerland. Mr. Poulsen is deemed an independent director of the Company and is deemed an “audit committee financial expert”.

About Deyu Agriculture

Deyu Agriculture Corp. is a vertically integrated producer, processor, marketer and distributor of organic and other agricultural products made from corn and grains operating in Shanxi Province of the People’s Republic of China. The Company has access to over 109,000 acres of farmland in Shanxi Province for breeding, cultivating, processing, warehousing and distributing grain and corn products. Deyu has an extensive wholesale network in over 15 provinces and a retail distribution network of approximately 20,000 supermarkets and convenience stores in 29 provinces across China. Deyu’s facilities include advanced production lines and modern warehouses with a total production capacity of over 105,000 tons for grain products, storage capacity of over 100,000 tons and annual turnover of 700,000 tons for corn products. The Company’s website is located at www.deyuagri.com.

Safe Harbor Statements

This press release contains forward-looking statements made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements are based upon the current plans, estimates and projections of Deyu’s management and are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. Such statements include, among others, those concerning market and industry segment growth and demand and acceptance of new and existing products; any projections of sales, earnings, revenue, margins or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding future economic conditions or performance; uncertainties related to conducting business in China, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. Therefore, you should not place undue reliance on these forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: business conditions in China, general economic conditions; geopolitical events and regulatory changes, availability of capital, changes in the agricultural industry, the Company’s ability to maintain its competitive position. Additional Information regarding risks can be found in the Company’s quarterly and annual reports filed with the U.S. Securities and Exchange Commission at www.sec.gov.

Investor Contact:

Mr. Kevin Fickle, President
NUWA Group LLC
Tel: +1-925-330-8315
Email: kevin@nuwagroup.com

Company Contact:

Mr. Greg CHEN, President
Deyu Agriculture Corp.
Tel: 1-646-820-8085
Email: gregchen@china-deyu.com

Ms. Amy He, Chief Financial Officer
Deyu Agriculture Corp.
Tel: +86-10-5224-1802 X389
Email: amy@china-deyu.com

Thursday, October 18th, 2012 Uncategorized Comments Off on Deyu Agriculture (DEYU) Expands Board of Directors, Appoints New President

GreeneStone (GRST) Seeks Amex Listing – New Report Confirms Demand

GreeneStone Healthcare Corporation (OTCBB: GRST) (“GreeneStone” or “the Company”) announces today that it will begin the process of applying to the New York Stock Exchange (“NYSE”) to list on the NYSE-Amex exchange. The Company’s recent performance has brought the Company to, or near to, the levels required to meet the listing requirements for the NYSE-Amex under its Standard 3 definitions. It is anticipated that the Company will meet all the requirements at the time it has completed the application process. The Company has determined that the NYSE-Amex listing will best serve the Company’s needs to attract capital to support its recently announced ‘build and buy’ expansion strategy. The ‘build and buy’ expansion strategy is designed to stay ahead of the market to take advantage of the green field opportunity in Canada and the ever growing demand in the US in the underserviced mental healthcare sector. The focus of the expansion strategy is to reach the 300 bed level in its in-patient addiction treatment business in the next twenty-four months.

A recently released report has emphasized the huge demand that the Company has identified. The report was released on October 10th, 2012 by the Institute for Clinical Evaluation Sciences (ICES) and Public Health Ontario. The report demonstrates that “the burden of mental illness and addictions in Ontario is more than 1.5 times that of all cancers and more than seven times that of all infectious diseases.” The report goes on to say “five conditions have the highest impact on the life and health of Ontarians: depression, bipolar disorder, alcohol use disorders, social phobia and schizophrenia.” Research has shown that mental disorders and addictions are very prevalent (e.g. one in five Canadians will experience a mental disorder each year) and cost Canada billions of dollars (e.g. forty to fifty billion dollars annually). This study confirms that the burden of mental disorders and addictions is very high and outstrips the burden of many physical illnesses. “This report does not surprise me, the numbers are staggering”, stated Shawn Leon CEO of the Company. “ The awareness of mental health is growing and we are set to carve out a niche in this sector” he added. ICES is an independent, non-profit organization that produces knowledge to enhance the effectiveness of health care for Ontarians. The summary (6 pages) and the full report are available on the ICES web site at

http://www.ices.on.ca/webpage.cfm?site_id=1&org_id=31&morg_id=0&gsec_id=0&item_id=7718

Follow GreeneStone Healthcare Corp. and the company’s activities at the following Facebook sites:
GreeneStone Muskoka: https://www.facebook.com/pages/GreeneStone-Muskoka/510641255628356
GreeneStone Yorkville: https://www.facebook.com/pages/GreeneStone-Yorkville/452197614820117

About GreeneStone Healthcare Corporation

GreeneStone is a provider of mental health services, specializing in the areas of addiction treatment, eating disorders, nutrition and weight loss, and executive healthcare. GreeneStone is a new company in the behavioral treatment sector in Canada, an industry that has been well developed in the US but remains in its early evolutionary stages in Canada. GreeneStone is among the many nascent healthcare companies re-defining the healthcare space for the modern economy, which include Roche Holding Ltd. (OTCQB: RHHBY), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Nektar Therapeutics (NASDAQ: NKTR), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Zogenix, Inc. (NASDAQ: ZGNX). The company operates medical and healthcare clinics in Ontario, Canada, serving a North American and international clientele. GreeneStone’s clinics meet several ends: (1) GreeneStone adds overflow capacity to an increasingly stretched public healthcare system in Canada, (2) GreeneStone mental health clinics provide private alternatives to publicly available but highly underserviced healthcare subsectors, and (3) GreeneStone meets newly developing healthcare needs undisturbed by the public/private market, such as eating disorders. The company is headquartered in Toronto, Canada.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as “expect,” “plan,” “will,” “may,” “anticipate,” “believe,” “should,” “intend,” “estimate,” and variations of such words. Forward-looking statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, those risks and uncertainties contained in this press release and those identified in the periodic reports that the company files with the Securities and Exchange Commission (the “SEC”) pursuant to the Exchange Act.

Investor information and email sign-up:
http://www.greenestoneinvestor.com

Thursday, October 18th, 2012 Uncategorized Comments Off on GreeneStone (GRST) Seeks Amex Listing – New Report Confirms Demand

KIT digital (KITD) Gets Bloomberg on Air in Mongolia

LONDON and ULAN BATOR, MONGOLIA — (Marketwire) — 10/17/12 — KIT digital, Inc., (NASDAQ: KITD), a leading video management software and services company, working in partnership with the Trade & Development Bank (TDB) of Mongolia, today announced that leading business broadcaster Bloomberg Television has launched Bloomberg TV Mongolia, the first international news operation based in one of the fastest-growing investment environments in Asia. The HD channel went on air on the 8th of October 2012, using a tightly integrated production and playout platform designed and built by KIT digital.

The production team, including more than 30 local journalists trained by Bloomberg, will create five hours of content each week reflecting the business world in Mongolia and the Asia-Pacific region. The rest of the channel output, which can be seen on cable television as well as on the national digital terrestrial platform, will be derived from Bloomberg’s international content. This includes the pan-Asia Bloomberg feed as well as content from London, with BTV Mongolia adding its own graphics and tickers as well as realtime translation from other languages. BTV Mongolia will also provide information on the Mongolian market to other Bloomberg services, providing a unique insight.

“We are honoured to be a part of this exciting launch, and to be able to offer our experience and expertise in broadcast journalism to an important region,” said Parry Ravindranathan, Head of Bloomberg Television for Asia-Pacific. “Our partnership with The Trade & Development Bank of Mongolia is part of our momentum in establishing strategic long-term partnerships in Asia which we believe will enhance market transparency in local markets.”

The system in Ulan Bator combines studio production with fast turnaround editing and graphics to package content for different services. Automated graphics technology from Vizrt is an important element in localising the international content.

Bloomberg is a pioneering user of the FIMS (framework for interoperable media systems) standard to speed systems integration in file-based workflows, and it is an important part of the interface between the local system and the international content repository in London. Work on the project began in April 2012, with a tight timescale of just six months to create the whole system and complete training and rehearsals for the launch.

“This was a project where our integration skills were brought to bear on a typical modern challenge: the need to create a highly productive, highly flexible environment which could be operated intuitively by journalists and technicians in a new venture,” said Nicole Dixon, Managing Director of KIT digital Asia-Pacific. “In a rapidly changing media world, agility is critical if opportunities are to be seized as they are presented. The Trade & Development Bank of Mongolia had the rare opportunity to work with Bloomberg on a dedicated channel, and wanted it on air as quickly as possible to stake its claim in the local broadcast environment as it is refined. We were delighted to make that project happen.”

About KIT digital, Inc.
KIT digital (NASDAQ: KITD) is a leading video management software and services company. Cosmos and Cloud, the company’s video asset management systems, enable leading broadband media companies to produce, manage and deliver multiscreen socially-enabled video experiences to audiences wherever they are. KIT digital services nearly 2,500 clients in 50+ countries including some of the world’s biggest brands, such as Airbus, The Associated Press, AT&T, BBC, BSkyB, Disney-ABC, Google, HP, Mediaset, MTV, News Corp, RCS Media Group, Sky Deutschland, Sky Italia, Telecom Argentina, Telecom Italia, Telefonica O2, Universal Studios, Verizon, Vodafone, VRT and Volkswagen. KIT digital maintains headquarters in New York City and offices in more than a dozen countries around the world. Visit the company at www.kitd.com or follow on Twitter at www.twitter.com/KITdigital

About Bloomberg Television
Bloomberg Television, an award-winning, multi-platform 24-hour business and financial news network, provides continuous coverage of the people, companies and ideas that move global markets. Broadcasting from centers in New York, London, Singapore and Hong Kong and powered with an unparalleled news gathering team of 2,300 news professionals in 146 bureaus across 72 countries worldwide, Bloomberg Television delivers real-time business news to over 310 million households globally. In addition to major cable and satellite providers, Bloomberg.com and Bloomberg Mobile, the network is available on the Bloomberg Professional service, used by the most influential individuals, corporations, financial institutions, investors and the world’s central banks, commercial banks, government agencies, legal professionals and news organizations. With Asia being one of the most active growth regions in the world, Bloomberg Television is delivering more local content, and fast, accurate, unbiased, market-moving news from market makers in Asia. For more information on Bloomberg Television, please visit www.bloomberg.com/tv and follow us on Twitter (@BloombergTV) and Facebook.

About Trade & Development Bank of Mongolia
Trade & Development Bank of Mongolia TDB, with its leading position in universal banking, offers a full range of services, including large corporate, SME and retail lending and acts as a primary lender to most of the country’s leading corporations. The Bank has consolidated its market-leading position in the handling of international trade finance and remittance, with access to credit lines from major international lenders and correspondent banking relationships with over 150 international financial institutions. TDB offers over 100 types of international standard banking products and has about 1000 highly qualified staff providing personal attention and user friendly banking services through a network of 43 branches and settlement centers. TDB is undoubtedly the major player in the financial and banking markets as well as a major innovator of the Mongolian financial sector. In 2004, TDB was the first bank in the country to receive the investment from the Asian Development Bank (ADB) and International Finance Corporation (IFC). In 2006 TDB became the first commercial bank in Mongolia rated by Moody’s Investors Service. The Bank continuously increases its income figures and asset size.

Add to Digg Bookmark with del.icio.us Add to Newsvine

KIT digital Media Contact:
Werbayne McIntyre
Interim SVP, Global Marketing and Communications
Tel. +44 7590 554 845
Email Contact

KIT digital Investor Contact:
Murray Arenson
SVP, Investor Relations & Corporate Initiatives
Tel. +1-646-553-4900

Wednesday, October 17th, 2012 Uncategorized Comments Off on KIT digital (KITD) Gets Bloomberg on Air in Mongolia

NovaCopper (NCQ) Continues to Intercept High-Grade Copper Mineralization

NovaCopper Continues to Intercept High-Grade Copper Mineralization at the South Reef Zone of the Bornite Deposit

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 10/17/12 — NovaCopper Inc. (TSX:NCQ)(NYSE MKT:NCQ)(NYSE Amex:NCQ) (“NovaCopper” or “the Company”) is pleased to announce additional significant results from exploration diamond drilling at the South Reef Zone of the Bornite Property, one of its Upper Kobuk Mineral Projects (“UKMP”) located in the Ambler mining district of Northwest Alaska. This is the third set of drill results, comprised of five drill holes, and is in addition to the six drill holes which were released by the Company on September 12, 2012 and the four drill holes which were released by the Company on September 25, 2012. During the recently completed drilling program, the Company drilled 22 holes at the South Reef Zone of the Bornite Property comprising 15,457 meters. Additional drill results are anticipated to be released regularly over the next couple of months, as they become available.

Highlights

Four holes intersected significant high-grade copper mineralization:

At a cutoff grade of 1.0% copper the results are as follows:

--  RC12-209 intersected four mineralized intervals starting at 667.5
    meters, totaling 71.2 meters, within a composite total of 97.2 meters,
    at a grade of 3.66% copper, which is comprised of:
    --  14.9 meters at a grade of 1.68% copper;
    --  28.8 meters at a grade of 3.79% copper;
    --  15.2 meters at a grade of 5.94% copper; and
    --  12.3 meters at a grade of 2.93% copper.

--  RC12-207 intersected one mineralized interval starting at 540.0 meters,
    totaling 11.7 meters at a grade of 5.02% copper.

--  RC12-206 intersected two mineralized intervals starting at 516.6 meters,
    totaling 12.2 meters, within a composite total of 144.6 meters, at a
    grade of 4.80% copper, which is comprised of:
    --  8.0 meters at a grade of 4.44% copper; and
    --  4.2 meters at a grade of 5.50% copper.

--  RC12-205 intersected two mineralized intervals starting at 621.2 meters,
    totaling 22.9 meters, within a composite total of 26.0 meters, at a
    grade of 2.60% copper, which is comprised of:
    --  14.3 meters at a grade of 2.67% copper; and
    --  8.6 meters at a grade of 2.48% copper.

At a cutoff grade of 0.5% copper the results are as follows:

--  RC12-209 intersected one mineralized interval starting at 667.5 meters,
    totaling 122.6 meters at a grade of 2.44% copper.

--  RC12-207 intersected one mineralized interval starting at 540.0 meters,
    totaling 11.7 meters at a grade of 5.02% copper.

--  RC12-206 intersected two mineralized intervals starting at 516.6 meters,
    totaling 13.1 meters, within a composite total of 144.6 meters, at a
    grade of 4.52% copper, which is comprised of:
    --  8.0 meters at a grade of 4.44% copper; and
    --  5.1 meters at a grade of 4.64% copper.

--  RC12-205 intersected one mineralized interval starting at 618.1 meters,
    totaling 46.8 meters at a grade of 1.58% copper.

--  RC12-208 was terminated at a depth of approximately 200 meters below
    surface due to unfavorable ground conditions.

“We are delighted with these results, which have now expanded the high-grade copper mineralization at the South Reef Zone in three directions. The fact that the system remains open to the north, east and southwest is highly encouraging,” said Rick Van Nieuwenhuyse, NovaCopper’s President and Chief Executive Officer. “The 71 meters of 3.66% in drill hole RC12-209 along the northeast edge of the deposit is a particularly exciting result given that it supports our hypotheses that the northeast portion of the South Reef Zone hosts the longest intervals of high-grade copper mineralization. As we move our drilling to the north and northeast, we will continue to target this high-grade copper mineralization along strike.”

To date, drilling at South Reef has outlined a 300-meter by 700-meter northeast trending zone of mineralization. Copper mineralization remains open to the north and east and to the southwest. Figure 1 shows a plan map of drill hole locations and assay results on the South Reef at a 0.5% cutoff grade. Additional drill results for holes RC12-210 through 216 will be released as they become available.

The 2012 Bornite drilling program was focused on further defining the South Reef Zone which was identified as a significant potential high grade resource area during the 2011 exploration drilling program where three holes (DDH’s RC11-0187, RC11-0192 and RC11-0194) contained significant high grade intersections of copper mineralization (please see the NOVAGOLD Resources Inc. press release dated December 14, 2011 at http://www.novagold.com/). On September 12, 2012, NovaCopper released the assay results for the first six holes from the 2012 drilling program (DDH’s RC12-0195, RC12-0196, RC12-0197, RC12-0198, RC12-0201, and RC12-0202 – please see this press release at http://www.novacopper.com/). All six holes contained significant intersections of copper mineralization. Subsequently, on September 25, 2012, NovaCopper released the assay results for an additional four drill holes from the 2012 drilling program (DDH’s RC12-0199, RC12-0200, RC12-0203 and RC12-0204 – please see this press release at http://www.novacopper.com/). Three out of the four drill holes were found to contain significant intersections of copper mineralization.

On July 18, 2012, the Company announced a National Instrument 43-101 (“NI 43-101”) compliant resource estimate for the near surface Ruby Creek Zone, located just west of the South Reef Zone. The NI 43-101 report was filed on SEDAR and EDGAR on August 28, 2012 and is available on the Company’s website at (http://www.novacopper.com/). At a copper cutoff grade of 0.5%, the Ruby Creek Zone is estimated to contain Indicated Resources of 6.8 million tonnes at 1.19% Cu for 178.7 million lbs of contained copper and Inferred Resources of 47.7 million tonnes at 0.84% Cu for 883.2 million lbs of contained copper.

Current drilling is focusing on defining the extent of the South Reef Zone in order to support an updated NI 43-101-compliant resource estimate for the Bornite Property anticipated to be completed in Q1 2013.

Copper mineralization at the Ruby Creek and South Reef Zones is hosted by a section of dolomitized limestones within the Devonian-age Bornite Carbonate Sequence. Mineralization is selectively developed in massive dolostones and both sedimentary and hydrothermal breccias as seen in a cross section in Figure 2. Mineralization occurs as a roughly 50 to 200 meters thick shallowly dipping tabular zone centered roughly over a basement discontinuity. The mineralized system is strongly zoned with a distal zinc rich pyrite halo surrounding progressively more proximal chalcopyrite stockworks and disseminations, bornite stockworks and disseminations, and finally, local semi-massive sulphide zones of chalcocite, bornite, and chalcopyrite.

Results are presented in Table 1 at a cutoff grade of 0.5% copper so as to be comparable with previous South Reef drill results released by NOVAGOLD Resources Inc. in 2011. In addition, results at a more selective higher grade cutoff of 1.0% copper are also presented in Table 2.

TABLE 1. Significant Copper Composites - South Reef Zone - 0.5%
         Cutoff
----------------------------------------------------------------------------
                                                                          Cu
                          thickness thickness    Cu    Co    Au    Ag      %
               from    to    meters      feet     %     %   gpt   gpt meters
----------------------------------------------------------------------------
DDH RC12-0205 618.1 665.9      46.8     153.6  1.58     -     -     -   74.1
1 interval                     46.8     153.6  1.58     -     -     -   74.1
----------------------------------------------------------------------------
DDH RC12-0206 516.6 524.6       8.0      26.2  4.44     -     -     -   35.5
              656.1 661.2       5.1      16.9  4.64     -  0.15     -   23.8
2 intervals                    13.1      43.1  4.52     -     -     -   59.4
----------------------------------------------------------------------------
DDH RC12-0207 540.0 551.7      11.7      38.5  5.02     -     -     -   58.9
1 interval                     11.7      38.5  5.02     -     -     -   58.9
----------------------------------------------------------------------------
DDH RC12-0208 hole lost before target depth             -     -     -
----------------------------------------------------------------------------
DDH RC12-0209 667.5 790.2     122.6     402.4  2.44     -     -     -  299.7
1 interval                    122.6     402.4  2.44     -     -     -  299.7
----------------------------------------------------------------------------

----------------------------------------------------------------------------

Footnotes to Drill Interval Table:

1.  Significant interval defined as a minimum 20% x meter Cu interval
2.  Cutoff grade of 0.5% Cu
3.  Internal dilution up to 6 continuous meters of less than 0.5% Cu
4.  Intervals of less than 0.1gpt Au, less than 0.05% Co and less than 5.0
    gpt Ag not reported
5.  Significant quantities of Au, Ag, and Co are reported in high-grade
    intervals
6.  Some rounding errors may occur
7.  Individual composite intervals of greater than 2.0% Cu are highlighted
8.  Though mineralization is tabular and shallowly dipping - no true
    thicknesses are implied in the results

TABLE 2. Significant Copper Composites - South Reef Zone - 1.0%
         Cutoff
----------------------------------------------------------------------------
                                                                          Cu
                          thickness thickness    Cu    Co    Au    Ag      %
               from    to    meters      feet     %     %   gpt   gpt meters
----------------------------------------------------------------------------
DDH RC12-0205 621.2 635.5      14.3      46.9  2.67     -     -     -   38.1
              638.6 647.2       8.6      28.3  2.48     -     -     -   21.4
2 intervals                    22.9      75.1  2.60     -     -     -   59.5
----------------------------------------------------------------------------
DDH RC12-0206 516.6 524.6       8.0      26.2  4.44     -     -     -   35.5
              657.1 661.2       4.2      13.6  5.50     -  0.15     -   22.9
2 intervals                    12.2      39.9  4.80     -     -     -   58.4
----------------------------------------------------------------------------
DDH RC12-0207 540.0 551.7      11.7      38.5  5.02     -     -     -   58.9
1 interval                     11.7      38.5  5.02     -     -     -   58.9
----------------------------------------------------------------------------
DDH RC12-0208 hole lost before target depth             -     -     -
----------------------------------------------------------------------------
DDH RC12-0209 667.5 682.4      14.9      48.8  1.68     -     -     -   25.0
              686.9 715.7      28.8      94.4  3.79     -  0.13     -  109.0
              723.0 738.2      15.2      50.0  5.94     -     -     -   90.5
including(i)  729.1 731.7       2.6       8.4 22.26     -  0.30     -   57.0
              752.5 764.8      12.3      40.3  2.93     -     -     -   35.9
4 intervals                    71.2     233.4  3.66     -     -     -  260.3
----------------------------------------------------------------------------

----------------------------------------------------------------------------

Footnotes to Drill Interval Table:

1.  Significant interval defined as a minimum 20% x meter Cu interval
2.  Cutoff grade of 1.0% Cu
3.  Internal dilution up to 6 continuous meters of less than 0.5% Cu
4.  Intervals of less than 0.1gpt Au, less than 0.05% Co and less than 5.0
    gpt Ag not reported
5.  Significant quantities of Au, Ag, and Co are reported in high-grade
    intervals
6.  Some rounding errors may occur
7.  Individual composite intervals of greater than 2.0% Cu are highlighted
8.  Though mineralization is tabular and shallowly dipping - no true
    thicknesses are implied in the results

The Ambler mining district is one of the richest and most prospective known copper districts located in one of the safest geopolitical jurisdictions in the world. It hosts world-class volcanogenic massive sulfide (“VMS”) deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits rich in copper, but also contain significant amounts of cobalt, silver and gold. Exploration efforts have been focused on two deposits in the Ambler district – the Arctic VMS deposit with approx. 7% copper-equivalent grades(2) and the Bornite carbonate replacement deposit. Both deposits are located within the Company’s UKMP land package that spans approximately 143,000 hectares. The Arctic deposit had a post-tax net present value of between approximately US$500 million and US$1.0 billion, depending on metal price assumptions in the Preliminary Economic Assessment (“PEA”) filed April 24, 2012(3). The PEA was preliminary in nature and included inferred mineral resources that are considered too speculative geologically to have the economic characteristics applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized.

Quality Control

The drill program and sampling protocol were managed by qualified persons employed by NovaCopper. The diamond drill holes were typically collared at HQ diameter drill core and reduced to NQ diameter during the drilling process. Samples were collected using a 0.5-meter minimum length, three-meter maximum length and 1.5-meter average sample length. Drill core recovery averaged 90%. Three quality control samples (one blank, one standard and one duplicate) were inserted into each batch of 20 samples. The drill core was sawn, with half sent to ALS Chemex in Fairbanks for sample preparation and the sample pulps forwarded to ALS’s North Vancouver facility for analysis. ALS Minerals in North Vancouver, B.C., Canada, is a facility certified as ISO 9001:2008 and accredited to ISO / IEC 17025:2005 from the Standards Council of Canada. NovaCopper will also be submitting 5% of the assay intervals from prospective lithologies to an independent check assay lab.

Qualified Person

Scott Petsel, P.Geo, UKMP Project Manager for NovaCopper, and a Qualified Person as defined by NI 43-101, has reviewed the results of the drill program and confirmed that all procedures, protocols and methodologies used in the drill program conform to industry standards. Mr.Petsel has reviewed and accepts responsibility for the technical information contained within this press release.

About NovaCopper

NovaCopper Inc. is a base metals exploration company focused on exploring and developing the Ambler mining district in Alaska. It is one of the richest and most-prospective known copper-dominant districts located in one of the safest geopolitical jurisdictions in the world. It hosts world-class VMS deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits which have been found to host high-grade copper mineralization. Exploration efforts have been focused on two deposits in the Ambler district – the Arctic VMS deposit with approx. 7%(4) copper-equivalent grades and the Bornite carbonate replacement deposit. At Bornite, drill hole RC11-187 contained 178 meters of 4.0% copper, including 34.7 meters of 12.0% copper. Both properties are located within NovaCopper’s land package that spans approximately 143,000 hectares. NovaCopper has formed an alliance with NANA, an Alaskan Native Corporation and both companies are committed to developing the Ambler mining district in cooperation with the local communities. Our vision is to develop the Ambler mining district into a premier North American copper producer.

More information on the Company, its properties and its management team is available on the Company’s website at www.novacopper.com.

To view Figures 1 and 2, click on the following link: http://media3.marketwire.com/docs/nc116m.pdf

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of NovaCopper, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. These forward-looking statements may include statements regarding perceived merit of properties; exploration results and budgets; mineral reserves and resource estimates; work programs; capital expenditures; timelines; strategic plans; completion of transactions; market prices for precious and base metals; or other statements that are not statements of fact. Forward-looking statements involve various risks and uncertainties.

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from NovaCopper’s expectations include the uncertainties involving the need for additional financing to explore and develop properties and availability of financing in the debt and capital markets; uncertainties involved in the interpretation of drilling results and geological tests and the estimation of reserves and resources; the need for cooperation of government agencies and native groups in the development and operation of properties; the need to obtain permits and governmental approvals; risks of construction and mining projects such as accidents, equipment breakdowns, bad weather, non-compliance with environmental and permit requirements, unanticipated variation in geological structures, ore grades or recovery rates; unexpected cost increases, which could include significant increases in estimated capital and operating costs; fluctuations in metal prices and currency exchange rates; and other risk and uncertainties disclosed in NovaGold Resources Inc.’s Management Information Circular dated February 27, 2012 for the special meeting of securityholders held to consider the spin-out of NovaCopper Inc. filed with the Canadian securities regulatory authorities, and NovaCopper’s registration statement on Form 40-F filed with the United States Securities and Exchange Commission and in other NovaCopper reports and documents filed with applicable securities regulatory authorities from time to time. NovaCopper’s forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. NovaCopper assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cautionary Note to United States Investors

This press release has been prepared in accordance with the requirements of the securities laws in effect in Canada, which differ from the requirements of U.S. securities laws. Unless otherwise indicated, all resource and reserve estimates included in this press release have been prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101”) and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by the Canadian Securities Administrators which establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. Canadian standards, including NI 43-101, differ significantly from the requirements of the United States Securities and Exchange Commission (“SEC”), and resource and reserve information contained herein may not be comparable to similar information disclosed by U.S. companies. In particular, and without limiting the generality of the foregoing, the term “resource” does not equate to the term “reserves”.

Under U.S. standards, mineralization may not be classified as a “reserve” unless the determination has been made that the mineralization could be economically and legally produced or extracted at the time the reserve determination is made. The SEC’s disclosure standards normally do not permit the inclusion of information concerning “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” or other descriptions of the amount of mineralization in mineral deposits that do not constitute “reserves” by U.S. standards in documents filed with the SEC. Investors are cautioned not to assume that any part or all of mineral deposits in these categories will ever be converted into reserves. U.S. investors should also understand that “inferred mineral resources” have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an “inferred mineral resource” will ever be upgraded to a higher category. Under Canadian rules, estimated “inferred mineral resources” may not form the basis of feasibility or pre-feasibility studies except in rare cases. Investors are cautioned not to assume that all or any part of an “inferred mineral resource” exists or is economically or legally mineable. Disclosure of “contained ounces” in a resource is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in-place tonnage and grade without reference to unit measures. The requirements of NI 43-101 for identification of “reserves” are also not the same as those of the SEC, and reserves reported by the Company in compliance with NI 43-101 may not qualify as “reserves” under SEC standards. Accordingly, information concerning mineral deposits set forth herein may not be comparable with information made public by companies that report in accordance with U.S. standards.

(1) Drill hole locations represent the mid-point of the mineralization projected to surface using a 0.5% copper cutoff.

(2) The Ambler copper-equivalent resource is calculated using the following metals price assumptions: (in USD) $3.93/lb Cu, $1,815/oz Au, $40.55/oz Ag, $0.98/lb Zn, and $1.08/lb Pb; and is based on grades of 4.05% Cu, 0.80 g/t Au, 59.55 g/t Ag, 5.81% Zn, and 0.97% Pb.

(3) NovaCopper filed a PEA for the Ambler Project on April 24, 2012 entitled “NI 43-101 Preliminary Economic Assessment Ambler Project Kobuk, AK” Report March 9, 2012. It is available for download on NovaCopper’s website at www.novacopper.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

(4) CuEq basis calculated using the following metal price assumptions (in USD): $3.93/lb. Cu, $1,815/oz Au, $40.55/oz Ag, $1.08/lb. Pb, and $1.00/lb. Zn. and is based on grades of 4.05% Cu, 0.80 g/t Au, 59.55 g/t Ag, 5.81% Zn, and 0.97% Pb. Calculation excludes any adjustments for metal recoveries.

Contacts:
NovaCopper Inc.
Patrick Donnelly
Vice President, Corporate Communications
604-638-8088 or 1-855-638-8088
patrick.donnelly@novacopper.com

Wednesday, October 17th, 2012 Uncategorized Comments Off on NovaCopper (NCQ) Continues to Intercept High-Grade Copper Mineralization

Sify (SIFY) Reports Revenues of INR 2059 Million for Q2 of Fiscal Year 2012-13

Sify Technologies Limited (NASDAQ Global Markets: SIFY), a leader in Managed Enterprise, Network and IT Services in India with growing global delivery capabilities, today announced its consolidated results under International Financial Reporting Standards (IFRS) for the second quarter of fiscal year 2012-13.

Performance Highlights Q2 FY 2012-13:

  • Sify reported revenues of INR 2059 million for the quarter ended September 30, 2012 against revenues of INR 1815 million for the corresponding quarter of the previous year, a growth of 13%.
  • EBITDA for the quarter increased to INR 161 million, as compared to INR 136 million in the corresponding quarter previous year.
  • Net profit for the quarter was INR 612 million, as against a net loss of INR 89 million in the corresponding quarter previous year. This quarter includes a one time profit of approximately INR 658 million, realised on exit from our erstwhile affiliate, MF Global Sify Securities India Pvt Ltd. Without this item, the net loss for the quarter would have been INR 45 million.
  • CAPEX during the quarter was INR 1338 million. Cash balance at the end of the quarter was INR 907 million.

Mr. Raju Vegesna, Chairman, said, “We have come through a challenging phase in our growth and I am happy to state that our focused approach is generating measurable results. At the beginning of the financial year, I had shared my vision to turn Sify into a Services and Solutions leader. Our strong showing across all major business lines is a positive indicator of the direction we are moving in. On the business environment, we are pleased that the Government is opening up several sectors for FDI. The true effect of these measures will take some time to bear results, but we believe this would allow several sectors to aggressively ramp-up, thus opening up additional growth opportunity for us. We will continue in our endeavor to become a prominent solutions expert catering to large and emerging Enterprises, SMBs and the Government services.”

Mr. Kamal Nath, CEO, said, “We are in a unique position to establish ourselves into a broad based IT Services and Solutions player by integrating the products, applications, professional services and managed services portfolio. Vertical Solutions and Cloud based Services model will be the two key propositions for the market. Our future growth will be primarily led by leveraging our Cloud Services model around both Infrastructure and Applications and with increased focus around Integration and Managed Services offerings.”

Mr. M P Vijay Kumar, CFO, said, “Our investments in infrastructure over the past years have given us a strong base as a Solutions and Services provider. Many of these investments should start generating significant revenue over the coming quarters, as they are in an advance stage of commissioning. At the same time, we are engaged in a continuing exercise to keep a strict eye on the cost and completion without time overruns, thus saving us valuable capital. As I remarked in our previous report, a large share of this incremental capital and operating expenditure will be incurred to support the large network integration contract previously announced and our two new state-of-the-art Data Centres in Delhi and Mumbai.

“The successful sale of our interest in MF Global Sify Securities India Private Limited has improved our cash position, and will help support the forecasted investments. Cash balance at the end of the quarter was INR 907 million.”

FINANCIAL HIGHLIGHTS

Unaudited Consolidated income statement as per IFRS
(In INR millions)
Description Quarter ended Quarter ended Quarter ended
Sept Sept June
2012 2011 2012
Enterprise 1,882 1,613 1,817
Software 177 202 157
Revenue 2,059 1,815 1,974
Cost of Revenues (1,101 ) (1,060 ) (1,123 )
Selling, General and Administrative Expenses (797 ) (619 ) (672 )
EBITDA 161 136 179
Depreciation and Amortisation expense (208 ) (172 ) (197 )
Net Finance Expenses (16 ) (72 ) (55 )
Other Income 17 5
Share of Affiliates 19
Profit from sale of shares in affiliate and rights therein 658
Profit / (loss) Before tax 612 (89 ) (68 )
Income Taxes
Profit / (loss) for the period 612 (89 ) (68 )
Profit attributable to:
Reconciliation with Non-GAAP measure
Profit / (loss) for the period 612 (89 ) (68 )
Add:
Depreciation and Amortisation expense 208 172 197
Net Finance Expenses 16 72 55
Less:
Other Income (17 ) (5 )
Share of Affiliates (19 )
Profit from sale of shares in affiliate and rights therein (658 )
EBITDA 161 136 179

BUSINESS HIGHLIGHTS:

Network services

  • Network services continue to see an increase in growth rate in its core data business.
  • Revenue is up 17% over same quarter last year and 4% over last quarter. Key wins include a large PSU bank and retail chain.
  • Our network now covers 970 cities Pan India with over 1795 base stations
  • Our strategy of focusing on the SME/SMB market and Tier 2/3 cities has started yielding results. The business growth in this segment is a major component of the overall data revenue growth rate for the company.
  • The business continues to report wins in the retail segment, a focus area for Sify. With the recent announcement in FDI in retail, we expect greater adoption of technology in this segment as local retail chains prepare to compete in a fast changing market.

IT Services

  • Overall, IT services have grown 16% over the same period last year.
  • The hosting business has won major contracts from Indian software, telecom and banking majors. These are all multi year contracts ensuring a healthy revenue inflow. The new data centers being commissioned over the next 2 quarters will also help improve growth in this segment.
  • We also won a large multi-year Network system Integration and Managed services contract from an Indian Insurance major.
  • Our Cloud hosting platform chalked up multiple multi-year wins from Media, FMCG and Telecom companies. We are now accredited by two global cloud services majors for offering their tools on our platform, with one of them also recognising us as “Power of Choice Partner.”
  • The newest stock exchange in the country opted for our Security services. Sify’s Safescrypt services continue to maintain its leadership position.
  • In the first quarter, we launched a new business segment with alliance partners. We are happy to report that this business has taken off well with major contracts from Indian software majors.

Software Services

  • Overall, Software Services registered a growth of 22% over the prior quarter, led by Enterprise applications services, which grew over 40% with wins across a number of industries.
  • In addition to a 6th consecutive win of the Brandon Hall award, Sify’s E-learning team also picked up the Asian Learning Leadership Award (Dubai) and Asia Pacific Learning and Development Award (India).
  • Over the last 12 months, as per Comscore, http://www.sify.com/ grew by 34% Y on Y. New channels launched were Sify Skills and Sify Gold & Silver Line, along with an application for Facebook called “Sify Social Reader.”

About Sify Technologies

Sify is among the largest integrated Managed Network, IT and Software services companies in India, offering end-to-end solutions with a comprehensive range of products delivered over a common telecom data network infrastructure reaching more than 900 cities and towns in India.

A significant part of the company’s revenue is derived from Corporate Enterprise Services, which include Network and IT services, Connectivity, Security, Network management services, Enterprise applications, Hosting and Remote Infrastructure Management Services. A varied product portfolio at multiple price points allows Sify to also cater to the burgeoning demands of the SMB/SOHO community and the retail consumer, much of it on the cloud platform.

Sify is a recognized ISO 9001:2008 certified service provider for network operations, data center operations and customer support, and for provisioning of VPNs, Internet bandwidth, VoIP solutions and integrated security solutions, and ISO / IEC 20000 – 1:2005 and ISO/IEC 27001:2005 certified for Internet Data Center operations. Sify has also built a credible reputation in the emerging Cloud Computing market and is today, regarded as a domain expert. Sify has licenses to operate NLD (National Long Distance) and ILD (International Long Distance) services and offers VoIP backhaul to long distance subscriber telephony services. With the Sify Cable landing station and the partnerships inked with several cable companies globally, Sify is present in almost all the spheres of the ICT eco system.

The company has an expanding base of Managed Services customers, both in India and overseas, and is also India’s first enterprise managed services provider to launch a Security Operations Center (SOC) to deliver managed security services.

Sify Software develops applications and offers services to improve business efficiencies of its current clients and prospective client bases. Sify also offers services in the specialized domains of eLearning for-profit, not-for-profit and government institutions both in India and globally. The business also operates two of the most popular portals in India, Sify.com and Samachar.com.

For more information about Sify, visit www.sifycorp.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Sify undertakes no duty to update any forward-looking statements.

For a discussion of the risks associated with Sify’s business, please see the discussion under the caption “Risk Factors” in the company’s Annual Report on Form 20-F for the year ended March 31, 2012, which has been filed with the United States Securities and Exchange Commission and is available by accessing the database maintained by the SEC at www.sec.gov, and Sify’s other reports filed with the SEC.

Wednesday, October 17th, 2012 Uncategorized Comments Off on Sify (SIFY) Reports Revenues of INR 2059 Million for Q2 of Fiscal Year 2012-13

Peregrine Pharma (PPHM) Provides Update on Corporate Activities

TUSTIN, CA — (Marketwire) — 10/17/12 — Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided a company update on financing activities, its contract manufacturing business and upcoming potential clinical milestones.

Financial Update
Since September 27, 2012, the company has raised $14.3 million in gross proceeds in order to replace the initial funding it repaid under an earlier loan facility. The funds were raised under an At Market Sales Issuance Agreement with McNicoll, Lewis & Vlak LLC at an average price per share of $0.93. The company issued no warrants in connection with the At Market Sales Issuance Agreement. Based on current financial projections for ongoing clinical trials and operations including cash inflows under signed contracts with Avid’s existing customers, and assuming the company does not receive additional proceeds from other potential sources of capital, this funding should provide the company with sufficient capital to reach potential upcoming clinical and development milestones through the third quarter of calendar year 2013.

Avid Bioservices Update
Avid Bioservices continues to be an integral part of our corporate strategy. Avid is on track for a record revenue year with projections in excess of $15 million for fiscal year 2013. In September 2012, Avid announced that it had signed a contract with Advanced BioScience Laboratories, Inc. to provide development and large-scale manufacturing services to support cGMP production of the gp145 HIV envelope protein, as a component of a preventive vaccine against HIV infection. With existing and recently signed business, Avid’s backlog for services is in excess of $30 million covering services to be performed during the remainder of fiscal year 2013 and fiscal year 2014.

Clinical Pipeline Update

Bavituximab Oncology Program
There are currently seven ongoing clinical trials for our lead oncology product bavituximab, including two randomized Phase II clinical trials sponsored by Peregrine and five independent Investigator-Sponsored Trials (or ISTs). With this number of ongoing clinical trials, Peregrine is well positioned for constant clinical news flow for the remainder of 2012 and into 2013. Peregrine expects to have important median overall survival (OS) data from two of its randomized Phase II trials in front-line non-small cell lung cancer (NSCLC) and pancreatic cancer towards year-end or early next calendar year. Both of these trials are open-label, Phase II clinical trials evaluating bavituximab plus chemotherapy versus chemotherapy alone.

The ongoing ISTs include:

  • The Phase II portion of a Phase I/II IST investigating bavituximab in combination with sorafenib in up to 48 patients with advanced hepatocellular carcinoma (liver cancer).
  • A Phase I/II IST evaluating bavituximab in combination with cabazitaxel in up to 31 patients with second-line castration-resistant prostate cancer.
  • A Phase Ib IST evaluating bavituximab in combination with carboplatin and pemetrexed in up to 21 patients with previously untreated Stage IV NSCLC.
  • A Phase I IST evaluating bavituximab in combination with paclitaxel in up to 14 patients with HER2-negative metastatic breast cancer.
  • A Phase I IST evaluating bavituximab in combination with capecitabine and radiation therapy in up to 18 patients with Stage II or III rectal adenocarcinoma.

While continuing to oversee these ongoing clinical trials, Peregrine is also conducting a detailed internal review into the discrepancies tied to the randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line NSCLC that were discovered as part of the routine collection of data in advance of the company’s end-of-Phase II meeting with regulatory authorities. The goal of this review is to gain a thorough understanding of the events leading up to, including and following the patient treatment group assignments and investigational drug coding and distribution. This review includes the testing of investigational product, patient samples, reviewing the operations of multiple vendors, among other activities. Investors are reminded not to rely on clinical data that the company disclosed on or before September 7, 2012 regarding this trial.

PS-Targeting Molecular Imaging Program
The company continues to enroll patients as part of its exploratory trial of an experimental phosphatidylserine (PS)-targeting molecular imaging candidate, 124I-PGN650, in the imaging of multiple solid tumor types. The primary goal of the trial is to estimate radiation dosimetry in critical and non-critical organs. Secondary objectives of the trial are tumor imaging and safety.

Cotara® Program
Peregrine continues to have discussions with the U.S. Food and Drug Administration surrounding the pivotal trial design for its single-administration approach to treating recurrent glioblastoma multiforme (GBM). The company plans to seek partners both in the U.S. and internationally to support the development of Cotara for this deadly form of brain cancer.

Annual Stockholders Meeting Update
Peregrine’s Annual Meeting of Stockholders will take place at 10:00 am Pacific Daylight Time (PDT) on Thursday, October 18, 2012 at the Wyndham Orange County Hotel, 3350 Avenue of The Arts in Costa Mesa, California. The company will conduct formal business as outlined in the Notice of Annual Meeting of Stockholders and will provide a company overview. The company overview portion of the meeting will be available by webcast and conference call (access information provided below). With the internal review of discrepancies surrounding patient treatment code assignments from its Phase II trial of bavituximab in second-line NSCLC still ongoing, management will not be making any statements or taking questions regarding this trial, the internal review or any other matters related thereto. Persons wishing to attend the Annual Meeting of Stockholders will be required to show a photo identification card and provide either proof of ownership of Peregrine stock as of the record date of August 22, 2012 (such as a Proxy Card or Voter Instruction Card) or sign a company-provided certification verifying status as a stockholder as of the record date. Attendees are asked to arrive 10-15 minutes early to accommodate the registration process and to ensure a prompt start to the meeting at 10:00 am PDT.

Webcast and Conference Call Information
Peregrine will host a webcast and conference call beginning at 10:10 am PDT (1:10 pm Eastern Daylight Time) on Thursday, October 18, 2012.

  • To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm
  • To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals conference call. A replay of the call will be available starting approximately two hours after the conclusion of the call through October 25, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 43418967

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that final data from the randomized, double-blind, placebo-controlled Phase IIb may never support future development in second-line NSCLC, the risk that the company may not have or raise adequate financial resources to sustain its operations, the risks associated with the recently filed class action lawsuits or potential regulatory investigations due to the uncertainty created by the above referenced discrepancies, the risk that Avid’s revenue growth may slow or decline, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, and the risk that one or more existing Avid customers, including those with committed manufacturing or representing its backlog, terminates its contract prior to completion. It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the our SEC reports including, but not limited to, the annual report on Form 10-K for the fiscal year ended April 30, 2012 and quarterly report on Form 10-Q for the quarter ended July 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256

Wednesday, October 17th, 2012 Uncategorized Comments Off on Peregrine Pharma (PPHM) Provides Update on Corporate Activities

East-Side Drilling (LODE) Intercepts Significant Gold And Silver Mineralization

East-Side Drilling Intercepts Significant Gold And Silver Mineralization

Comstock Updates Drill Results In Lucerne

VIRGINIA CITY, Nev., Oct. 16, 2012 /PRNewswire/ — Comstock Mining Inc. (the “Company” or “Comstock”) (NYSE MKT: LODE) announced significant progress on its extended development drilling and initial step-out drilling programs, both in the Company’s Lucerne Resource Area (the “Lucerne”).   The step-out drilling concluded in the East-side of the Lucerne on October 7, 2012. Assays for this program have been received for the first ten holes out of 20 holes drilled, with highlights including an assay of 1.693 ounces of gold per ton in hole E12-05, contained in a 20 foot interval averaging 0.621 ounces of gold and 1.408 ounces of silver per ton, and an assay of 6.000 ounces of silver per ton in hole E12-10, contained in a 75 foot interval averaging 0.111 ounces of gold and 1.382 ounces of silver per ton.  Seven of the holes had multiple intervals of significant mineralization totaling 150 feet or more, up to 370 feet per hole, including five of the holes with contiguous intervals of 100 feet or more.

The East-side step-out program was drilled concurrently with the conclusion of the extended development-drilling program that began on March 13, 2012, in the Lucerne Mine. That program was designed to optimize and extend the life of the currently operating Lucerne Mine and included 237 reverse circulation (RC) drill holes to-date, totaling over 87,000 feet and 25 core holes totaling 6,126 feet.  The Lucerne development-drilling is scheduled for completion in late October.

“Our Lucerne drilling is expected to extend our initial mine life by at least one year, at current production rates,” stated Corrado De Gasperis, President and CEO of Comstock, “and the East-side developments, both the higher grades and significant thicknesses, continue to exceed expectation and generate incredible resource expansion opportunity.  We look forward to completing this phase of the program and formally updating the results in our next NI 43-101 report in the fourth quarter.”

East-side 2012 Preliminary Results

The Lucerne East-side drilling began July 24, 2012, with plans to drill twelve deep RC holes from the top of Donovan Ridge, on the east side of State Route 342.  These holes were designed to test the continuity and down-dip extensions of the mineralization encountered in the 2010 and 2011 East-side drilling, with depths planned of up to 1,400 feet.  The initial, positive results of the program encouraged the Company to extend the program to a total of 18 RC holes.  An additional two holes were drilled to test the location for a future water monitoring well.  Twenty East-side holes were completed altogether, totaling 21,310 feet of RC drilling.

Assay results have been received for the first ten RC drill holes, showing that all holes encountered intervals of significant mineralization (gold grades greater than 0.010 ounces per ton or silver grades greater than 0.100 ounces per ton, and length of at least ten feet).

Highlights of the results from the first ten holes include hole E12-05, with total significant mineralization of 370 feet in multiple zones, including contiguous significant mineralization of 120 feet (0-120′), 90 feet (965-1055′), and 55 feet (1065-1120′).  The 120-foot interval averaged 0.050 ounces of gold and 0.267 ounces of silver per ton.  Hole E12-05 also includes a 10-foot interval averaging 1.016 ounces of gold and 2.589 ounces of silver per ton, contained in a 20-foot interval averaging 0.621 ounces of gold and 1.408 ounces of silver per ton.

Also of note was hole E12-02, with total significant mineralization of 280 feet in multiple zones, including 135 feet (675-810′) of contiguous significant mineralization.  Hole E12-02 also includes a 20 foot interval averaging 0.273 ounces of gold and 0.264 ounces of silver per ton.  Visible gold was logged in the RC chips from this interval.

Hole E12-04 has total significant mineralization of 290 feet in multiple zones, including 145 feet (660-805′) of contiguous significant mineralization, which contains a 75-foot interval averaging 0.018 ounces of gold and 0.400 ounces of silver per ton.  Hole E12-06 is also of note for a 10 foot interval averaging 0.213 ounces of gold and 1.605 ounces of silver per ton, contained in a 35 foot interval averaging 0.091 ounces of gold and 0.897 ounces of silver per ton.

Hole E12-07 has a total of 265 feet of significant mineralization in multiple zones, including contiguous intervals of significant mineralization of 105 feet (505-610′) and 140 feet (735-875′).  Hole E12-09 includes a 45 foot interval averaging 0.142 ounces of gold and 1.165 ounces of silver per ton, and hole E12-10 includes a 75 foot interval averaging 0.111 ounces of gold and 1.382 ounces of silver per ton.

Significant Mineralized Intervals

A sample from each five-foot interval in each drill hole has been sent for analysis to American Assay Labs, of Reno, Nevada, a certified independent laboratory.  Assay results have been received to date for ten of the RC holes in the program.

East-side 2012 RC Drill Results

Drill Hole

Interval

(ft)

Length
(ft)

Gold
(oz/ton)

Silver
(oz/ton)

Length
(m)

Gold
(g/t)

Silver
(g/t)

E12-01

235-245

10

0.046

0.325

3.05

1.56

11.11

430-440

10

0.036

0.270

3.05

1.23

9.23

755-785

30

0.017

0.403

9.14

0.58

13.78

805-820

15

0.023

0.150

4.57

0.79

5.14

E12-02

260-325

65

0.029

0.660

19.81

0.99

22.59

INCLUDES

260-280

20

0.054

1.676

6.10

1.83

57.40

375-385

10

0.030

0.102

3.05

1.03

3.48

410-430

20

0.273

0.264

6.10

9.34

9.05

INCLUDES

410-420

10

0.506

0.439

3.05

17.31

15.03

510-550

40

0.031

0.105

12.19

1.07

3.60

675-715

40

0.354

12.19

12.11

715-750

35

0.019

1.088

10.67

0.67

37.26

INCLUDES

715-735

20

0.027

1.491

6.10

0.92

51.07

750-765

15

0.324

4.57

11.10

765-780

15

0.021

0.325

4.57

0.73

11.14

780-810

30

0.009

0.191

9.14

0.30

6.54

820-830

10

0.007

0.267

3.05

0.22

9.14

E12-03

10-20

10

0.015

0.037

3.05

0.50

1.25

45-80

35

0.059

0.572

10.67

2.02

19.60

INCLUDES

70-80

10

0.087

1.492

3.05

2.96

51.10

780-845

65

0.038

0.599

19.81

1.29

20.52

INCLUDES

815-825

10

0.141

2.058

3.05

4.81

70.46

855-885

30

0.013

0.275

9.14

0.43

9.42

1035-1050

15

0.044

0.404

4.57

1.50

13.84

E12-04

5-25

20

0.047

0.077

6.10

1.59

2.63

35-50

15

0.016

0.157

4.57

0.55

5.39

75-100

25

0.075

0.573

7.62

2.55

19.62

120-130

10

0.107

3.05

3.66

545-565

20

0.076

0.063

6.10

2.60

2.15

565-580

15

0.121

4.57

4.14

600-610

10

0.135

3.05

4.61

610-620

10

0.032

0.397

3.05

1.10

13.58

660-720

60

0.017

0.617

18.29

0.57

21.12

INCLUDES

695-705

10

0.029

1.460

3.05

0.99

50.00

720-730

10

0.379

3.05

12.96

730-805

75

0.018

0.400

22.86

0.60

13.70

INCLUDES

740-760

20

0.032

1.030

6.10

1.08

35.27

860-870

10

0.011

0.100

3.05

0.36

3.42

900-910

10

0.012

0.091

3.05

0.41

3.10

E12-05

0-120

120

0.050

0.267

36.58

1.71

9.16

INCLUDES

40-65

25

0.147

0.265

7.62

5.03

9.07

INCLUDES

65-85

20

VOID

6.10

420-430

10

0.083

0.105

3.05

2.83

3.60

515-540

25

0.053

0.072

7.62

1.83

2.47

865-880

15

0.013

0.186

4.57

0.46

6.38

895-905

10

0.023

0.090

3.05

0.77

3.08

930-950

20

0.621

1.408

6.10

21.26

48.22

INCLUDES

930-940

10

1.016

2.589

3.05

34.78

88.66

965-1010

45

0.096

0.273

13.72

3.28

9.33

INCLUDES

970-980

10

0.370

0.473

3.05

12.65

16.18

1010-1025

15

0.279

4.57

9.55

1025-1040

15

0.024

0.157

4.57

0.83

5.37

1040-1055

15

0.187

4.57

6.39

1065-1080

15

0.134

4.57

4.60

1080-1100

20

0.025

0.213

6.10

0.85

7.29

1100-1120

20

0.123

6.10

4.20

1130-1145

15

0.221

4.57

7.57

1145-1155

10

0.017

0.127

3.05

0.57

4.35

E12-06

120-135

15

0.019

0.283

4.57

0.64

9.69

710-735

25

0.017

0.372

7.62

0.58

12.75

790-805

15

0.004

0.124

4.57

0.14

4.24

805-840

35

0.091

0.897

10.67

3.10

30.73

INCLUDES

810-820

10

0.213

1.605

3.05

7.28

54.95

E12-07

505-610

105

0.027

0.279

32.00

0.93

9.56

685-705

20

0.011

0.091

6.10

0.37

3.13

735-780

45

0.443

13.72

15.18

780-800

20

0.012

0.419

6.10

0.42

14.35

800-820

20

0.365

6.10

12.48

820-830

10

0.015

0.600

3.05

0.50

20.53

830-845

15

0.706

4.57

24.17

845-875

30

0.021

0.293

9.14

0.73

10.02

E12-08

10-20

10

0.273

3.05

9.35

20-40

20

0.049

0.152

6.10

1.66

5.21

65-90

25

0.016

0.086

7.62

0.55

2.93

105-135

30

0.028

0.056

9.14

0.94

1.92

675-695

20

0.027

0.071

6.10

0.93

2.43

970-980

10

0.011

0.059

3.05

0.38

2.00

1025-1070

45

0.038

0.450

13.72

1.30

15.40

1070-1085

15

0.199

4.57

6.80

1095-1120

25

0.009

0.222

7.62

0.32

7.61

1130-1200

70

0.126

21.34

4.32

E12-09

335-380

45

0.142

1.165

13.72

4.87

39.90

INCLUDES

345-370

25

0.205

1.391

7.62

7.03

47.65

730-745

15

0.015

0.505

4.57

0.51

17.31

745-795

50

0.212

15.24

7.27

795-830

35

0.041

1.014

10.67

1.39

34.71

E12-10

305-320

15

0.046

0.376

4.57

1.59

12.87

325-340

15

0.016

0.168

4.57

0.54

5.76

555-565

10

0.031

0.485

3.05

1.04

16.61

745-765

20

0.093

0.066

6.10

3.19

2.27

805-820

15

0.038

0.258

4.57

1.30

8.82

830-905

75

0.111

1.382

22.86

3.79

47.34

INCLUDES

830-845

15

0.242

3.750

4.57

8.28

128.41

INCLUDES

875-900

25

0.160

1.441

7.62

5.47

49.36

905-915

10

0.144

3.05

4.91

Ongoing Drilling Programs

The previously completed Spring Valley exploration drilling, the Lucerne West-side development drilling and the initial East-side step-out drilling were the first phases of the Company’s ambitious, 2012-2013 exploration program.  Further phases will include Infill drilling in the Dayton Resource Area, to support a mine plan and permitting activities for a second mine; Infill drilling in the East-side of the Lucerne Resource Area, to support a mine plan and permitting activities for an expansion of the existing Lucerne Mine; and ultimately, Exploration drilling on high-priority targets outside the Lucerne and Dayton Resource Areas.

“The remaining East-side of Lucerne and Dayton Infill drill programs will develop and expand mine plans for both Lucerne and Dayton and provide the precise engineering and economic plans for implementing our production growth plans in 2013 and beyond,” stated Corrado De Gasperis, President and CEO of Comstock.

About Comstock Mining Inc.
Comstock Mining Inc. is a Nevada-based gold and silver mining company with extensive, contiguous property in the Comstock District.  The Company began acquiring properties in the Comstock District in 2003.  Since then, the Company has consolidated a significant portion of the Comstock District, amassed the single largest known repository of historical and current geological data on the Comstock region, secured permits, built an infrastructure and commenced production in 2012.  The Company continues acquiring additional properties in the district, expanding its footprint and creating opportunities for further exploration and mining.  The goal of its strategic plan is to deliver stockholder value by validating qualified resources (at least measured and indicated) and reserves (probable and proven) of 3,250,000 gold equivalent ounces in 2013, and commencing commercial mining and processing operations with annual production rates of 20,000 gold equivalent ounces.

Forward-Looking Statements
This press release and any related calls or discussions may contain forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.  Forward-looking statements include statements about matters such as: future prices and sales of and demand for our products; future industry market conditions; future changes in our exploration activities, production capacity and operations; future exploration, production, operating and overhead costs; operational and management restructuring activities (including implementation of methodologies and changes in the board of directors); future employment and contributions of personnel; tax and interest rates; capital expenditures and their impact on us; nature, timing and accounting for restructuring charges, gains or losses on debt extinguishment,  derivative liabilities and the impact thereof; productivity, business process, rationalization, restructuring, investment, acquisition, consulting, operational, tax, financial and capital projects and initiatives; contingencies; environmental compliance and changes in the regulatory environment; offerings, sales and other actions regarding debt or equity securities; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, earnings and growth.

The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our SEC filings and the following: the current global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, including risks of diminishing quantities or grades of qualified resources and reserves; operational or technical difficulties in connection with exploration or mining activities; contests over our title to properties; potential dilution to our stockholders from our recapitalization and balance sheet restructuring activities; potential inability to continue to comply with government regulations; adoption of or changes in legislation or regulations adversely affecting our businesses; business opportunities that may be presented to or pursued by us; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to unexpected equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, copper, diesel fuel, and electricity); changes in generally accepted accounting principles; geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues organically; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies and equipment raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the SEC; potential inability to list our securities on any securities exchange or market; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows or the market price of our securities.  All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors.  We undertake no obligation to publicly update or revise any forward-looking statement.

Neither this press release nor any related calls or discussions constitutes an offer to sell or the solicitation of an offer to buy any securities.

Contact information for Comstock Mining Inc.:

P.O. Box 1118

Virginia City, NV 89440

questions@comstockmining.com

http://www.comstockmining.com

Doug McQuide

Kimberly Shipley

Director of External Relations

Manager of Investor Relations

Tel (775) 847-7376

Tel (775) 847-0545

mcquide@comstockmining.com

shipley@comstockmining.com

SOURCE Comstock Mining Inc.

Tuesday, October 16th, 2012 Uncategorized Comments Off on East-Side Drilling (LODE) Intercepts Significant Gold And Silver Mineralization

First South Bancorp (FSBK) Quarterly and Nine Months Operating Results Up

First South Bancorp, Inc. Reports Increase in September 30, 2012 Quarterly and Nine Months Operating Results

WASHINGTON, N.C., Oct. 16, 2012 /PRNewswire/ — First South Bancorp, Inc. (NASDAQ: FSBK) (the “Company”), the parent holding company of First South Bank (the “Bank”), reports its unaudited operating results for the quarter ended September 30, 2012, and for the nine months ended September 30, 2012.

For the 2012 third quarter, net income increased 100.9% to $965,965 ($0.10 per diluted common share), from net income of $480,751 ($0.05 per diluted common share) for the linked 2012 second quarter, and increased 139.5% when compared to net income of $403,271 ($0.04 per diluted common share) for the comparative 2011 third quarter. Net income for the nine months ended September 30, 2012 increased 71.6% to $1,908,612 ($0.20 per diluted common share), from net income of $1,112,143 ($0.11 per diluted common share) earned for the nine months ended September 30, 2011. The improvement in earnings for the current quarter in comparison to the linked second quarter are primarily attributed to a significant reduction in non-interest expenses and partially offset by lower net interest income and higher credit provisioning expense.

Bruce Elder, President and CEO, commented, “I am pleased to report the Company’s operating results for the third quarter of 2012. The Company has been able to generate solid core earnings while simultaneously taking a very conservative approach to providing for credit quality issues.  Although the level of our nonperforming assets has declined by approximately $8.2 million this year, we continue to closely monitor and manage the financial stress some of our borrowers are facing.  Consequently, we have provisioned accordingly to maintain our allowance for loan and lease losses at an adequate level.  Mitigating the Bank’s nonperforming assets will continue to be a top priority for the remainder of 2012 and into 2013.”

Asset Quality

Total nonperforming assets, including loans on non-accrual status, restructured loans on non-accrual status and other real estate owned (OREO), declined to $52.8 million at September 30, 2012, from $55.7 million at June 30, 2012 and $60.0 million at December 31, 2011.  Loans on non-accrual status declined to $34.8 million at September 30, 2012, from $37.8 million at June 30, 2012 and $43.0 million at December 31, 2011.

The Bank recorded $2.0 million of provisions for credit losses in the 2012 third quarter, compared to $775,000 in the linked 2012 second quarter and $2.6 million in the comparative 2011 third quarter. Credit loss provisions are necessary to maintain the allowance for loan and lease losses (ALLL) at a level that management believes is adequate.  The ALLL was $15.0 million at September 30, 2012 (3.1% of total loans), compared to $14.0 million at June 30, 2012 (2.8% of total loans) and $15.2 million at December 31, 2011 (2.9% of total loans). Net charge offs were $958,614 in the 2012 third quarter, compared to $1.2 million in the linked 2012 second quarter and $3.0 million in the comparative 2011 third quarter.  We believe the current level of our ALLL is adequate, however, there is no assurance that regulators, increased risks in the loan portfolio, or changes in economic conditions will not require additional adjustments to the ALLL.

Other real estate owned increased marginally to $18.0 million at September 30, 2012, from $17.8 million at June 30, 2012 and $17.0 million at December 31, 2011, reflecting foreclosure activity net of sales and write-downs of certain real estate properties.  Management has performed its quarterly evaluation of these OREO properties and believes their adjusted carrying values are representative of their fair market values, although there is also no assurance that the ultimate sales will be equal or greater than the carrying values.

Net Interest Income

Net interest income declined to $7.2 million for the 2012 third quarter, from $7.5 million for the linked 2012 second quarter and $8.0 million for the comparative 2011 third quarter. The change in levels of net interest income is influenced by the volume of interest-earning assets and interest-bearing liabilities and the management of rates earned and paid during each respective reporting period. The net interest margin on average earning assets remained relatively consistent at 4.4% for both the 2012 third quarter and the linked 2012 second quarter, and 4.6% for the comparative 2011 third quarter.

Non-Interest Income

Total non-interest income was $2.7 million for both the 2012 third quarter and the linked 2012 second quarter, compared to $2.3 million for the 2011 third quarter.  The Bank strives to maintain a consistent level of revenue across loan and deposit service offerings.  Fees, service charges and loan servicing fees also remained relatively constant at $1.6 million for the 2012 third quarter, compared to $1.7 million for both the linked 2012 second quarter and the comparative 2011 third quarter.

Net gains from mortgage loan sales increased to $858,483 for the 2012 third quarter, from $264,266 for the linked 2012 second quarter and $165,418 for the comparative 2011 third quarter.  Net gains from investment securities sales declined to $27,979 for the 2012 third quarter, from $485,047 for the linked 2012 second quarter and $204,248 for the comparative 2011 third quarter.

Mr. Elder stated, “For several prior quarters, we have securitized originated mortgage loans and in effect transferred the originations from loans held for sale to securities available for sale in order to manage liquidity.  During the third quarter, a significant portion of our time deposit portfolio matured and in order to reduce our cost of funds, a larger number of CD’s were redeemed. To better manage liquidity, some volume of originated mortgage loans during the third quarter were sold, servicing retained, which significantly increased our net gains from mortgage loan sales.”

In its efforts to reduce nonperforming assets, the Bank recognized net losses of $56,176 on the sale of OREO properties during the 2012 third quarter, $47,056 in the linked 2012 second quarter and $15,710 in the comparative 2011 third quarter.

Non-Interest Expense

Total non-interest expense declined to $6.4 million for the 2012 third quarter, from $8.6 million for the linked 2012 second quarter and $7.0 million for the comparative 2011 third quarter.  Compensation and benefits, the largest component of these expenses, declined to $3.6 million for the 2012 third quarter, from $4.4 million for the linked 2012 second quarter and $3.7 million for the comparative 2011 third quarter. Compensation and benefits expense for the 2012 second quarter included the final accrual of anticipated lump-sum retirement benefits payable to the former CEO upon his retirement and the employment of the successor CEO.

Expenses attributable to valuation adjustments, ongoing maintenance and property taxes for other real estate owned properties declined to $315,660 for the 2012 third quarter, from $1.3 million for the linked 2012 second quarter and $579,001 for the comparative 2011 third quarter.  “The stabilization of property values continues to be an issue in some of our markets.  We will continue monitoring these values, prudently adjust carrying values as appropriate and dispose of other real estate owned properties as quickly as feasible,” said Mr. Elder.

FDIC insurance premiums declined to $234,061 for the 2012 third quarter, from $259,087 for the linked 2012 second quarter and $387,679 for the comparative 2011 third quarter, reflecting a change in the FDIC’s deposit insurance assessment calculation based on assets and tier one capital versus deposits.

Data processing costs declined to $344,322 for the 2012 third quarter, from $604,250 for the linked 2012 second quarter and $699,089 for the comparative 2011 third quarter, reflecting favorable initial pricing from our recently completed core data processing system upgrade.  Upon the expiration of these pricing concessions, data processing expenses are anticipated to approximate previously reported amounts.

Other noninterest expenses including premises and equipment, advertising, repairs and maintenance, office supplies, professional fees, taxes and insurance, etc., remained relatively consistent during the respective reporting periods.

Income tax expense increased to $552,067 for the 2012 third quarter, from $272,348 for the linked 2012 second quarter and $255,588 for the comparative 2011 third quarter, reflecting changes in the volume of pretax income, deductible expenses, the application of permanent and temporary differences and the applicable income tax rates in effect during each period.

Balance Sheet

Total assets declined to $717.2 million at September 30, 2012, from $742.0 million at June 30, 2012 and $746.9 million at December 31, 2011. Net loans and leases receivable declined to $476.5 million at September 30, 2012, from $491.5 million at June 30, 2012 and $525.2 million at December 31, 2011, reflecting the net of principal repayments, the volume of loans originated, foreclosures, sales, and securitizations of loans into mortgage-backed securities during the current year.

Investment securities increased to $172.7 million at September 30, 2012, from $165.0 million at June 30, 2012 and $138.5 million at December 31, 2011, reflecting the net of purchases, sales, principal repayments and securitizations of certain mortgage loans.  Mortgage-backed securities increased to $148.2 million at September 30, 2012, from $146.4 million at June 30, 2012 and $138.5 million at December 31, 2011.  During 2012, the Bank implemented a strategy to diversify its investment portfolio through the purchase of certain tax-exempt municipal securities.  At September 30, 2012, the balance of the municipal securities portfolio was $24.5 million, compared to $18.6 million at June 30, 2012.

Cash and overnight investments declined to $17.5 million at September 30, 2012, from $34.8 million at June 30, 2012 and $32.8 million at December 31, 2011, reflecting net changes in the Bank’s cash flow and liquidity position used primarily to fund the net growth in the investment portfolio and the net decline in total deposits.

Total deposits declined to $609.5 million at September 30, 2012, from $634.6 million at June 30, 2012 and $642.6 million at December 31, 2011.  Core checking and savings accounts increased to $298.9 million at September 30, 2012, from $291.6 million at June 30, 2012 and $272.7 at December 31, 2011; while certificates of deposits declined to $310.6 million at September 30, 2012, from $343.0 million at June 30, 2012 and $369.9 million at December 31, 2012.  The Bank strives to manage its cost of deposits by monitoring the volume and rates paid on maturing certificates of deposits in relationship to current funding needs and market interest rates.  The Bank did not renew certain higher rate maturing time deposits during the 2012 third quarter, and was able to reprice new and maturing time deposits at lower rates.  The cost of funds improved to 0.69% for the 2012 third quarter, from 0.83% for the linked 2012 second quarter and 1.08% for the comparative 2011 third quarter.

Stockholders’ equity increased to $88.1 million at September 30, 2012, from $86.2 million at June 30, 2012 and $84.1 million at December 31, 2011, reflecting year-to-date net income and changes in accumulated other comprehensive income.  The tangible equity to assets ratio increased to 11.69% at September 30, 2012, from 11.04% at June 30, 2012 and 10.69% at December 31, 2011.  There were 9,751,271 common shares outstanding at September 30, 2012, June 30, 2012 and December 31, 2011, respectively.  The book value per common share increased to $9.04 at September 30, 2012, from $8.84 at June 30, 2012 and $8.63 at December 31, 2011.

“The Company has been internally focused on reducing certain loan concentrations and addressing asset quality issues.  We have recently established a group dedicated solely on nonperforming asset management which will allow our bankers and credit personnel to focus on new businesses development.  We have streamlined our credit process, hired new bankers and credit personnel and are revamping our deposit products to be more competitive and drive non-interest revenue.  Our employees, management and the Board are united and focused on making First South Bank a high performing financial institution,” said Mr. Elder.

Key Performance Ratios

Return on average assets (ROA), return on average equity (ROE), and the efficiency ratio all improved during the 2012 third quarter.  ROA is 0.53% for the 2012 third quarter, compared to 0.26% for the linked 2012 second quarter and 0.21% for the 2011 third quarter.  ROE is 4.42% for the 2012 third quarter, compared to 2.26% for the linked 2012 second quarter and 1.97% for the comparative 2011 third quarter.  The Company continues placing efforts on improving its operating efficiency by managing net interest income, growing non-interest income, and controlling operating expenses.  The efficiency ratio improved to 64.78% for the 2012 third quarter, from 84.84% for the linked 2012 second quarter and 67.77% for the comparative 2011 third quarter.

First South Bancorp, Inc. may be accessed on its website at www.firstsouthnc.com.  The Company’s common stock symbol as traded on the NASDAQ Global Select Market is “FSBK”.

First South Bank has been serving the citizens of eastern North Carolina since 1902 and offers a variety of financial products and services, including a leasing company.  Securities brokerage services are made available through an affiliation with an independent broker/dealer. The Bank operates through its main office headquartered in Washington, North Carolina, and has 26 full service branch offices located throughout central and eastern North Carolina.

Statements contained in this release, which are not historical facts, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those currently anticipated due to a number of factors which include the effects of future economic conditions, governmental fiscal and monetary policies, legislative and regulatory changes, the risks of changes in interest rates, the effects of competition, and including without limitation to other factors that could cause actual results to differ materially as discussed in documents filed by the Company with the Securities and Exchange Commission from time to time.

(NASDAQ: FSBK)

First South Bancorp, Inc. and Subsidiary

Consolidated Statements of Financial Condition

September 30,

December 31,

2012

2011

*

Assets

(unaudited)

Cash and due from banks

$

11,480,221

$

14,298,146

Interest-earning deposits with banks

6,030,941

18,476,173

Investment securities available for sale, at fair value

172,714,688

138,515,210

Loans and leases receivable:

Held for sale

699,928

6,435,983

Held for investment

490,784,538

533,960,226

Allowance for loan and lease losses

(15,007,009)

(15,194,014)

Loans and leases receivable, net

476,477,457

525,202,195

Premises and equipment, net

12,428,109

11,679,430

Other real estate owned

18,003,025

17,004,874

Federal Home Loan Bank stock, at cost

1,634,200

1,886,900

Accrued interest receivable

2,409,473

2,210,314

Goodwill

4,218,576

4,218,576

Mortgage servicing rights

1,339,719

1,237,161

Identifiable intangible assets

47,160

70,740

Income tax receivable

2,472,843

2,194,677

Prepaid expenses and other assets

7,905,197

9,946,459

Total assets

$

717,161,609

$

746,940,855

Liabilities and Stockholders’ Equity

Deposits:

Demand

$

268,243,332

$

243,719,526

Savings

30,611,359

28,988,522

Large denomination certificates of deposit

157,823,418

195,429,182

Other time

152,822,862

174,479,477

Total deposits

609,500,971

642,616,707

Borrowed money

1,973,638

2,096,189

Junior subordinated debentures

10,310,000

10,310,000

Other liabilities

7,255,336

7,804,687

Total liabilities

629,039,945

662,827,583

Common stock, $.01 par value, 25,000,000 shares authorized; 11,254,222 shares issued; 9,751,271 shares outstanding

97,513

97,513

Additional paid-in capital

35,757,978

35,815,098

Retained earnings, substantially restricted

78,418,693

76,510,081

Treasury stock, at cost

(31,967,269)

(31,967,269)

Accumulated other comprehensive income, net

5,814,749

3,657,849

Total stockholders’ equity

88,121,664

84,113,272

Total liabilities and stockholders’ equity

$

717,161,609

$

746,940,855

*Derived from audited consolidated financial statements

First South Bancorp, Inc. and Subsidiary

Consolidated Statements of Operations and Comprehensive Income

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2012

2011

2012

2011

Interest income:

Interest and fees on loans

$

6,903,027

$

8,582,320

$

22,016,871

$

26,312,194

Interest and dividends on investments and deposits

1,442,019

1,278,399

4,059,730

3,628,175

Total interest income

8,345,046

9,860,719

26,076,601

29,940,369

Interest expense:

Interest on deposits

1,002,028

1,767,524

3,572,852

5,669,228

Interest on borrowings

2,456

1,513

4,495

30,480

Interest on junior subordinated notes

91,671

83,019

274,981

248,250

Total interest expense

1,096,155

1,852,056

3,852,328

5,947,958

Net interest income

7,248,891

8,008,663

22,224,273

23,992,411

Provision for credit losses

1,961,965

2,643,282

4,576,965

8,173,293

Net interest income after provision for credit losses

5,286,926

5,365,381

17,647,308

15,819,118

Non-interest income:

Fees and service charges

1,445,990

1,485,776

4,380,751

4,554,400

Loan servicing fees

191,774

195,338

607,352

590,409

Gain (loss) on sale of other real estate, net

(56,176)

(15,710)

(132,197)

(44,418)

Gain on sale of mortgage loans

858,483

165,418

1,427,357

396,946

Gain on sale of investment securities

27,979

204,248

1,546,883

256,394

Other  income

186,492

257,074

719,002

1,018,074

Total non-interest income

2,654,542

2,292,144

8,549,148

6,771,805

Non-interest expense:

Compensation and fringe benefits

3,634,348

3,658,126

12,179,449

11,389,382

Federal deposit insurance premiums

234,061

387,679

745,547

972,462

Premises and equipment

520,663

416,189

1,487,943

1,272,981

Advertising

23,217

45,670

156,782

131,055

Payroll and other taxes

332,598

338,058

1,095,872

1,092,206

Data processing

344,322

699,089

1,558,281

1,922,489

Amortization of intangible assets

115,388

149,257

340,887

442,038

Other real estate owned expense

315,660

579,001

2,901,057

1,063,602

Other

903,179

725,597

2,796,671

2,486,766

Total non-interest expense

6,423,436

6,998,666

23,262,489

20,772,981

Income before income tax expense

1,518,032

658,859

2,933,967

1,817,942

Income tax expense

552,067

255,588

1,025,355

705,799

NET INCOME

$

965,965

$

403,271

$

1,908,612

$

1,112,143

Other comprehensive income, net of taxes

1,042,543

810,839

2,156,900

1,434,070

Comprehensive income

$

2,008,508

$

1,214,110

$

4,065,512

$

2,546,213

Per share data:

Basic earnings per share

$

0.10

$

0.04

$

0.20

$

0.11

Diluted earnings per share

$

0.10

$

0.04

$

0.20

$

0.11

Average basic shares outstanding

9,751,271

9,751,271

9,751,271

9,751,271

Average diluted shares outstanding

9,754,794

9,751,271

9,752,434

9,751,271

First South Bancorp, Inc.

Supplemental Financial Data (Unaudited)

Quarterly

Year to Date

9/30/2012

6/30/2012

3/31/2012

12/31/2011

9/30/2011

9/30/2012

9/30/2011

(dollars in thousands except per share data)

Consolidated balance sheet data:

Total assets

$

717,162

$

741,965

$

750,350

$

746,941

$

768,411

$

717,162

$

768,411

Loans receivable (net):

Mortgage

$

72,659

$

73,455

$

80,263

$

66,249

$

80,453

$

72,659

$

80,453

Commercial

332,438

341,385

352,459

378,823

405,712

332,438

405,712

Consumer

65,444

70,168

71,270

72,821

74,097

65,444

74,097

Leases

5,936

6,453

7,393

7,309

7,972

5,936

7,972

Total loans (net)

$

476,477

$

491,461

$

511,385

$

525,202

$

568,234

$

476,477

$

568,234

Cash and investments

$

17,511

$

34,759

$

64,662

$

32,774

$

32,909

$

17,511

$

32,909

Investment securities

172,715

164,977

123,036

138,515

119,764

172,715

119,764

Premises and equipment

12,428

12,621

12,985

11,679

11,209

12,428

11,209

Goodwill

4,219

4,219

4,219

4,219

4,219

4,219

4,219

Mortgage servicing rights

1,340

1,333

1,268

1,237

1,091

1,340

1,091

Deposits:

Savings

$

30,611

$

30,347

$

31,068

$

28,988

$

27,551

$

30,611

$

27,551

Checking

268,244

261,295

262,500

243,720

243,582

268,244

243,582

Certificates

310,646

342,988

354,780

369,909

394,007

310,646

394,007

Total deposits

$

609,501

$

634,630

$

648,348

$

642,617

$

665,140

$

609,501

$

665,140

Borrowings

$

1,974

$

1,758

$

1,681

$

2,096

$

1,986

$

1,974

$

1,986

Junior subordinated debentures

10,310

10,310

10,310

10,310

10,310

10,310

10,310

Stockholders’ equity

88,122

86,168

84,343

84,113

82,061

88,122

82,061

Consolidated earnings summary:

Interest income

$

8,345

$

8,818

$

8,914

$

9,363

$

9,861

$

26,077

$

29,940

Interest expense

1,096

1,342

1,415

1,608

1,852

3,853

5,948

Net interest income

7,249

7,476

7,499

7,755

8,009

22,224

23,992

Provision for credit losses

1,962

775

1,840

2,640

2,643

4,577

8,173

Noninterest income

2,655

2,653

3,243

2,648

2,292

8,549

6,772

Noninterest expense

6,424

8,601

8,239

7,180

6,999

23,262

20,773

Income tax expense

552

272

201

142

256

1,025

706

Net income

$

966

$

481

$

462

$

441

$

403

$

1,909

$

1,112

Per Share Data:

Basic earnings per share

$

0.10

$

0.05

$

0.05

$

0.05

$

0.04

$

0.20

$

0.11

Diluted earnings per share

$

0.10

$

0.05

$

0.05

$

0.05

$

0.04

$

0.20

$

0.11

Book value per share

$

9.04

$

8.84

$

8.65

$

8.63

$

8.42

$

9.04

$

8.42

Average basic shares

9,751,271

9,751,271

9,751,271

9,751,271

9,751,271

9,751,271

9,751,271

Average diluted shares

9,754,794

9,751,271

9,751,271

9,751,271

9,751,271

9,752,434

9,751,271

First South Bancorp, Inc.

Supplemental Financial Data (Unaudited)

Quarterly

Year to Date

9/30/2012

6/30/2012

3/31/2012

12/31/2011

9/30/2011

9/30/2012

9/30/2011

(dollars in thousands except per share data)

Performance ratios:

Yield on average earning assets

5.02%

5.22%

5.26%

5.44%

5.64%

5.18%

5.67%

Cost of funds

0.69%

0.83%

0.87%

0.96%

1.08%

0.80%

1.13%

Net interest spread

4.33%

4.39%

4.39%

4.48%

4.56%

4.38%

4.54%

Net interest margin/average earning assets

4.36%

4.42%

4.42%

4.51%

4.58%

4.41%

4.54%

Earning assets to total assets

91.24%

90.94%

90.90%

91.09%

90.47%

91.24%

90.47%

Return on average assets (annualized)

0.53%

0.26%

0.25%

0.23%

0.21%

0.34%

0.19%

Return on average equity (annualized)

4.42%

2.26%

2.18%

2.12%

1.97%

2.97%

1.83%

Efficiency ratio

64.78%

84.84%

76.63%

68.95%

67.77%

74.85%

67.47%

Average assets

$

730,204

$

742,690

$

744,395

$

757,905

$

774,383

$

737,684

$

774,383

Average earning assets

$

664,609

$

676,041

$

678,043

$

688,457

$

698,984

$

671,795

$

698,984

Average equity

$

87,437

$

85,018

$

84,582

$

82,708

$

81,757

$

85,763

$

81,757

Equity/Assets

12.29%

11.61%

11.24%

11.26%

10.68%

12.29%

10.68%

Tangible Equity/Assets

11.69%

11.04%

10.67%

10.69%

10.12%

11.69%

10.12%

Asset quality data and ratios:

Loans on nonaccrual status:

Nonaccrual loans

Earning

$

1,984

$

1,494

$

2,255

$

10,601

$

3,179

$

1,984

$

3,179

Non-Earning

12,319

11,151

8,757

11,007

15,107

12,319

15,107

Total Non-Accrual Loans

$

14,303

$

12,645

$

11,012

$

21,608

$

18,286

$

14,303

$

18,286

Nonaccrual restructured loans

Past Due TDRs

$

7,649

$

9,100

$

6,029

$

9,170

$

12,568

$

7,649

$

12,568

Current TDRs

12,849

16,065

20,456

12,247

11,172

12,849

11,172

Total TDRs

$

20,498

$

25,165

$

26,485

$

21,417

$

23,740

$

20,498

$

23,740

Total loans on nonaccrual status

$

34,801

$

37,810

$

37,497

$

43,025

$

42,026

$

34,801

$

42,026

Other real estate owned

18,003

17,845

17,324

17,005

12,886

18,003

12,886

Total nonperforming assets

$

52,804

$

55,655

$

54,821

$

60,030

$

54,912

$

52,804

$

54,912

Allowance for credit losses

$

15,251

$

14,268

$

14,637

$

15,448

$

18,563

$

15,251

$

18,563

Allowance for credit losses to loans

3.10%

2.82%

2.78%

2.85%

3.16%

3.10%

3.16%

Net charge-offs

$

959

$

1,167

$

2,638

$

5,752

$

3,018

$

4,764

$

8,697

Net charge-offs to loans

0.20%

0.24%

0.52%

1.10%

0.53%

1.00%

1.53%

Nonaccrual loans to loans

7.30%

7.69%

7.33%

8.19%

7.40%

7.30%

7.40%

Nonperforming assets to assets

7.36%

7.50%

7.31%

8.06%

7.15%

7.36%

7.15%

Loans to deposits

80.80%

79.80%

81.25%

84.26%

88.35%

80.80%

88.35%

Loans to assets

68.67%

68.26%

70.21%

72.66%

76.48%

68.67%

76.48%

Loans serviced for others

$

328,976

$

326,021

$

316,297

$

319,363

$

302,307

$

328,976

$

302,307

For more information contact:
Bruce Elder (CEO) (252-940-4936)
Bill Wall (SVP) (252-940-5017)
Website: www.firstsouthnc.com

SOURCE First South Bancorp, Inc.

Tuesday, October 16th, 2012 Uncategorized Comments Off on First South Bancorp (FSBK) Quarterly and Nine Months Operating Results Up

Identive’s (INVE) iAuthenticate™ Reader Secure ID Card Authentication for Apple® Mobile Devices

Identive’s iAuthenticate(TM) Reader Extends Secure ID Card Authentication to Apple(R) Mobile Devices

New Reader Allows iPad(R), iPhone(R) and iMac(R) Users to Safely Log on to Secure Networks and Websites, Make Electronic Payments and More

SANTA ANA, Calif. and ISMANING, Germany, Oct. 16, 2012 (GLOBE NEWSWIRE) — Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV), a provider of products and services for the identification, security and RFID industries, today announced a new smart card reader for Apple mobile devices that allows iPad®, iPhone® and iMac® users to authenticate themselves to secure networks, websites and payment systems using their smart chip-based IDs or credit cards. The initial version of the reader is targeted at the U.S. government and worldwide enterprise markets.

“Mobile computing devices are fun to use and allow people to be productive wherever they are. The popularity of the iPad in particular is creating a “bring your own device” culture as employees seek to use their personal devices to accomplish work tasks both within and outside the office. This presents security problems for organizations that maintain strict policies around network access, as these employee-owned devices typically do not have a way to read and authenticate highly secure smart card-based employee IDs. Identive’s iAuthenticate reader addresses this problem by enabling authentication of corporate or federally-issued smart identification credentials using an Apple iPad, iPhone or iMac,” explained Louis Modell, vice president of Identive’s Identification Products division.

One of the world’s largest smart card-based ID programs is operated by the U.S. federal government. However, device mobility has been elusive for the more than five million federal workers who must present their Common Access Card (CAC) or Personal Identification Verification (PIV) credentials to securely authenticate their identities whenever they log on to the network. Identive’s new iAuthenticate reader allows employees and contractors of the Department of Defense, Department of Homeland Security and other government agencies to securely log in to federal websites and web-based accounts, access email and perform other secure collaboration activities without needing to carry a laptop or return to their offices.

To address the unique requirements of the U.S. government and other high-security organizations, Identive’s iAuthenticate reader includes the PKard® for iOS CAC/PIV web/email app from Thursby Software Systems, a leading provider of smart card middleware and applications for Apple devices. Additionally, the reader complies with all relevant federal standards including TAA, FIPS 140-2 and FIPS 201 and an application is in process for its inclusion on the U.S. General Services Administration’s Approved Product List.

“The iAuthenticate reader builds on the wealth of experience and technological know-how Identive has gained from delivering 20 million smart card readers and five million reader ICs to more than 400 PC customers in over 50 countries. Users of Apple iOS devices now can experience this same security, ease of use and cost performance on their mobile devices, from the leader in smart card reader technology,” concluded Dr. Manfred Mueller, executive vice president and COO Identification Products for Identive.

The iAuthenticate reader may be pre-ordered now for November delivery by Identive and its authorized resellers including SHI, PC Mall, NEXCOM, CompSource and Army Air Force Exchange Service locations. For more information or to place an order, please visit: www.identive-infrastructure.com/iAuthenticate.

About Identive

Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV) is focused on building the world’s signature company in Secure ID. The company’s products, software, systems and services address the markets for identity management, physical and logical access control, cashless payment, NFC solutions and a host of RFID-enabled applications for customers in the government, enterprise, consumer, education and healthcare sectors. Identive’s mission is to build a lasting business of scale and technology based on a combination of strong technology-driven organic growth and disciplined acquisitive expansion. The company delivers up-to-date information on its activity as well as industry trends through its industry-leading social media initiatives and educational resource, AskIdentive.com. For additional information, please visit www.identive-group.com or follow on Twitter at @IdentiveGroup.

Note: iAuthenticate is a trademark of Identive Group, Inc. Apple, iMac, iPad and iPhone are registered trademarks of Apple Inc. PKard is a registered trademark of Thursby Software Systems.

The Identive Group, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8072

CONTACT: Darby Dye
         +1 949 553-4251
         ddye@identive-group.com

Identive Group, Inc. Logo

Tuesday, October 16th, 2012 Uncategorized Comments Off on Identive’s (INVE) iAuthenticate™ Reader Secure ID Card Authentication for Apple® Mobile Devices

DayStar (DSTI) Acquisition of Hawaii Commercial Renewable Energy Projects From Avatar Solar

UNION CITY, CA — (Marketwire) — 10/16/12 — DayStar Technologies, Inc. (NASDAQ: DSTI) (“DayStar”) (“the Company”) announced the purchase of solar projects from Avatar Solar of Simi Valley, California. DayStar’s acquisition is a first step and it’s for the Avatar Solar’s Hawaiian-based projects. This is a cash and equity deal that prices DayStar’s common equity at $2.00 per share. Total purchase price was $850,000.00

Avatar states: “We are excited about this arrangement with DayStar. This now gives us the opportunity to bring our project pipelines to DayStar. As such, we currently have projects ready for development in Hawaii, California and India. This relationship will allow us to expand our project capacities.”

Mark (Lorne) Roseborough, President of DayStar, said, “This transaction is representative of opportunities that we are evaluating and marks the start of a new segment of business growth for DayStar.”

Avatar is a full service provider in renewable solar projects which has multiple solar productions sites throughout the islands of Hawaii and the state of California. This acquisition continues DayStar Technologies’ commitment to enhance and grow the ownership of renewable projects, as well as engineering, installation and the maintenance segments of the company. Avatar has a ten year history of growth in California, Hawaii and India, and offers DayStar an opportunity to partner in other renewable energy markets.

Solar energy is an increasingly affordable option without any incentives, however, both the state and federal governments have fully recognized the benefits of solar energy and offer solar tax incentives and tax rebates.

About Avatar Solar:

Avatar Solar is an alternative energy service provider, specializing in solar electric systems through the sale of long term electricity sale by way of Power Purchase Agreements (PPA). Avatar Solar has designed and implemented cost-effective solar electricity solutions for large scale commercial properties in both California and Hawaii.

About DayStar Technologies, Inc.

DayStar Technologies, Inc. (DSTI) is a developer of solar photovoltaic products based upon GIGS thin film deposition technology and is currently embarked on a strategy of strategic partnerships to enter new markets within the global renewal energy industry including ownership and construction of solar and renewable power plants. For more information, visit the DayStar website at http://www.daystartech.com/.

For further information contact, William J Nalley, Orsay Groupe, 305-515-8077, Info@orasygroupe.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
William Nalley
Orsay Groupe
Email Contact

Tuesday, October 16th, 2012 Uncategorized Comments Off on DayStar (DSTI) Acquisition of Hawaii Commercial Renewable Energy Projects From Avatar Solar

VistaGen Therapeutics (VSTA) Completes $3.25M Financing and $3.0M Debt Restructuring

SOUTH SAN FRANCISCO, CA — (Marketwire) — 10/16/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening, today announced the completion of the previously announced $3.25 million financing commitment with Platinum Long Term Growth VII, LLC (Platinum) and approximately $3.0 million strategic debt restructuring. The combined transactions involve the Company’s three largest institutional shareholders and its patent counsel.

“Today marks a significant turning point for VistaGen. These transactions represent a tremendous vote of confidence by four of our major stakeholders and position us to realize the full measure of our commercial opportunities involving our stem cell technology platform and AV-101 clinical program,” said Shawn K. Singh, VistaGen’s Chief Executive Officer.

“Our expectations are set very high. Over the next 12 months, we plan to achieve multiple transformative milestones, both in the lab and in the clinic. This funding provided by Platinum, combined with our strategic equity-based restructuring transactions with Cato Research, Morrison & Foerster and University Health Network, will be instrumental in our success,” concluded Mr. Singh.

Allen Cato, M.D., Ph.D., co-founder and Chief Executive Officer of Cato Research, stated, “By more closely approximating human biology, VistaGen’s stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development. We are pleased to support VistaGen’s efforts to transform the drug development process and to bring safer, more effective therapies to market.”

Michael Goldberg, M.D., Portfolio Manager of Platinum Long Term Growth VII, commented, “VistaGen has been, and continues to represent, an excellent investment opportunity for Platinum. Our continued commitment toward supporting VistaGen underscores our confidence in the Company’s novel stem cell technologies and AV-101.”

Further information regarding the Company’s recent financing transaction with Platinum Long Term Growth Fund, and its strategic debt restructuring transactions with Cato Research, Morrison & Foerster and University Health Network, is set forth in the Company’s Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) and available on both the SEC’s website at www.sec.gov and the Company’s website at www.VistaGen.com.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening. VistaGen’s drug rescue activities are focused on combining its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart or liver toxicity after substantial investment and development by large pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen’s orally-available, small molecule drug candidate, AV-101, is completing Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward-Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the development and commercialization of the Company’s stem cell technology platform, successful completion of the Company’s Phase 1 clinical development program for AV-101, the failure of the Company’s future drug rescue and predictive toxicology programs involving its stem cell technology-based Human Clinical Trial in a Test Tube™ platform, the Company’s ability to enter into third-party research, development and drug rescue collaborations, risks and uncertainties relating to the availability of substantial additional capital from Platinum or any other investor to support the Company’s research, development and commercialization activities, and the success of its research and development plans and strategies, including plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen or its collaborators. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the SEC. These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Tuesday, October 16th, 2012 Uncategorized Comments Off on VistaGen Therapeutics (VSTA) Completes $3.25M Financing and $3.0M Debt Restructuring

Neuralstem (CUR) Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke

Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke Rats With Neuralstem NSI-566 Cells

ROCKVILLE, Md., Oct. 15, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that data on Neuralstem’s NSI-566 spinal cord-derived neural stem cell line in a rat model of  ischemic stroke was presented in a poster, “Histopathological Assessment of Adult Ischemic Rat Brains after 4 Weeks of Intracerebral Transplantation of NSI-566RSC Cell Line,” at The Society for Neurosciences Annual Meeting (http://www.sfn.org/AM2012/).  This study was conducted independently in the laboratory of Dr. Cesar Borlongan, who is the director at the Center of Excellence for Aging and Brain Repair at the University of South Florida College of Medicine.  Post-mortem histology was conducted in collaboration with Neuralstem.  Rats that suffered ischemic stroke by middle cerebral artery occlusion, were transplanted 7 days post-stroke with increasing doses of NSI-566 into the stroke area.  The animals were followed for safety and behavioral response for 56 days post-transplantation.  Researchers reported Saturday that there was significant improvement in both motor and neurological tests in the stem cell-treated rats. There were significant dose-dependent differences in the behavioral improvement across treatment groups at post-transplantation periods, with the highest dose showing the most significant improvement in both motor and neurological tests.  Similarly, there were significant differences in the behavioral performance among treatment groups at post-transplantation periods, with the most significant improvement in both motor and neurological tests seen at day 56 post-transplantation.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

“This study was designed to evaluate the potential therapeutic value of intracerbral dosing of human neural stem cells (NSI-566, supplied by Neuralstem) in an animal model of adult ischemic stroke,” said  Cesar V. Borlongan, Ph.D., University of South Florida College of Medicine, and the lead study author. “The results are very clear. The recovery of motor and neurological tests demonstrated by high-dose transplanted stroke animals was significantly better throughout the 56-day study period compared to vehicle-infused stroke animals, or low-dosed animals. In addition, there was stable improvement in the high-dose animals, and they showed a trend of better improvement over time.”

A separate poster, “Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain,” was also presented on Saturday.   This study was independently carried out by Dr. Martin Marsala and his colleagues.  Dr. Marsala is a professor and the head of the Neuroregeneration Laboratory at University of California San Diego and also a member of the Sanford Consortium for Regenerative Medicine.  In this study, the same stem cells were transplanted into the brains of pigs that received an ischemic stroke on one side of the brain.  8-9 weeks after the ischemic event, which models chronic stroke in humans, feasibility and safety of escalating cell doses and injections were assessed.  Body temperature, behavior, muscle tone and coordination, sensory function, food consumption, defecation, and micturition were monitored at least twice daily for the first 7 days, and once weekly thereafter, until termination.  Up to 12 million cells in 25 cell injection deposits via 5 cannula penetrations were shown to be safe, which closely mimics the intended clinical route and method of delivery in future human clinical trials.  At 6 weeks post-transplantation, there were no complications from the cell transplantation method or the cells.  All animals recovered and showed progressive improvement with no distinction.  All treated animals showed effective engraftment and neuronal maturation with extensive axonal projections.  These data support the application of NSI-566RSC cell line to be transplanted into a chronic stage of previously ischemia-injured brain for treatment of motor deficits resulting from stroke.

“Our study was designed to evaluate the potential value of Neuralstem’s cells in a chronic model of ischemic stroke and in a species that allowed for the use of  human scale transplantation tools and dosing,” said Martin Marsala, MD, at the University of California at San Diego Medical School, and the lead study author of the porcine study. “We have demonstrated clearly that both the route of administration and the cells are safe and well tolerated and that the cells survived and differentiated into mature neurons in the host brain tissue.”

“We have demonstrated safety and efficacy of NSI-566RSC in a  subacute model of ischemic stroke in rats and feasibility and safety in a chronic model of ischemic stroke in mini-pigs,” said Karl Johe, PhD, Chairman of Neuralstem’s Board of Directors and Chief Scientific Officer. “Together, these two studies demonstrate strong proof of principle data that our NSI-566 cells are ready to go into humans to treat paralysis in stroke patients.”

Neuralstem has recently completed a Phase I trial testing the safety of NSI-566 in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and has been approved to initiate a human clinical trial in ischemic stroke in China, through its subsidiary, Suzhou Neuralstem.

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

SOURCE Neuralstem, Inc.

Monday, October 15th, 2012 Uncategorized Comments Off on Neuralstem (CUR) Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke

Swisher Hygiene (SWSH) Relaunches DALEY™ Brand at the 2012 ISSA/INTERCLEAN

Swisher Hygiene Relaunches DALEY(TM) Brand at the 2012 ISSA/ INTERCLEAN Show in Chicago, October 16 — 19

Relaunch Designed to Enhance Growth Opportunities and Achieve Greater Consistency Across DALEY(TM) Brand

CHARLOTTE, N.C., Oct. 15, 2012 (GLOBE NEWSWIRE) — Swisher Hygiene Inc. (“Swisher Hygiene”) (Nasdaq:SWSH) (TSX: SWI), a leading provider of essential hygiene and sanitation products and services, today announced that it will relaunch its DALEY™ brand at the 2012 ISSA/INTERCLEAN Show at McCormick Place in Chicago, Illinois from October 16-19. Acquired by Swisher Hygiene in September 2011, Daley International (“DALEY”) is one of the largest manufacturers and marketers of private-label and brand name institutional and industrial cleaning products in the United States.

With its roots firmly in Chicago and dating back over 100 years, DALEY has a rich history of product innovation, reliability and unparalleled customer care. Today, the DALEY™ brand includes an extensive line of floor care, personal care, laundry, housekeeping, food service and building maintenance products along with a private label program tailored to meet its customers’ exact needs. To better reflect DALEY’s leading position and enhance its future growth opportunities across all product and service categories, Swisher Hygiene will introduce a modernized image and marketing materials to promote consistency and embody the product innovation that DALEY continues to pursue.  In concert with the rebranding, Swisher has dedicated a new highly experienced and skilled sales team responsible for prospecting, selling to, and servicing DALEY’s current and future clients.

“The DALEY brand carries a great deal of brand equity in the industry, and we believe the ISSA/INTERCLEAN show is the perfect time to showcase DALEY’s new brand and products, while also highlighting Swisher Hygiene’s ability to manufacture an extensive array of products at all of our strategically located regional chemical facilities,” said Thomas Byrne, Interim President and Chief Executive Officer of Swisher Hygiene. “This rebranding initiative will allow us to effectively expand the non-service segment of our business and reach a broader segment of the chemical industry.  DALEY is a shining example of how Swisher Hygiene continues to provide best-in-class products as well as outstanding customer service.”

The new DALEY brand image is reflected in its marketing materials and should resonate with prospects and better communicate its points of differentiation, helping to further distinguish the company as a progressive brand and an industry leader.  Attendees interested in viewing the new DALEY brand and learning about the company’s different products and services are encouraged to visit booth #608.

About Swisher Hygiene Inc.

Swisher Hygiene Inc. is a NASDAQ and TSX listed company that provides essential hygiene and sanitation solutions to customers throughout much of North America and internationally through its global network of company-owned operations, franchises and master licensees operating in countries across Europe and Asia. These essential solutions include cleaning and sanitizing chemicals, foodservice and laundry products, restroom hygiene programs and a full range of related products and services. Through its DALEY operation, Swisher Hygiene also provides branded and private-label products for those customers that do not require Swisher Hygiene’s installation, preventative maintenance and emergency service offerings. Together, this broad set of offerings is designed to promote superior cleanliness and sanitation in all commercial environments from door to dumpster, enhancing the safety, satisfaction and well-being of employees and patrons. Swisher Hygiene’s customers include a wide range of commercial enterprises, with a particular emphasis on the foodservice, hospitality, retail, industrial and healthcare industries.

CONTACT: Swisher Hygiene Inc.

         Investor Contact:
         Amy Simpson
         Phone: (704) 602-7116

         Garrett Edson, ICR
         Phone: (203) 682-8331

         Media Contact:
         Jason Chudoba, ICR
         Phone: (646) 277-1249
         Jason.Chudoba@icrinc.com
Monday, October 15th, 2012 Uncategorized Comments Off on Swisher Hygiene (SWSH) Relaunches DALEY™ Brand at the 2012 ISSA/INTERCLEAN

American Lorain Corp. (ALN) Announces Receipt of “Going Private” Proposal

JUNAN COUNTY, China, Oct. 15, 2012 /PRNewswire-FirstCall/ — American Lorain Corporation (NYSE Amex: ALN) (the “Company”), an international processed snack foods, convenience foods, and frozen foods company based in the Shandong Province, China, today announced that its Board of Directors has received a preliminary, non-binding proposal letter dated October 9, 2012 from Mr. Si Chen, Chairman, CEO and President of the Company, to acquire all of the outstanding ordinary shares of the Company not currently owned by Mr. Chen at a proposed price of $1.6 per ordinary share, in cash, subject to certain conditions. Mr. Chen currently beneficially owns, in the aggregate, approximately 46.5% of the Company’s outstanding ordinary shares.

According to the proposal letter, Mr. Chen will form an acquisition vehicle for the purpose of pursuing the acquisition and the acquisition is intended to be financed by a combination of debt and equity capital. A copy of the proposal letter is attached hereto as Exhibit A.

The Company’s board of directors has formed an independent committee (the “Independent Committee“), composed of Mr. Dekai Yin, Mr. Tad M. Ballantyne and Mr. Maoquan Wei, and elected Mr. Yin as its chairman, to consider the proposal. The Independent Committee has the authority to retain independent legal and financial advisors to assist it. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that a transaction with Mr. Chen or any other transaction will be approved or consummated.

The Independent Committee has appointed Sidley Austin LLP as its legal counsel.

About American Lorain Corporation

American Lorain Corporation products include chestnut products, convenience food products and frozen food products. The Company currently sells over 240 products to 26 provinces and administrative regions in China as well as to 42 foreign countries. The Company operates through its five direct and indirect subsidiaries and one leased factory located in China. For further information about American Lorain Corporation, please visit the Company’s website at http://www.americanlorain.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects” and similar references to future periods.  Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions.  Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Potential risks and uncertainties include, but are not limited to, those relating to whether any definitive offer will be made, whether any agreement will be executed or whether this or any other transaction will be approved or consummated. Our actual results may differ materially from those contemplated by the forward-looking statements.  They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors that could cause actual results to differ materially from such statements, as well as additional risk factors, are detailed in the Company’s most recent filings with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made.  We undertake no obligation to publicly update any forward-looking information contained in this press release or with respect to the announcements described herein, except as may be required by law.

Investor Relations Contact:

At the Company:
American Lorain Corporation
Mr. David She, CFO
+86-10 8411 3393
david.she@americanlorain.com
Web: http://www.americanlorain.com

Exhibit A

Private and Confidential

PROPOSAL LETTER

October 9, 2012

The Board of Directors
American Lorain Corporation
Beihuan Zhong Road, Junan County
Shandong, China 276600

Dear Sirs,

I, Chen Si, am pleased to submit this preliminary non-binding proposal to acquire all of the common stock of American Lorain Corporation (the “Company“) that are not currently owned by me in a going private transaction (the “Acquisition“).

I believe that my proposal provides a very attractive opportunity to the Company’s shareholders. My proposal represents a premium of 39.1% to the Company’s closing price on October 8, 2012.

1. Purchase Price.

The consideration payable for each share of the common stock of the Company (other than those common stock held by me and my affiliates) will be $1.6 in cash.

2. Financing.

I intend to finance the Acquisition with a combination of debt and equity capital.

I have held preliminary discussions with a Chinese bank which is experienced in financing going-private transactions and expect to receive a letter of intent from them in due course. I expect commitments for the debt financing, subject to the terms and conditions set forth therein, to be in place when the Definitive Agreements (to be defined below) are executed. I have also had preliminary discussions with potential sources of equity financing, and may make agreements with them relating to possible investments in the Acquisition.

3. Due Diligence.

Parties providing financing will require a timely opportunity to conduct customary due diligence on the Company. I would like to ask the board of directors of the Company to accommodate such due diligence request and approve the provision of confidential information relating to the Company and its business to possible sources of equity and debt financing under a customary form of confidentiality agreement.

4. Definitive Agreements.

I am prepared to promptly negotiate and finalize definitive agreements (the “Definitive Agreements“) providing for the Acquisition and related transactions.  These documents will provide for representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions of this type.

5. Process.

I believe that the Acquisition will provide superior value to the Company’s shareholders. I recognize that the Company’s board of directors will evaluate the Acquisition independently before it can make its determination to endorse it. Given my involvement in the Acquisition, I appreciate that the independent members of the board of directors will proceed to consider the proposed Acquisition and I will recuse myself from participating in any board deliberations and decisions related to the Acquisition.

6. Confidentiality.

I intend promptly file an amendment to my Schedule 13D to disclose this letter. However, I am sure you will agree that it is in all of our interests to ensure that we proceed in a strictly confidential matter, unless otherwise required by law, until we have executed the Definitive Agreements or terminated our discussions.

7. Advisors.

I have retained HFG China as my financial advisor and Squire Sanders (US) LLP as my legal counsel in connection with this proposal and the Acquisition.

8. No Binding Commitment.

This letter constitutes only a preliminary indication of my interest and does not constitute any binding commitment with respect to the Acquisition or any other transactions. A binding commitment will result only from the execution of the Definitive Agreements, and then will be on the terms provided in such documentation.

In closing, I would like to express my commitment to working together to bring this Acquisition to a successful and timely conclusion. Should you have any questions regarding this proposal, please do not hesitate to contact me. I look forward to hearing from you.

By:      _________________________
Name:  Chen Si

Monday, October 15th, 2012 Uncategorized Comments Off on American Lorain Corp. (ALN) Announces Receipt of “Going Private” Proposal

Yongye International (YONG) Announces Receipt of “Going Private” Proposal at $6.60

BEIJING, Oct. 15, 2012 /PRNewsiwre-Firstcall/ — Yongye International, Inc. (NASDAQ:  YONG) (“Yongye” or the “Company”), a leading developer, manufacturer and distributor of crop nutrient products in China, today announced that its Board of Directors has received a preliminary, non-binding proposal letter dated October 15, 2012 from (i) Mr. Zishen Wu (“Mr. Wu”), the Company’s Chairman and Chief Executive Officer, (ii) Full Alliance International Limited (“Full Alliance”), (iii) MSPEA Agriculture Holding Limited (“MSPEA”), and (iv) Abax Global Capital (Hong Kong) Limited, on behalf of funds managed and/or advised by it and its nominee entities and its and their affiliates (collectively, “Abax,” together with Mr. Wu, Full Alliance and MSPEA, the “Buyer Parties”), to acquire all of the outstanding shares of common stock of the Company not currently owned by the Buyer Parties in a going private transaction for $6.60 per share of common stock in cash, subject to certain conditions.

According to the proposal letter, an acquisition vehicle will be formed for the purpose of completing the acquisition, and the acquisition is intended to be financed through a combination of debt and equity capital.  Equity financing will be provided by the Buyer Parties or their affiliates in the form of cash and/or rollover equity in the Company.  Debt financing will be primarily provided by third party financial institutions.  The proposal letter states that the Buyer Parties have been in discussions with a Chinese bank which is experienced in financing going private transactions and has expressed interest in providing loans to finance the acquisition.  Please refer to the enclosed Exhibit A for a copy of the proposal letter.

A special committee (the “Special Committee”) of the Board of the Directors, consisting of Mr. Sean Shao, Mr. Xiaochuan Guo and Mr. Xindan Li, was formed to consider certain potential transactions involving the Company (including this proposal) and has retained Cleary Gottlieb Steen & Hamilton LLP as its legal counsel to assist it in consideration of such matters.  The Special Committee will also retain an independent financial advisor to assist it in its work.  The Board of Directors cautions the Company’s stockholders and others considering trading in its securities that the Board has just received the non-binding proposal from the Buyer Parties and that no decisions have been made by the Special Committee with respect to the Company’s response to the proposal.  There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

About Yongye International, Inc.

Yongye International, Inc. is a leading crop nutrient company headquartered in Beijing, with its production facilities located in Hohhot, Inner Mongolia, China.  Yongye’s principal product is a liquid crop nutrient, from which the Company derived substantially all of the sales in 2011.  The Company also produces powder animal nutrient product which is mainly used for dairy cows.  Both products are sold under the trade name “Shengmingsu”, which means “life essential” in Chinese.  The Company’s patented formula utilizes fulvic acid as the primary compound base and is combined with various micro and macro nutrients that are essential for the health of the crops.  The Company sells its products primarily to provincial level distributors, who sell to the end-users either directly or indirectly through county-level and village-level distributors.  For more information, please visit the Company’s website at www.yongyeintl.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this announcement may be viewed as “forward-looking statements” within the meaning of Section 27A of U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual performance, financial condition or results of operations of the Company to be materially different from any future performance, financial condition or results of operations implied by such forward-looking statements.  The accuracy of these statements may be affected by a number of business risks and uncertainties that could cause actual results to differ materially from those projected or anticipated.  The Company undertakes no ongoing obligation, other than that imposed by law, to update these statements.

Exhibit A

The Board of Directors
Yongye International, Inc.
6th Floor, Suite 608, Xue Yuan International Tower
No. 1 Zichun Road, Haidian District
Beijing, China

October 15, 2012

Dear Sirs:

Zishen Wu (“Mr. Wu”), Full Alliance International Limited (“Full Alliance”), MSPEA Agriculture Holding Limited (“MSPEA”) and Abax Global Capital (Hong Kong) Limited, on behalf of funds managed and/or advised by it and its nominee entities and its and their affiliates (collectively “Abax”, together with Mr. Wu, Full Alliance, MSPEA and Abax, the “Buyer Parties” and each a “Buyer Party”) are pleased to submit this preliminary non-binding proposal to acquire all outstanding shares of common stock (the “Shares”) of Yongye International, Inc. (the “Company”) not beneficially owned by the Buyer Parties (the “Acquisition”).

We believe that our proposal of US$6.60 in cash per share of the Company’s common stock will provide a very attractive opportunity to the Company’s shareholders. This price represents a premium of approximately 37.8% to the Company’s closing price on October 12, 2012 and a premium of approximately 47.2% to the volume-weighted average price during the last 30 trading days, a premium of 70.4% to the volume-weighted average price during the last 90 trading days, and a premium of 84.4% to the volume-weighted average price during the last 180 trading days.

The terms and conditions upon which we are prepared to pursue the Acquisition are set forth below. We are confident in our ability to consummate an Acquisition as outlined in this letter.

1.     Buyer.  The Buyer Parties have entered into a letter agreement dated October 15, 2012 (the “Consortium Agreement”), pursuant to which Full Alliance will form an acquisition vehicle for the purpose of pursuing the Acquisition (“Acquisition Vehicle”), and the Buyer Parties will work with each other on an exclusive basis in pursuing the Acquisition during the term of the Consortium Agreement.

2.     Purchase Price.  The Buyer Parties are prepared to pay for the Shares acquired in the Acquisition at a price of US$6.60 per share, in cash.

3.     Financing.  We intend to finance the Acquisition with a combination of debt and equity capital.  Equity financing will be provided by the Buyer Parties or its affiliated entities in the form of cash and/or rollover equity in the Company.  Debt financing will be primarily provided by third party financial institutions.  We have held discussions with a Chinese bank which is experienced in financing going-private transactions and has expressed interest in providing loans to finance the Acquisition.  We are confident that we will secure adequate financing to consummate the Acquisition.

4.     Due Diligence.  We will be in a position to commence our due diligence for the Acquisition immediately upon receiving access to the relevant materials.

5.     Definitive Agreements.  We are prepared to negotiate and finalize definitive agreements (the “Definitive Agreements”) concurrently with our due diligence review.  This proposal is subject to execution of the Definitive Agreements.  These documents will include provisions typical for transactions of this type.

6.     Confidentiality.  We are sure you will agree with us that it is in all of our interests to ensure that we proceed in a confidential manner, unless otherwise required by law, until we have executed the Definitive Agreements or terminated our discussions.

7.     Process.  We believe that the Acquisition will provide superior value to the Company’s shareholders.  We recognize of course that the Company’s Board of Directors will evaluate the proposed Acquisition independently before it can make its determination whether to endorse it.  In considering the proposed Acquisition, you should be aware that we are interested only in acquiring the outstanding shares that the Buyer Parties and their affiliates do not already own, and that the Buyer Parties and their affiliates do not intend to sell their stake in the Company to a third party.

8.     About MSPEA. MSPEA is a vehicle controlled by Morgan Stanley Private Equity Asia III, L.P., a fund managed by Morgan Stanley Private Equity Asia.  Morgan Stanley Private Equity Asia is one of the leading private equity investors in the Asia Pacific region, having invested in the region for over 19 years. The team has invested approximately US$2.4 billion in Asia, focusing on profitable, growth-oriented companies. Morgan Stanley Private Equity Asia has offices located in Hong Kong, Shanghai, Mumbai, Seoul, Tokyo and New York.

9.     About Abax.  Abax Global Capital is a leading Hong-Kong-based investment fund focused on Pan-Asian private and public investments with an emphasis on Greater China. Founded in 2007, Abax Global Capital’s objective is to invest in and create value for small-to-mid-sized Asian enterprises.

10.  Advisors.  Mr. Wu and Full Alliance have retained Skadden, Arps, Slate, Meagher & Flom LLP as its legal counsel, MSPEA has retained Paul, Weiss, Rifkind, Wharton & Garrison LLP as its legal counsel and Abax Global Capital has retained Weil, Gotshal & Manges LLP as its legal counsel in connection with this proposal and the Acquisition.

11.  No Binding Commitment.  This letter constitutes only a preliminary indication of our interest, and does not constitute any binding commitment with respect to an Acquisition.  Such a commitment will result only from the execution of Definitive Agreements, and then will be on the terms provided in such documentation.

In closing, each of us would like to personally express our commitment to working together to bring this Acquisition to a successful and timely conclusion.  Should you have any questions regarding this proposal, please do not hesitate to contact Mr. Wu at +86 10 8231-9608, Mr. Homer Sun of MSPEA at +852 2848-5844 or Mr. Chee-Kong Chan at Abax at +852 3602-1835. We look forward to speaking with you.

Sincerely,

Zishen Wu
By:
Full Alliance International Limited
By: 
Name:
Title:

MSPEA Agriculture Holding Limited
By: 
Name:
Title:

Abax Global Capital (Hong Kong) Limited
By: 
Name:
Title:

Contacts:

Yongye International, Inc.
Ms. Kelly Wang
Finance Director – Capital Markets
Phone: +86-10-8231-9608
E-mail: ir@yongyeintl.com

Ms. Wendy Xuan
Business Associate
Phone: +86-10-8232-8866 x 8827
E-mail: ir@yongyeintl.com

FTI Consulting
Mr. John Capodanno (U.S.)
Phone: +1-212-850-5705
E-mail: john.capodanno@fticonsulting.com

Ms. May Shen (Beijing)
Phone: +86-10-8591-1951
E-mail: may.shen@fticonsulting.com

Monday, October 15th, 2012 Uncategorized Comments Off on Yongye International (YONG) Announces Receipt of “Going Private” Proposal at $6.60

China Shengda (CPGI) Non-Binding “Going Private” Proposal of $1.40 per Share

China Shengda Packaging Announces Receipt of Chairman’s Non-Binding “Going Private” Proposal of $1.40 per Share

HANGZHOU, China, Oct. 15, 2012 /PRNewswire-FirstCall/ — China Shengda Packaging Group Inc. (NASDAQ: CPGI) (“China Shengda Packaging” or the “Company”), a leading Chinese paper packaging manufacturer, today announced that that its Board of Directors has received a preliminary, non-binding proposal (the “Proposal”) from its Chairman, Mr. Nengbin Fang (“Mr. Fang”), in which Mr. Fang has offered to acquire all of the outstanding shares of the Company’s common stock he and his family currently do not own in a going-private transaction at a proposed price of $1.40 per share to be paid in cash. According to the Proposal, Mr. Fang intends to fund the acquisition with a combination of debt and equity financing. Currently, Mr. Fang and his family collectively beneficially own approximately 54.03% of the Company’s common stock. A copy of the proposal letter is attached as Exhibit A.

The Company’s Board of Directors has established a special committee (the “Special Committee”) to consider this Proposal and any additional proposals that may be made by Mr. Fang and his affiliates, if any. The Special Committee is comprised of the following independent directors of the Company: Mr. Zhihai Mao, Mr. Michael Zhang, and Mr. Yaoquan Zhang.

There can be no assurance that any definitive offer will be made, that any agreement will be executed, or that a transaction with Mr. Fang or any other transaction will be approved or consummated.

About China Shengda Packaging Group Inc.

China Shengda Packaging Group Inc. is a leading paper packaging company in China. It is principally engaged in the design, manufacturing and sale of flexo-printed and color-printed corrugated paper cartons in a variety of sizes and strengths. It also manufactures corrugated paperboards, which are used for the production of its flexo-printed and color-printed cartons. The company provides paper packaging solutions to a wide variety of industries, including food, beverage, cigarette, household appliance, consumer electronics, pharmaceuticals, chemicals, machinery and other consumer and industrial sectors in China. For more information, visit http://www.cnpti.com.

Company Contact:

Investor Relations Contact:

China Shengda Packaging Group Inc.

CCG Investor Relations

Cindy Hu, Board Secretary

Mark Collinson

Tel: +86-571 8283 8770

Tel: +1-310-954-1343

E-mail: cindy.hu@cnpti.com

Email: mark.collinson@ccgir.com

Website: http://www.cnpti.com

Website: http://www.ccgasiair.com

Exhibit A

October 15, 2012

Board of Directors
No. 2 Beitang Road
Xiaoshan Economic and Technological Development Zone
Hangzhou, Zhejiang Province 311215
People’s Republic of China

Dear Sirs:

I, Nengbin Fang, am pleased to submit this preliminary non-binding proposal (the “Proposal”) to acquire all of the common stock of China Shengda Packaging Group Inc. (the “Company”) that are not currently owned by me and my family in a going-private transaction (the “Acquisition”).

I believe that my proposal of $1.40 in cash per share of common stock of the Company will provide a very attractive alternative to the Company’s public stockholders. My proposal represents a premium of approximately 57.5% to the volume-weighted average closing price during the last 30 trading days and a premium of approximately 54% to the Company’s closing price on October 12, 2012.

The terms and conditions upon which I am prepared to pursue the Acquisition are set forth below. I am confident that an Acquisition can be closed on the basis as outlined in this letter.

1. Purchase Price.

The consideration payable for each share of common stock of the Company (other than those held by me and my affiliates) will be $1.40 in cash.

2. Financing.

I intend to finance the Transaction with a combination of debt and equity capital. A portion of the equity financing would be provided from my existing holdings of common stock of the Company. I will also immediately commence discussions with potential sources of financing (both debt and equity) and with certain stockholders of the Company, and may make agreements with them relating to possible investments in the Acquisition.

At this time there is no arrangement whatsoever with any stockholder of the Company or potential source of debt or equity financing for the Acquisition, and I do not propose to make any commitment prior to reaching transaction terms approved by the board of directors of the Company.

3. Due Diligence.

Parties providing financing will require a timely opportunity to conduct customary due diligence on the Company. I would like to ask the board of directors of the Company to accommodate such due diligence request and approve the provision of confidential information relating to the Company and its business to possible sources of equity and debt financing under a customary form of confidentiality agreement.

4. Definitive Agreements.

I am prepared to negotiate and finalize definitive agreements (the “Definitive Agreements”) providing for the Acquisition and related transactions very promptly. These documents will provide for covenants and conditions typical and appropriate for transactions of this type.

5. Confidentiality.

I am sure you will agree that it is in all of our interests to proceed in a confidential manner, other than as required by law, until definitive agreements providing for a transaction have been executed or we have terminated our discussions.

6. Process.

I believe that the Acquisition will provide superior value to the Company’s public stockholders. I recognize that the board of directors of the Company will evaluate the Proposal independently before it can make its determination to endorse the Acquisition. Given my involvement in the proposed Acquisition, I also recognize that independent members of the Board will proceed to consider the proposed Acquisition. In considering my offer, you should be aware that I am interested only in acquiring the common stock of the Company that I do not already own, and that I do not intend to sell my stake in the Company to a third party.

7. No Binding Commitment.

This Proposal does not constitute any binding commitment with respect to the Acquisition or any other transaction.  Any commitment will result only from the execution of Definitive Agreements, and then will be on the terms provided in such documentation.

In closing, I would like to personally express my sincerity to work with the board of directors of the Company to bring this Acquisition to a successful and timely conclusion.  Should you have any questions regarding these matters, please do not hesitate to contact me.

Sincerely,

/s/ Nengbin Fang
Nengbin Fang

Monday, October 15th, 2012 Uncategorized Comments Off on China Shengda (CPGI) Non-Binding “Going Private” Proposal of $1.40 per Share

Updated Phase 2 Survival Data of Cyclacel’s (CYCC) Sapacitabine for MDS

Updated Phase 2 Survival Data of Cyclacel’s Sapacitabine for MDS Presented at The Eighth Annual Hematologic Malignancies 2012 Conference

Conference Call to Review Results to be Held on Monday, October 15 at 3:30pm ET

BERKELEY HEIGHTS, N.J., Oct. 12, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) announced that updated data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company’s lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine (Vidaza®) and/or decitabine (Dacogen®), will be discussed at two separate sessions at The Eighth Annual Hematologic Malignancies 2012 Conference being held on October 10-14, 2012, in Houston, Texas. Median overall survival to date for all 63 patients is 252 days or approximately 8 months. Median overall survival for 41 out of 63 patients with 10% or more blasts in their bone marrow is 274 days or approximately 9 months.

“The updated survival data reported from this sapacitabine study in MDS patients after treatment failures of hypomethylating agents are impressive in our experience,” said Guillermo Garcia-Manero, M.D., Chief of the Section of Myelodysplastic Syndromes and Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center and an investigator for the study. “If they are reproduced in subsequent studies, sapacitabine may become a new treatment standard for older patients.”

“MDS patients have a poor outcome after treatment failures with front-line therapies. The updated survival data support previously reported data indicating that sapacitabine is active in this patient population,” said Hagop Kantarjian, M.D., Chairman & Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center and principal investigator for the study. “Median survival for patients with intermediate-2 or high-risk MDS following treatment failures of hypomethylating agents is 4.3 to 5.6 months. We urgently need effective therapies for these patients.”

Results

The updated median survival for all three arms is 252 days (approximately 8 months). The median survival for each arm was 291 days (approximately 10 months) for Arm G, 274 days (approximately 9 months) for Arm H, and 227 days (approximately 8 months) for Arm I. Twenty-seven percent of all patients received 6 or more cycles. Twenty-two percent of patients are still alive and longer follow-up is needed to assess 1-year survival and overall survival of each arm.

Study Design

The open-label, multi-center, Phase 2 study randomized 63 patients aged 60 years or older with MDS of intermediate-2 (n=52) or high-risk (n=11) classification by the International Prognostic Scoring System (IPSS) at study entry to receive sapacitabine every 4 weeks on one of 3 dosing schedules: 200 mg twice daily for 7 days (Arm G), 300 mg once daily for 7 days (Arm H), or 100 mg once daily for 5 days per week for 2 weeks (Arm I). The primary efficacy endpoint of the study is 1-year survival with the objective of identifying a dosing schedule that produces a better 1-year survival rate in the event that all three dosing schedules are active. All patients in the study progressed after receiving azacitidine, decitabine, or both agents.

The Eighth Annual Hematologic Malignancies 2012 Conference

Information on The Eighth Annual Hematologic Malignancies 2012 Conference can be at accessed at: http://hm2012.homestead.com. Presentation times are as follows:

Session IV: Myelodysplastic Syndromes I
Guillermo Garcia-Manero, MD: “New MDS Strategies”
Date/Time: Thursday, October 11, 2012, 5:40 PM Central
Session X: Myelodysplastic Syndromes II
Hagop Kantarjian, MD: “Keynote Speaker: MDS/MPD (with award from MDACC1/Mayo Clinic)”
Date/Time: Saturday, October 13, 2012, 4:00 PM Central
Guillermo Garcia-Manero, MD and Hagop Kantarjian, MD will discuss on a Company conference call the updated data from the above presentations. Conference call details are as follows:
Date/Time: Monday, October 15, 2012, 3:30 PM Eastern
US/Canada call: (877) 493-9121/ international call: (973) 582-2750
US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406
Code for live and archived conference call is 44048598

About Myelodysplastic Syndromes (MDS)

MDS is a family of clonal myeloid neoplasms, or malignancies of the blood, caused by the failure of blood cells in the bone marrow to develop into mature cells. Patients with MDS typically suffer from bone marrow failure and cytopenias, or reduced counts of platelets, red and white blood cells. The exact incidence and prevalence of MDS are unknown because it can go undiagnosed and a national survey canvassing both hospitals and office practitioners has not been completed. Some estimates place MDS incidence at 15,000 to 20,000 new cases each year in the US alone with some authors estimating incidence as high as 46,000. Literature evidence suggests that there is a rising incidence of MDS as the age of the population increases with the majority of patients aged above 60 years.

Median survival for patients with intermediate-2 or high-risk disease, as defined by the International Prognostic Scoring System (IPSS), is 4.3 to 5.6 months.1, 2 Patients with high IPSS scores also have a high probability of experiencing transformation of their MDS into AML, an aggressive form of blood cancer with typically poor survival.

1 Prebet T, Gore S, et al, Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure, Journal of Clinical Oncology 2011, 10.1200/JCO.2011.35.8135.

2 Jabbour E, Garcia-Manero G, et al, Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy, Cancer 2010, 10.1002/cncr.25247.

About sapacitabine

Sapacitabine (CYC682), an orally-available nucleoside analogue, is in the SEAMLESS, registration-directed, Phase 3 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML), and in the investigator-led, Phase 2/3 LI-1 Trial in patients aged 60 years or older with previously untreated AML or high risk MDS who are unfit for intensive chemotherapy. Sapacitabine is in Phase 2 trials in patients with hematological malignancies, including myelodysplastic syndromes (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and non-small cell lung cancer (NSCLC), a Phase 1 trial in combination with seliciclib in patients with advanced solid tumors and an investigator-led, Phase 2/3 study comparing sapacitabine to low dose cytarabine as front-line treatment of elderly patients with AML or high risk MDS unfit for intensive chemotherapy. Sapacitabine acts through a novel DNA single-strand breaking mechanism, leading to production of DNA double strand breaks (DSBs) and/or checkpoint activation. Unrepaired DSBs cause cell death. Repair of sapacitabine-induced DSBs is dependent on the homologous recombination DNA repair (HRR) pathway. Both sapacitabine and CNDAC, its major metabolite, have demonstrated potent anti-tumor activity in preclinical studies.

Over 500 patients have received sapacitabine in Phase 2 studies in AML, MDS, CTCL and NSCLC and Phase 1 studies in both hematological malignancies and solid tumors. At the 2009 Annual Meeting of the American Society of Hematology (ASH), Cyclacel reported data from a randomized Phase 2, single-agent study of sapacitabine including promising 1-year survival in elderly patients with AML aged 70 years or older. At the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Cyclacel reported data from a pilot Phase 1/2 study including promising response rate, low 4-week and 8-week mortality in elderly patients with AML aged 70 years or older receiving sapacitabine alternating with decitabine. Cyclacel is currently enrolling patients in the SEAMLESS, Phase 3, randomized, registration-directed study of sapacitabine in elderly patients with acute myeloid leukemia (AML). The FDA and the European Medicines Agency have designated sapacitabine as an orphan drug for the treatment of both AML and MDS.  Sapacitabine is part of Cyclacel’s pipeline of small molecule drugs designed to target and stop uncontrolled cell division.

About sapacitabine in MDS

A total of 124 patients aged 60 years or older with MDS previously treated with hypomethylating agents (HMA) were treated in a Cyclacel Phase 2 study. Initially 61 patients were randomized across 3 dosing schedules of sapacitabine. Mature survival data from this cohort were presented at the 2010 Annual Meeting of the American Society of Hematology (ASH) on the basis of which the study was subsequently expanded to compare additional dosing schedules. Interim data on a further 63 patients were presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), with median survival of 8.4 months. This survival level is considered clinically significant by MDS experts in light of historical control expectations of 4 to 5 months. At the time of ASCO 2012 over 34% of the patients were still alive and longer follow-up is needed to assess 1-year survival and overall survival. Updated mature survival data will be reported in late 2012 or early 2013. Cyclacel is developing a pivotal development plan for the indication of second-line MDS to present to regulatory authorities.

At ASCO 2012 Cyclacel reported interim data from three schedules of sapacitabine administered as single-agent treatment over a 4-week cycle in 63 patients with IPSS intermediate-1 or higher risk MDS after treatment failure of hypomethylating agents: 200 mg twice daily for 7 days as Arm G, 300 mg once daily for 7 days as Arm H, or 100 mg once daily for 5 days per week for 2 weeks as Arm I.  Median overall survival was 240 days (approx. 8 months) for Arm G, 290 days (approx. 10 months) for Arm H, and 153 days (approx. 5 months) for Arm I. Median overall survival for all three arms is 252 days (approx. 8 months). In terms of secondary efficacy endpoints complete remissions (CRs) and major hematologic improvement (HI) in platelet counts or neutrophils, were observed on all 3 dosing schedules: 1 CR and 3 HIs in Arm G, 1 CR and 2 HIs in Arm H, and 2 CRs and 1 HI in Arm I. The 30-day mortality from all causes is 5%. Forty-one percent of all patients received 4 or more cycles. At the time of ASCO 2012 more than 34% of the patients were still alive and longer follow-up is needed to assess 1-year survival and overall survival.

At ASH 2010 Cyclacel reported interim data from three schedules of sapacitabine administered as single-agent treatment over a 4-week cycle in 61 patients with IPSS intermediate-1 or higher risk MDS after treatment failure of hypomethylating agents: 200 mg twice daily for 7 days as Arm A, 300 mg twice daily for 7 days as Arm B, or 400 mg twice daily for 3 days per week for 2 weeks as Arm C. The primary endpoint of 1-year survival was achieved in 29%, 30% and 35% of the patients respectively among the 3 schedules tested. Median overall survival was 217 days (approx. 7 months), 232 days (approx. 8 months) and 236 days (approx. 8 months) respectively. Two patients achieved a CR and 13 achieved major hematologic improvement. The 30-day mortality from all causes was 6.6%.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine oral capsules is in the SEAMLESS Phase 3 trial being conducted under an SPA with the FDA as front-line treatment of acute myeloid leukemia (AML) in the elderly, Phase 2 studies for AML, myelodysplastic syndromes (MDS) and solid tumors including lung cancer and in investigator-led studies including a Phase 2/3 study comparing sapacitabine to low dose cytarabine as front-line treatment of elderly patients with AML or high risk MDS unfit for intensive chemotherapy and a Phase 2 study in chronic lymphocytic leukemia. Cyclacel’s pipeline includes seliciclib oral capsules in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

© Copyright 2012 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Vidaza® is a registered trademark of Celgene Corporation. Dacogen® is a registered trademark used by Eisai Inc. under license from Astex Pharmaceuticals, Inc.

1 MDACC = The University of Texas MD Anderson Cancer Center.

CONTACT: Investors/Media:
         Corey Sohmer
         (908) 517-7330
         csohmer@cyclacel.com
Friday, October 12th, 2012 Uncategorized Comments Off on Updated Phase 2 Survival Data of Cyclacel’s (CYCC) Sapacitabine for MDS

Optibase (OBAS) Acquires Beneficial Interest in Commercial Office Building in Philadelphia

Optibase Ltd. Announces the Acquisition of a Beneficial Interest in the Owner of a Commercial Office Building in Philadelphia Known as Two Penn Center Plaza

Optibase Ltd. (NASDAQ: OBAS) today announced that it had acquired an approximately 19.66% beneficial interest in the owner of a Class A 20-story commercial office building in Philadelphia known as Two Penn Center Plaza.

The acquisition was undertaken by the Company’s wholly-owned subsidiary, Optibase 2 Penn, LLC as a limited partner in a larger joint venture that acquired 88% of the beneficial interests in the owner of the 2 Penn Center Plaza.

2 Penn Center Plaza has approximately 500,000 rentable square feet and is located in the Center City neighborhood of Philadelphia opposite City Hall and Love Park.

The transaction was based on a valuation of 2 Penn Center Plaza of approximately $66 million including existing nonrecourse mortgage financing in the principal amount of approximately $51.7 million provided by UBS Real Estate Securities (“UBS”). The UBS mortgage loan has a fixed interest rate of 5.61%, matures in May 2021, and requires monthly payments of principal and interest of approximately $300,000.

Optibase made a capital contribution of approximately $4,025,000 to acquire a 19.66% indirect beneficial interest in the owner of the Property.

For further information, please refer to our proxy statement dated July 12, 2012

Commenting on the transaction, CEO of Optibase, Amir Philips, said, “We are pleased to have completed and closed this transaction for a property at such prime location at the heart of Philadelphia business area. We would like to thank our shareholders who approved this transaction in our most recent annual general meeting for their vote of confidence in the Company.” Mr. Philips concluded, “We are working diligently on increasing our portfolio with such quality assets complemented by long term business partners.”

About Optibase

Optibase invests in the real estate field mostly in Switzerland and the United States and continues looking for additional real estate investment opportunities. Optibase was previously engaged in the field of digital video technologies until the sale of its video solutions business to Optibase Technologies Ltd., a wholly owned subsidiary of VITEC Multimedia (“Vitec”) in July 2010. For further information, please visit www.optibase-holdings.com.

This press release contains forward-looking statements concerning our marketing and operations plans. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. All forward-looking statements in this press release are made based on management’s current expectations which involve risks, uncertainties and other factors that could cause results to differ materially from those expressed in forward-looking statements. These statements involve a number of risks and uncertainties including, but not limited to, difficulties in finding suitable real-estate properties for investment, availability of financing for the acquisition of real-estate, difficulties in leasing of real-estate properties, insolvency of tenants, difficulties in the disposition of real-estate projects, risk relating to collaborative arrangements with our partners relating to our real-estate properties, risks relating to the full consummation of the transaction for the sale of our video solutions business, general economic conditions and other risk factors. For a more detailed discussion of these and other risks that may cause actual results to differ from the forward looking statements in this news release, please refer to Optibase’s most recent annual report on Form 20-F. The Company does not undertake any obligation to update forward-looking statements made herein.

Friday, October 12th, 2012 Uncategorized Comments Off on Optibase (OBAS) Acquires Beneficial Interest in Commercial Office Building in Philadelphia

MGT Capital (MGT) Receives Delisting Notice from NYSE MKT expects appeal

MGT Capital Investments, Inc. Receives Delisting Notice from NYSE MKT Expects to Appeal the Staff’s Determination with Plan to Meet Exchange Standards

MGT Capital Investments, Inc. (NYSE-MKT: MGT.BC), announced today that the Company received a notice dated October 5, 2012 from the NYSE MKT (the “Exchange”) Staff indicating that the Company was not in compliance with the Exchange’s continued listing standards. Specifically, the Company is not in compliance with Section 1003(a)(i) of the Company Guide since it reported stockholders’ equity of less than $2,000,000 at March 31, 2011 and losses from continuing operations and net losses in two of its three most recent fiscal years ended December 31, 2010, Section 1003(a)(ii) of the Company Guide since it reported stockholders’ equity of less than $4,000,000 at March 31, 2011 and losses from continuing operations and/or net losses in three of its four most recent fiscal years ended December 31, 2010 and Section 1003(a)(iii) of the Company Guide since it reported stockholders’ equity of less than $6,000,000 at March 31, 2011 and losses from continuing operations and net losses in its five most recent fiscal years ended December 31, 2010, and as a result its securities are subject to being delisted from the Exchange pursuant to Section 1009 of the Company Guide.

As previously disclosed, MGT has been operating under a Plan of Compliance approved by the Exchange on August 23, 2011 that allowed the Company until December 8, 2012 to regain compliance with the deficiencies noted above. During this period, the Company has been subject to periodic review by Exchange Staff, and was informed of the requirement to make progress consistent with the Plan or to regain compliance with the continued listing standards by the end of the extension period. In the October 5, 2012 notice, the Company was informed that the Staff concluded the Company has not made a reasonable demonstration of its ability to complete the initiatives and meet the equity standards by the end of the 18-month Equity Plan Period, and has therefore begun the delisting process.

MGT appreciates the time given to the Company to cure its deficiencies, and has informed NYSE MKT of its intention to pursue the right of appeal and request a hearing pursuant to Sections 1203 and 1009(d) of the Company Guide. There can be no assurance that the Company’s request for continued listing will be granted at this hearing. In the event MGT’s appeal is unsuccessful, the Company expects that its common stock will trade on OTC-QB no later than any official delisting from NYSE MKT.

After careful analysis, the Company’s board of directors concluded that current negotiations for equity capital, including one memorialized in a non-binding Term Sheet, would, if consummated quickly, put MGT compliance with the Exchange’s listing standards and allow MGT to retain its NYSE MKT listing. The marginal costs of the appeal and of continuing ongoing negotiations create a positive cost/benefit tradeoff. However, there can be no guarantee of retaining the Exchange listing even if the Company successfully cures its equity deficiency. In any scenario, MGT intends to remain as a fully reporting, current SEC filer with transparent accounting and proper corporate governance.

Robert Ladd, the Company’s President and Chief Executive Officer, concluded, “As the largest stockholder of MGT, I commend our board in only considering non-dilutive actions to meet the Exchange’s equity threshold. The out of pocket cash costs to retain listing status are manageable, but we should not enter into any transaction that we believe is destructive to shareholder value, solely to retain that status.”

As previously reported, in a step to improve the Company’s financial flexibility and reduce capital costs, MGT announced on October 8, 2012 that it entered into an exchange agreement with the holders of its Convertible Notes. The Company subsequently repaid the entire $3.5 million issue at face value plus 100,000 shares of MGT restricted common stock. MGT is now debt-free with approximately $1.4 million in cash.

The Company will continue to update its shareholders on its progress, including, but not limited to, the status of its NYSE MKT listing, as well as its patent enforcement activities. The trading symbol will bear the “BC” indicator until the Company regains the compliance with the Exchange’s continued listing requirements.

About MGT Capital Investments, Inc.

MGT and its subsidiaries are engaged in the business of monetizing intellectual property.

MGT Gaming, Inc., a majority-owned subsidiary, owns intellectual property relating to casino gaming systems, and has plans to enforce its property rights against possible infringers.

In addition, the Company owns a majority interest in Medicsight, Ltd, a medical technology company with patent ownership, as well as operations in imaging software and hardware devices. The company’s computer-aided detection software assists radiologists with detection of colorectal polyps, and has received regulatory approvals including CE Mark and U. S. FDA clearance.

Forward Looking Statements

This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” MGT’s financial and operational results reflected above should not be construed by any means as representative of the current or future value of its common stock. All information set forth in this news release, except historical and factual information, represents forward-looking statements. This includes all statements about the Company’s plans, beliefs, estimates and expectations. These statements are based on current estimates and projections, which involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include issues related to: rapidly changing technology and evolving standards in the industries in which the Company and its subsidiaries operate; the ability to obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new business, license and sign new agreements; the unpredictable nature of consumer preferences; and other factors set forth in the Company’s most recently filed annual report and registration statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risks and uncertainties described in other documents that the Company files from time to time with the U.S. Securities and Exchange Commission.

Friday, October 12th, 2012 Uncategorized Comments Off on MGT Capital (MGT) Receives Delisting Notice from NYSE MKT expects appeal

ChinaNet (CNET) Liansuo.com Launches New Cloud-Based Service System

BEIJING, Oct. 12, 2012 (GLOBE NEWSWIRE) — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (the “Company”), a leading B2B (business to business) Internet technology company focusing on providing online-to-offline (“O2O”) sales channel expansion services for small businesses (so-called small and medium-sized enterprises (“SMEs”) in China) and entrepreneurial management and LINK services for entrepreneurs in the People’s Republic of China, today announced that its operating unit for medium and large franchises – Liansuo.com – introduced a new cloud-based software system that allows businesses and existing and potential sales channel partners to communicate with each other more efficiently.

Quick Connect, its new software co-developed by ChinaNet and ChinaNet’s partners, allows new and existing sales channel partners to reach businesses to more efficiently communicate with one another by converting all incoming calls to a toll free telephone number starting with the “400” prefix to the party they are trying to reach. Quick Connect also keeps a detailed log of all incoming calls that businesses can port into their customer relations management (“CRM”) database to track every sales lead. Management expects the new cloud-based software system to drive additional spending for value-added services on Liansuo.com.

Mr. George Chu, COO of ChinaNet, said, “We developed a simple, cost effective way for small business customers to increase their client conversion rates. Most small businesses cannot afford to buy expensive CRM software. As a result of not maintaining an updated log of communications with potential clients and business partners, many small businesses lose sales they otherwise would have captured. A few Liansuo.com clients that have implemented Quick Connect have seen their conversion rates increased by 11% to 17% within a month. We plan to roll this product out to four million small and franchise business owners nationwide over the next few months. This new product will help augment the growth rate of Liansuo.com in the months ahead.”

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading B2B (business to business) Internet technology company focusing on providing O2O (online to offline) sales channel expansion service for small businesses (or so-called small and medium-sized enterprises (SMEs) in China) and entrepreneurial management and LINK service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese small businesses via its portal websites, 28.com, Liansuo.com and Chuangye.com (for entrepreneurs’ Linking services), TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Tel: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us
Friday, October 12th, 2012 Uncategorized Comments Off on ChinaNet (CNET) Liansuo.com Launches New Cloud-Based Service System

Lexicon (LXRX) Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results

Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome

Data Presented at North American Neuroendocrine Tumor Society

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 in San Diego, California.

Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by severe diarrhea and flushing episodes with long-term consequences including malnutrition, heart disease, and death. Carcinoid syndrome has been linked to excess production of serotonin by metastatic tumor cells. Telotristat etiprate is an oral investigational new drug designed to treat carcinoid syndrome by reducing serotonin production in patients with metastatic carcinoid tumors.  Telotristat etiprate has Fast Track status and Orphan Drug designation from the Food and Drug Administration, and Orphan Drug designation from the European Medicines Agency.

The primary efficacy endpoint of the trial was the reduction of bowel movements from baseline in patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy. Patients experienced a 46.4% median reduction from baseline at week 12, with the number of daily bowel movements steadily decreasing over time. All observed changes from baseline were statistically significant at p < 0.001. This change corresponded with an increased proportion of patients reporting adequate relief of their carcinoid symptoms, a global assessment which also improved over time, with 75% of the patients with data at week 12 reporting improvement. Clinically relevant decreases from baseline were likewise seen for a number of key secondary endpoints, including statistically significant improvements in stool consistency (p < 0.001) and trends of reductions in abdominal pain (p=0.09) and the number of cutaneous flushing episodes (p=0.052). The median percentage reductions from baseline of urinary 5-HIAA at weeks 8 and 12 were 68.3% (p=0.019) and 72.7% (p=0.031), respectively. Urinary 5-HIAA is a biomarker of serotonin synthesis and is of key interest in these patients.

“In this trial, telotristat etiprate provided rapid and durable benefit across several dimensions of carcinoid syndrome, a devastating metastatic cancer syndrome with few treatment options for patients,” said Dr. Pablo Lapuerta, Lexicon’s senior vice president and chief medical officer. “Of additional interest was improvement seen in two patients who were not on background somatostatin analog therapy, the only currently-approved treatment.”

The open-label, dose-escalation study was conducted in Europe in 15 patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy. Efficacy measures included change in bowel movement frequency, relief of symptoms, and reduction in serotonin synthesis. Patients received ascending doses of 150 mg, 250 mg, 350 mg and 500 mg of telotristat etiprate, administered three times daily (TID), for 14 days on each dose until reaching a maximal dose, which was then continued until the completion of 12 weeks of therapy. Escalation to a higher dose was contingent on tolerability and clinical response. Fourteen patients (93%) completed the trial, and 12 of these 14 patients were treated with 500 mg TID of study drug during the last four weeks of the treatment period. The one patient who discontinued early withdrew from the 350mg TID dose level for reasons not related to drug safety. Notably, the two patients in the study who were not receiving background somatostatin analog therapy observed reductions in bowel movements of 67% and 48% from baseline to week 12.

Telotristat etiprate was well tolerated. There was no evidence of dose–limiting toxicity, and no patient discontinued from the study early due to an adverse event. Only three patients reported a serious adverse event, none of which was related to study drug.

“The positive results from this second Phase 2 trial of telotristat etiprate further support its potential utility in the treatment of carcinoid syndrome in a population that is refractory to or cannot tolerate current therapies,” said Dr. Arthur T. Sands, Lexicon’s president and chief executive officer. “Building upon results from our previously reported placebo-controlled four-week Phase 2 trial, this study showed strongly positive results in multiple parameters over twelve weeks of therapy, the same treatment period in our upcoming registrational, Phase 3 clinical trial.”

About Telotristat Etiprate (LX1032)

Telotristat etiprate was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.  Excessive levels of serotonin have been associated with carcinoid syndrome, especially diarrhea and carcinoid heart disease.  Serotonin’s breakdown product, 5-HIAA, is a biomarker used in the diagnosis of the condition.  In preclinical studies, telotristat etiprate reduced 5-HIAA and peripheral serotonin in several different species without affecting serotonin levels in the brain.  Telotristat etiprate is being developed under Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and Orphan Drug designation from the European Medicines Agency. Telotristat etiprate is a member of a new class of oral drugs invented by Lexicon, the serotonin synthesis inhibitors, which are being developed in a spectrum of gastrointestinal indications.  Lexicon is also currently carrying out a Phase 2 trial of telotristat etiprate in mild to moderate ulcerative colitis.

About Carcinoid Syndrome

Carcinoid syndrome is a chronic condition caused by metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract.  Patients with carcinoid syndrome currently have limited therapeutic options, and the standard of care includes chronic therapy with somatostatin analogs, which are delivered by injection.  With current therapy, carcinoid syndrome symptoms return over time in most patients, hence the need for new agents.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon’s research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking” statements, including statements relating to Lexicon’s clinical development of telotristat etiprate (LX1032), including characterizations of the results of and projected timing of clinical trials, and the potential therapeutic and commercial potential of telotristat etiprate.  This press release also contains forward-looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to successfully conduct clinical development of telotristat etiprate and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant.  Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Friday, October 12th, 2012 Uncategorized Comments Off on Lexicon (LXRX) Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results

Ninetowns (NINE) Announces Receipt of “Going Private” Proposal

BEIJING, Oct. 12, 2012 /PRNewswire/ — Ninetowns Internet Technology Group Company Limited (NASDAQ: NINE) (“Ninetowns” or the “Company”), one of China’s leading providers of online solutions for international trade, today announced that its Board of Directors has received a preliminary non-binding proposal letter, dated October 12, 2012, from certain directors and officers of the Company, including Mr. Shuang Wang, Ms. Min Dong, Mr. Xiaoguang Ren, Mr. Kin Fai Ng, Mr. Bolin Wu, Mr. Zhonghai Xu, Mr. Tommy Siu Lun Fork and affiliates of some of these directors and officers (together, the “Consortium Members”), that proposes a “going-private” transaction involving the acquisition of all of the outstanding ordinary shares of the Company not already owned by the Consortium Members at a price per share in the range of US$1.80 to US$2.00 in cash (the “Transaction”). Each American depositary share of the Company represents one ordinary share.

According to the proposal letter, the Consortium Members will form an acquisition vehicle for the purpose of pursuing the Transaction, and the Transaction is intended to be financed with a combination of cash from the resources of the Company, its subsidiaries and the acquisition vehicle to be formed by the Consortium Members, as needed. A copy of the proposal letter is attached hereto as Exhibit A.

The Company’s Board of Directors has formed a special committee of independent directors (the “Special Committee”) consisting of Mr. Martin Cheung, Mr. Da Chun Zhang and Mr. Mark Ming Hsun Lee to consider the Transaction. The Special Committee is authorized to retain financial, legal and other advisors to assist it in its review of the Transaction. Paul Hastings LLP is acting as the Company’s U.S. counsel and Ropes & Gray is acting as U.S. counsel to the Consortium Members.

The Company cautions its shareholders and others considering trading in its securities that the Board of Directors has just received the non-binding proposal from the Consortium Members and no decisions have been made with respect to the Company’s response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to the Transaction or any other transaction, except as required under applicable law.

SAFE HARBOR: FORWARD-LOOKING STATEMENTS

Certain statements in this press release include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains; competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as the Company grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and the Company assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

ABOUT NINETOWNS INTERNET TECHNOLOGY GROUP COMPANY LIMITED

Ninetowns (NASDAQ: NINE) is a leading provider of online solutions for international trade, with its key services in automating import/export e-filing. Ninetowns has been listed on the NASDAQ Stock Exchange since December 2004 under the symbol “NINE”. More information can be found at ir.ninetowns.com.

Contacts:

Investor Relations (Beijing)
Daisy Wang
IR Manager
Ninetowns Internet Technology Group Company Limited
+86 (10) 6589-9904
daisywang@ninetowns.com

Investor Relations (Hong Kong)
Mahmoud Siddig
Managing Director
Taylor Rafferty
+852 3196-3712
ninetowns@taylor-rafferty.com

Exhibit A

Proposal

October 12, 2012
The Board of Directors
Ninetowns Internet Technology Group Company Limited

Dear Sirs:

We, Shuang Wang (the “Founder”), chief executive officer and a director of Ninetowns Internet Technology Group Company Limited (the “Company”), and certain other directors and officers of the Company as set forth in Appendix I hereto (collectively, the “ConsortiumMembers”), are pleased to submit this preliminary non-binding proposal to acquire all of the outstanding ordinary shares of the Company not already owned by us in a “going-private” transaction (the “Transaction”). The material terms and conditions related to our proposal and the Transaction are set forth below.  We are confident that the Transaction can be closed on a highly expedited basis as outlined in this letter.

1. Consortium.

The Consortium Members have entered into a consortium agreement, dated October 12, 2012 (the “Consortium Agreement”), pursuant to which the Consortium Members will form an acquisition vehicle for the purpose of pursuing the Transaction in the form of a merger of a subsidiary of such acquisition vehicle into the Company with the Company being the surviving entity from the merger, and have agreed to work with each other on an exclusive basis in pursuing the Transaction for the next six months (the “Exclusivity Period”).

The Consortium Agreement also obligates the Consortium Members (i) to vote for the proposed Transaction and not take any action inconsistent with it and (ii) not to transfer any of their respective shares in the Company within the Exclusivity Period. The Consortium Members currently own, in the aggregate, 10,410,165 ordinary shares, or approximately 26.84% of the outstanding shares of the Company (excluding outstanding options and unvested share awards of the Company).

2. Offer Price. We are prepared to acquire all of the outstanding ordinary shares of the Company not already owned by the Consortium Members at a price per share in the range of US$1.80 to US$2.00 in cash (the “Offer”), representing:

  • a premium of 66.7% to 85.2% to the closing price of the Company’s American Depositary Shares (each representing one ordinary share) (the “Closing Price”) on October 11, 2012;
  • a premium of 59.3% to 77.0% to the volume-weighted average Closing Price during the last 30 trading days;
  • a premium of 63.6% to 81.8% to the volume-weighted average Closing Price during the last 3months; and
  • a premium of 60.7% to 78.6% to the volume-weighted average Closing Price during the last 6 months.

Our Offer provides a highly attractive opportunity to the Company’s shareholders to realize superior value. We believe that the Transaction is in the best interest of the Company and its public shareholders and our Offer would be welcomed by them.

3. Process.  We recognize that the board of directors of the Company (the “Board”) will evaluate the proposed Transaction independently before it can make its determination to endorse it. Given ShuangWang and Kin Fai Ng’s involvement in the proposed Transaction, we expect that the Board would establish a special committee of independent directors (the “Special Committee”) to consider the Offer and the proposed Transaction. We also expect the Special Committee to retain independent advisors, including an independent financial advisor, to assist it in its evaluation of the Offer and the proposed Transaction.

In considering our Offer, you should be aware that we are interested only in acquiring the outstanding shares of the Company that are not already owned by the Consortium Members, and that we do not intend to sell our stake in the Company to a third party.

4. Financing.  We intend to finance the proposed Transaction with a combination of cash from the resources of the Company, its subsidiaries and the acquisition vehicle to be formed by the Consortium Members, as needed. We are confident that funds, subject to terms and conditions in connection therewith, will be in place by the time the definitive documentation for the Transaction is executed.

5. Due Diligence.  We are ready to move expeditiously to complete the proposed Transaction as soon as practicable. We believe that, with the full cooperation of the Company, we can complete our due diligence investigation on a highly expedited basis.

6. Definitive Documentation.  We are prepared to promptly negotiate and finalize mutually satisfactory definitive documentation for the Transaction and related transactions. Such documentation will contain terms customary for transactions of similar size and nature, including customary representations and warranties, covenants, termination provisions and closing conditions. We also expect that such documentation would include customary deal protection procedures and provisions. The negotiation of such documentation can be completed in parallel with our due diligence.  In this regard, we are preparing a draft merger agreement that we will provide to you shortly.

7. Closing Certainty and Required Approvals.  We believe that we offer a high degree of closing certainty and that we are well positioned to negotiate and complete the Transaction on an expedited basis. We will make the applicable filings to the relevant governmental authorities with respect to the Transaction under the antitrust laws of the relevant jurisdictions after execution of the definitive documentation (if any is required), and we do not expect that any regulatory approvals will be impediments to the closing of the Transaction.

8. Confidentiality.  The Consortium Members will, as required by law, promptly and jointly file a Schedule 13D to disclose their participation in this proposal and the Consortium Agreement.  However, we are sure you will agree with us that it is in our mutual interests to ensure that we proceed in a confidential manner, unless otherwise required by law, until we have executed definitive documentation or terminated our discussions.  Any written news releases by the Company or us pertaining to the proposed Transaction shall be reviewed and approved by the Company and us prior to their release, subject to any requirements of law.

9. No Binding Commitment.  This letter constitutes only a preliminary indication of our interest in engaging in the proposed Transaction on the terms and subject to the conditions set forth herein.  Our proposal is expressly subject to the satisfactory negotiation and execution of appropriate definitive documentation and the other matters referred to herein. This letter does not constitute a binding commitment and any such binding commitment will only be set forth in the definitive documentation (and no oral agreements will be deemed to exist). Either the Consortium Members, on the one hand, or the Company, on the other hand, may at any time prior to the execution of definitive documentation decide not to pursue the proposed Transaction.

In closing, we would like to express our commitment to working together to bring this proposed Transaction to a successful and timely conclusion. We are available at any time to discuss the terms of our proposal or to respond to any questions that may arise. We look forward to hearing from you.

Sincerely,

/s/ Shuang Wang
Shuang Wang

/s/ Min Dong
Min Dong

Value Chain International Limited

By:

/s/ Min Dong
Name: Min Dong
Title: Director

/s/ Xiaoguang Ren
XiaoguangRen

/s/ Kin Fai Ng
Kin Fai Ng

Oriental Plan Developments Limited

By:

/s/ Kin Fai Ng
Name: Kin Fai Ng
Title: Director

/s/ Bolin Wu
Bolin Wu

/s/ Zhonghai Xu
Zhonghai Xu

/s/ Tommy Siu Lun Fork
Tommy Siu Lun Fork

APPENDIX I

Consortium Members

(other than the Founder)

Name

Title/Status

·         Min Dong

Senior Vice President

·         Value Chain International Limited

50% owned by the Founder and 50% owned by Min Dong

·         Xiaoguang Ren

President

·         Kin Fai Ng

Director, Senior Vice President and Company Secretary

·         Oriental Plan Developments Limited

100% owned by Kin Fai Ng

·         Bolin Wu

Chief Technology Officer

·         Zhonghai Xu

General Manager, Research and Development

·         Tommy Siu Lun Fork

Chief Financial Officer

Friday, October 12th, 2012 Uncategorized Comments Off on Ninetowns (NINE) Announces Receipt of “Going Private” Proposal

Crumbs Bake Shop, Inc. (CRMB) Completes $9.8 Million in Equity Financing

Crumbs Bake Shop, Inc. (“Crumbs”) (NASDAQ: CRMB), the nation’s largest specialty cupcake retailer, today announced that it has executed a Securities Purchase Agreement with accredited investors pursuant to which it has agreed to sell 4,456,968 shares of its common stock at a price of $2.21 per share, resulting in gross proceeds to the Company of $9,849,900. Closing of the transaction is expected to occur on October 11, 2012.

After paying its expenses related to the transaction, the Company intends to use the net proceeds to fund new store growth, and to bolster general working capital in order to strengthen its financial condition.

“We are pleased with the support for Crumbs from the financial community, and are excited to have closed on this private placement. Clearly, we now have the desired additional capital to fund our new store growth strategy, and to strengthen our financial position,” said Julian R. Geiger, President and Chief Executive Officer of Crumbs. “With our capital needs now met, we can execute our real estate strategy of opening up to 25 new in-line stores and kiosks in hand picked super regional malls in 2013.”

Janney Montgomery Scott LLC acted as the lead financial advisor and Susman Partners LLC d/b/a Threadstone Partners acted as the co-financial advisor to Crumbs Bake Shop, Inc. in the transaction.

The shares of common stock will be sold only to accredited investors in a private placement in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder. The offer and sale of the shares have not been, and will not be, registered under the Securities Act, and the shares may not be offered or sold in the United States absent registration under such Act and applicable state securities laws or an applicable exemption from those registration requirements. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock sold in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Crumbs Bake Shop, Inc.

The first Crumbs bake shop opened in March 2003 on the Upper West Side of Manhattan. Crumbs is well known for its innovative and oversized gourmet cupcakes. Crumbs currently has 54 locations, including 35 locations in the New York Metro area, six locations on the West Coast, five locations in Washington, D.C., one location in Virginia, five locations in Chicago, Illinois and two locations in Boston, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not represent historical facts, but are statements about management’s beliefs, plans and objectives about the future, as well as its assumptions and judgments concerning such beliefs, plans and objectives. These statements are evidenced by terms such as “anticipate”, “estimate”, “should”, “expect”, “believe”, “intend”, and similar expressions. Although these statements reflect management’s good faith beliefs and projections, they are not guarantees of future performance and they may not prove true. These projections involve risk and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements. For a discussion of these risks and uncertainties, see the section of the periodic reports that Crumbs Bake Shops, Inc. files with the Securities and Exchange Commission entitled “Risk Factors”.

Thursday, October 11th, 2012 Uncategorized Comments Off on Crumbs Bake Shop, Inc. (CRMB) Completes $9.8 Million in Equity Financing

GeoPetro (GPR) Granted Extension by NYSE MKT to Regain Compliance

SAN FRANCISCO, Oct. 11, 2012 (GLOBE NEWSWIRE) — GeoPetro Resources Company (NYSE MKT:GPR) (“GeoPetro” or the “Company”) announced today that it has received a favorable determination from the NYSE MKT LLC (“NYSE MKT” or the “Exchange”) with regard to its continued listing. On October 9, 2012, the NYSE MKT notified the Company that the Exchange has determined that, in accordance with Section 1009 of the Company Guide, the Company made a reasonable demonstration of its ability to regain compliance with Section 1003(a)(iv) of the Company Guide by the end of the revised plan period, which is now determined by the Exchange to be December 31, 2012. As a result, the NYSE MKT is continuing the Company’s listing pursuant to this extension.

The Company will be subject to periodic reviews by the NYSE MKT during the extension period covered by the plan. Failure to make progress consistent with the plan or to regain compliance with continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

The Company had earlier received notice on June 28, 2012 from the Exchange that the Company was not in compliance with Section 1003(a)(iv) of the Exchange’s Company Guide in that the Exchange believes that the Company has sustained losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether it will be able to continue operations and/or meet its obligations as they mature.

The Company was afforded the opportunity to submit a plan of compliance, which the Company submitted on July 30, 2012. On August 27, 2012, the Exchange notified the Company that it accepted the Company’s plan of compliance and granted the Company until September 28, 2012 to regain compliance with the continued listing standards. This date has now been extended to December 31, 2012.

About GeoPetro

GeoPetro is an independent oil and natural gas company headquartered in San Francisco, California. GeoPetro currently has projects in the United States, Canada and Indonesia. GeoPetro has developed an oil and gas property in its Madisonville Field Project in Texas. Elsewhere, GeoPetro has assembled a geographically-diversified portfolio of exploratory and appraisal prospects.

The GeoPetro Resources Company logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11051

Cautionary Statements

This news release contains forward-looking information. Statements contained in this news release relating to future results, events and expectations are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may involve known and unknown risks involving market prices for natural gas and oil, economic and competitive conditions, regulatory changes, resource estimates, estimates of proved and probable reserves, production forecasts, geological and engineering uncertainties, potential failure to achieve production from development drilling projects, capital expenditures and other risks and uncertainties, which may cause the actual results to be materially different from those expressed or implied by such statements. Additional risk factors include, among others, those described in the Company’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. We do not have any intention or obligation to update forward-looking statements included in this press release after the date of this press release, except as required by law.

No stock exchange or regulatory authority has approved or disapproved of the information contained herein.

CONTACT: GeoPetro Resources Company
         Stuart J. Doshi, President & CEO
         Telephone: (415) 398-8186
         E-Mail: sdoshi@geopetro.com
         Website: www.geopetro.com

GeoPetro Resources Company Logo

Thursday, October 11th, 2012 Uncategorized Comments Off on GeoPetro (GPR) Granted Extension by NYSE MKT to Regain Compliance